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Birth	weight	(BW)	is	influenced	by	both	foetal	and	maternal	factors	and	in	observational	studies	is	1	
reproducibly	associated	with	future	risk	of	adult	metabolic	diseases	including	type	2	diabetes	2	
(T2D)	and	cardiovascular	disease1.	These	lifecourse	associations	have	often	been	attributed	to	the	3	
impact	of	an	adverse	early	life	environment.	We	performed	a	multi-ancestry	genome-wide	4	
association	study	(GWAS)	meta-analysis	of	BW	in	153,781	individuals,	identifying	60	loci	where	5	
foetal	genotype	was	associated	with	BW	(P<5x10-8).	Overall,	~15%	of	variance	in	BW	could	be	6	
captured	by	assays	of	foetal	genetic	variation.	Using	genetic	association	alone,	we	found	strong	7	
inverse	genetic	correlations	between	BW	and	systolic	blood	pressure	(rg=-0.22,	P=5.5x10-13),	T2D	8	
(rg=-0.27,	P=1.1x10-6)	and	coronary	artery	disease	(rg=-0.30,	P=6.5x10-9)	and,	in	large	cohort	data	9	
sets,	demonstrated	that	genetic	factors	were	the	major	contributor	to	the	negative	covariance	10	
between	BW	and	future	cardiometabolic	risk.	Pathway	analyses	indicated	that	the	protein	11	
products	of	genes	within	BW-associated	regions	were	enriched	for	diverse	processes	including	12	
insulin	signalling,	glucose	homeostasis,	glycogen	biosynthesis	and	chromatin	remodelling.	There	13	
was	also	enrichment	of	associations	with	BW	in	known	imprinted	regions	(P=1.9x10-4).	We	have	14	
demonstrated	that	lifecourse	associations	between	early	growth	phenotypes	and	adult	15	
cardiometabolic	disease	are	in	part	the	result	of	shared	genetic	effects	and	have	highlighted	some	16	
of	the	pathways	through	which	these	causal	genetic	effects	are	mediated.			17	
	18	
We	combined	GWAS	data	for	BW	in	153,781	individuals	representing	multiple	ancestries	from	37	19	
studies	across	three	components	(Extended	Data	Fig.	1	and	Supplementary	Table	1):	(i)	75,891	20	
individuals	of	European	ancestry	from	30	studies;	(ii)	67,786	individuals	of	European	ancestry	from	21	
the	UK	Biobank;	and	(iii)	10,104	individuals	of	diverse	ancestries	(African	American,	Chinese,	Filipino,	22	
Surinamese,	Turkish	and	Moroccan)	from	six	studies.	Within	each	study,	BW	was	z-score	23	
transformed	separately	in	males	and	females	after	excluding	non-singletons	and	premature	births	24	
and	adjusting	for	gestational	age	where	available.	Genotypes	were	imputed	using	reference	panels	25	
from	the	1000	Genomes	(1000G)2	or	combined	1000G	and	UK10K	Project3	(Supplementary	Table	2).	26	
We	performed	quality	control	assessments	to	confirm	that	the	distribution	of	BW	was	consistent	27	
across	studies,	irrespective	of	the	data	collection	protocol,	and	confirmed	that	self-reported	BW	in	28	
UK	Biobank	showed	genetic	and	phenotypic	associations	consistent	with	those	seen	for	measured	29	
BW	in	other	studies4	(Methods).		30	
		31	
We	identified	60	loci	(59	autosomal)	associated	with	BW	at	genome-wide	significance	(P<5x10-8)	in	32	
either	the	European	ancestry	or	trans-ancestry	meta-analyses	(Extended	Data	Fig.	2a,	Extended	33	
Data	Table	1a	and	Supplementary	Data;	Methods).	At	lead	SNPs,	we	observed	no	heterogeneity	in	34	
allelic	effects	between	the	three	study	components	(Cochran’s	Q	statistic	P>0.00083)	35	
(Supplementary	Table	3).	Fifty-three	of	these	loci	were	novel	in	that	the	lead	SNP	mapped	>2Mb	36	
away	from,	and	was	statistically	independent	(EUR	r2<0.05)	of,	the	seven	previously-reported	BW	37	
signals5,	all	of	which	were	confirmed	in	this	larger	analysis	(Supplementary	Table	4).	Approximate	38	
conditional	analysis	in	the	European	ancestry	data	indicated	that	three	of	these	novel	loci	(near	39	
ZBTB7B,	HMGA1	and	PTCH1)	harboured	multiple	distinct	association	signals	attaining	genome-wide	40	
significance	(Methods;	Supplementary	Table	5	and	Extended	Data	Fig.	3).		41	
	42	
The	lead	variants	for	most	signals	mapped	to	non-coding	sequence,	and	at	only	two	loci,	ADRB1	43	
(rs7076938;	r2=0.99	with	ADRB1	G389R)	and	NRIP1	(rs2229742,	R448G)	did	the	association	data	44	
point	to	likely	causal	non-synonymous	coding	variants	(Supplementary	Table	6;	Methods).	Lead	45	
SNPs	for	all	but	two	loci	(those	mapping	near	YKT6-GCK	and	SUZ12P1-CRLF3)	were	common	(minor	46	
allele	frequency	(MAF)	≥5%)	with	individually	modest	effects	on	BW	(β=0.020-0.053	standard	47	
deviations	(SD)	per	allele,	equivalent	to	10-26g).	This	was	despite	much	improved	coverage	of	low-48	
frequency	variants	in	this	study	(compared	to	previous	HapMap	2	imputed	meta-analyses5)	49	
reflecting	imputation	from	larger,	and	more	complete,	reference	panels	(Extended	Data	Table	1b).	50	
Indeed,	all	but	five	of	the	common	variant	association	signals	were	tagged	by	variants	(EUR	r2>0.6)	in	51	
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the	HapMap	2	reference	panel	(Supplementary	Tables	4,	5),	indicating	that	most	of	the	novel	52	
discovery	in	the	present	study	was	driven	by	increased	sample	size5.	Fine-mapping	analysis	yielded	53	
14	regions	within	which	fewer	than	ten	variants	contributed	to	the	locus-specific	credible	set	that	54	
accounted	for	>99%	of	the	posterior	probability	of	association	(Methods;	Supplementary	Table	7).	55	
The	greatest	refinement	was	at	YKT6-GCK,	where	the	credible	set	included	only	the	low	frequency	56	
variant	rs138715366,	which	maps	intronic	to	YKT6.	These	credible	set	variants	collectively	showed	57	
enrichment	for	overlap	with	DNaseI	hypersensitivity	sites,	particularly	those	generated,	by	ENCODE,	58	
from	foetal	(4.2-fold,	95%	CI	[1.8-10.7])	and	neonatal	tissues	(4.9	[1.8-11.0])	(Supplementary	Fig.	1	59	
and	Supplementary	Table	8;	Methods).		60	
	61	
In	combination,	the	62	distinct	genome-wide	significant	signals	at	the	59	autosomal	loci	explained	62	
2.0%	(standard	error	(SE)	1.1%)	of	variance	in	BW	(Supplementary	Table	9;	Methods),	similar	in	63	
magnitude	to	that	attributable	to	sex	or	maternal	body	mass	index	(BMI)5.	However,	the	variance	in	64	
BW	captured	collectively	by	all	autosomal	genotyped	variants	on	the	array	was	considerably	larger,	65	
estimated	at	15.1%	(SE=0.9)	in	UK	Biobank	(Methods).	These	figures	are	consistent	with	a	long	tail	of	66	
genetic	variants	of	smaller	effects	contributing	to	variation	in	BW.	67	
	68	
Associations	between	foetal	genotype	and	BW	could	result	from	indirect	effects	of	the	maternal	69	
genotype	influencing	BW	via	the	intrauterine	environment	given	the	correlation	(r	≈	0.5)	between	70	
maternal	and	foetal	genotype.	However,	two	lines	of	evidence	indicated	that	variation	in	the	foetal	71	
genome	was	the	predominant	driver	of	the	BW	associations.	First,	an	analysis	of	the	global	72	
contribution	of	maternal	vs.	foetal	genetic	variation,	using	a	maternal-GCTA	model6	(Methods)	73	
applied	to	4,382	mother-child	pairs,	estimated	that	the	child’s	genotype	(σC2=0.24,	SE=0.11)	makes	a	74	
larger	contribution	to	BW	variance	than	either	the	mother’s	genotype	(σM2=0.04,	SE=0.10),	or	the	75	
covariance	between	the	two	(σCM=0.04,	SE=0.08).	Second,	when	we	compared	the	point	estimates	of	76	
the	BW	effect	size	dependent	on	maternal	genotype	at	each	of	the	60	loci	(as	measured	in	up	to	77	
68,254	women7)	with	those	dependent	on	foetal	genotype	(using	European	ancestry	data	from	78	
143,677	individuals	in	the	present	study),	foetal	variation	had	greater	impact	than	maternal	at	93%	79	
of	loci	(55/60;	binomial	P=1x10-11)	(Supplementary	Table	10,	Extended	Data	Figs	4,	5;	Methods).	80	
Power	to	further	disentangle	maternal	and	foetal	contributions	using	analyses	of	foetal	genotype	81	
conditional	on	maternal	genotype	was	constrained	by	the	limited	sample	size	available	(n=12,909	82	
mother-child	pairs)	(Supplementary	Table	11).		83	
	84	
Collectively,	these	analyses	provide	compelling	evidence	that	foetal	genotype	has	a	substantial	85	
impact	on	early	growth,	as	measured	by	BW.	We	sought	to	use	these	genetic	associations	to	86	
understand	the	causal	relationships	underlying	observed	associations	between	BW	and	disease,	and	87	
to	characterise	the	processes	responsible.				88	
	 	89	
To	quantify	the	shared	genetic	contribution	to	BW	and	other	health-related	traits,	we	estimated	90	
their	genetic	correlations	using	LD	Score	regression8	(Methods).	BW	(in	European	ancestry	samples)	91	
showed	strong	positive	genetic	correlations	with	anthropometric	and	obesity-related	traits	including	92	
birth	length	(rg=0.81,	P=2.0x10-44),	and	in	adults,	height	(rg=0.41,	P=4.8x10-52),	waist	circumference	93	
(rg=0.18,	P=3.9x10-10)	and	BMI	(rg=0.11,	P=7.3x10-6).	In	contrast,	BW	showed	inverse	genetic	94	
correlations	with	indicators	of	adverse	metabolic	and	cardiovascular	health	including	coronary	artery	95	
disease	(CAD,	rg=-0.30,	P=6.5x10-9),	systolic	blood	pressure	(SBP,	rg=-0.22,	P=5.5x10-13)	and	T2D	(rg=-96	
0.27,	P=1.1x10-6)	(Fig.	1,	Supplementary	Table	12	and	Supplementary	Fig.	2).	These	correlations	97	
between	BW	and	adult	cardiometabolic	phenotypes	are	of	similar	magnitude,	although	directionally-98	
opposite,	to	the	reported	genetic	correlations	between	adult	BMI	and	those	same	cardiometabolic	99	
outcomes8.	These	findings	support	observational	associations	between	a	history	of	paternal	T2D	and	100	
lower	BW4,	and	establish	more	generally	that	the	observed	lifecourse	associations	between	early	101	
growth	and	adult	disease,	at	least	in	part,	reflect	the	impact	of	shared	genetic	variants	that	influence	102	
	 8	
both	sets	of	phenotypes.	In	an	effort	to	estimate	the	extent	of	genetic	contribution	to	these	103	
lifecourse	associations,	we	first	focused	on	data	from	UK	Biobank	(n=57,715).	For	many	of	the	traits	104	
for	which	data	were	available,	genetic	variation	contributed	substantially	to	the	lifecourse	105	
relationship	between	BW	and	adult	phenotypes,	and	in	some	cases	appeared	to	be	the	major	source	106	
of	covariance	between	the	traits.	For	example,	we	estimated	that	85%	(95%	CI=70%-99%)	of	the	107	
negative	covariance	between	BW	and	SBP	was	explained	by	shared	genetic	associations	captured	by	108	
directly	genotyped	SNPs	(Supplementary	Table	13;	Methods).	For	continuous	cardiometabolic	109	
measures,	including	lipids	and	fasting	glycaemia,	for	which	measures	are	not	currently	available	in	110	
UK	Biobank,	we	turned	to	the	Northern	Finland	Birth	Cohort	(n=5,009),	and	obtained	similar	results	111	
(Supplementary	Table	13).	However,	these	estimates	are	limited,	not	only	by	wide	confidence	112	
intervals,	but	also	by	the	assumption	of	a	linear	relationship	between	BW	and	each	of	the	113	
phenotypes	and	by	the	inability	to	explicitly	model	maternal	genotypic	effects.	In	other	words,	the	114	
inverse	genetic	correlations	between	BW	and	cardiometabolic	traits	may	not	exclusively	reflect	115	
genetic	effects	mediated	directly	through	the	offspring,	but	also	effects	mediated	by	maternal	116	
genotype	acting	indirectly	via	perturbation	of	the	in	utero	environment.	Nevertheless,	these	117	
estimates	indicate	that	a	substantial	proportion	of	the	variance	in	cardiometabolic	risk	that	covaries	118	
with	BW	can	be	attributed	to	the	effects	of	common	genetic	variation.	119	
	120	
To	elucidate	the	biological	pathways	and	processes	underlying	regulation	of	foetal	growth,	we	first	121	
performed	gene	set	enrichment	analysis	of	our	BW	GWAS	analysis	using	MAGENTA9	(Methods).	122	
Twelve	pathways	reached	study-wide	significance	(FDR<0.05),	including	pathways	involved	in	123	
metabolism	(insulin	signalling,	glycogen	biosynthesis,	cholesterol	biosynthesis),	growth	(IGF-124	
signalling,	growth	hormone	pathway)	and	development	(chromatin	remodelling)	(Extended	Data	125	
Table	2a).	Similar	pathways	were	detected	in	a	complementary	analysis	where	we	interrogated	126	
empirical	protein-protein	interaction	(PPI)	data	identifying	13	PPI	network	modules	with	marked	(z-127	
score	>5)	enrichment	for	BW-association	scores	(Extended	Data	Table	2b	and	Extended	Data	Figs	128	
6a,	b;	Methods).	The	proteins	within	these	modules	were	themselves	enriched	for	diverse	processes	129	
related	to	metabolism,	growth	and	development	(Extended	Data	Figs	6a,	b).			130	
	131	
We	also	observed	enrichment	of	BW	association	signals	across	the	set	of	77	imprinted	genes	defined	132	
by	the	Genotype-Tissue	Expression	(GTEx)	project10	(P=1.9x10-4;	Extended	Data	Table	2a	and	133	
Supplementary	Table	14).	Such	enrichment	is	consistent	with	the	“parental	conflict”	hypothesis	134	
regarding	the	allocation	of	maternal	resources	to	the	foetus11.	Although	the	role	of	imprinted	genes	135	
in	foetal	growth	is	described	in	animal	models	and	rare	human	disorders12,	our	result	is	the	first	136	
large-scale,	systematic	demonstration	of	their	contribution	to	normal	variation	in	BW.	Of	the	60	137	
genome-wide	significant	loci,	two	(INS-IGF2,	RB1)	fall	within	(or	near)	imprinted	regions	(Extended	138	
Data	Fig.	2b),	with	a	noteworthy	third	signal	at	DLK1	(previously	foetal	antigen-1;	P=5.6x10-8).	139	
Parent-of-origin	specific	analyses	to	further	investigate	these	individual	loci	(comparing	140	
heterozygote	vs.	homozygote	BW	variance	in	57,715	unrelated	individuals,	and	testing	BW	141	
associations	with	paternal	vs.	maternal	alleles	in	4,908	mother-child	pairs;	see	Methods)	proved,	142	
despite	these	sample	sizes,	to	be	underpowered	(Extended	Data	Fig.	7	and	Supplementary	Tables	143	
15,	16).		144	
	145	
Many	of	the	genome-wide	signals	for	BW	detected	here	are	also	established	genome-wide	146	
association	signals	for	a	wide	variety	of	cardiometabolic	traits	(Fig.	2).	These	include	the	BW	signals	147	
near	CDKAL1,	ADCY5,	HHEX/IDE	and	ANK1	(also	genome-wide	significant	for	T2D),	NT5C2	(for	blood	148	
pressure	(BP),	CAD	and	BMI)	and	ADRB1	(for	BP).	We	used	two	approaches	to	understand	whether	149	
this	pattern	of	adult	trait	association	represented	a	generic	property	of	BW-associated	loci,	or	150	
reflected	heterogeneous	mechanisms	linking	BW	to	adult	disease.		151	
	152	
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First,	we	applied	unsupervised	hierarchical	clustering	(Methods)	to	the	non-BW	trait	association	153	
statistics	for	the	60	significant	BW	loci.	The	resultant	heatmap	indicates	the	heterogeneity	of	locus-154	
specific	effect	sizes	across	the	range	of	adult	traits	(Fig.	2	and	Supplementary	Table	17).	For	155	
example,	it	shows	that	the	associations	between	BW-raising	alleles	and	increased	adult	height	are	156	
concentrated	amongst	a	subset	of	loci	including	HHIP	and	GNA12,	and	highlights	particularly	strong	157	
associations	with	lipid	traits	for	variants	at	the	TRIB1	and	MAFB	loci.			158	
	159	
Second,	we	constructed	trait-specific	“point-of-contact”	(PoC)	PPI	networks	from	proteins	160	
represented	in	both	the	global	BW	PPI	network	and	equivalent	PPI	networks	generated	for	each	of	161	
the	adult	traits	(Methods;	Extended	Data	Figs	6c-e).	We	reasoned	that	these	PoC	PPI	networks	162	
would	be	enriched	for	the	specific	proteins	mediating	the	observed	links	between	BW	and	adult	163	
traits,	generating	hypotheses	that	are	amenable	to	subsequent	empirical	validation.	To	highlight	164	
processes	implicated	in	specific	BW-trait	associations,	we	overlaid	these	PoC	PPI	with	the	50	165	
pathways	over-represented	in	the	global	BW	PPI	network.	These	analyses	revealed,	for	example,	166	
that	proteins	in	the	Wnt	canonical	signalling	pathway	were	only	detected	in	the	PoC	PPI	network	for	167	
BP	traits.	We	can	use	these	PPI	overlaps	to	highlight	the	specific	transcripts	within	BW	GWAS	loci	168	
that	are	likely	to	mediate	the	mechanistic	links.	For	example,	the	overlap	between	the	Wnt	signalling	169	
pathway	and	the	PoC	PPI	network	for	the	intersection	of	BW	and	BP-related	traits	implicates	FZD9	as	170	
the	likely	effector	gene	at	the	MLXIPL	BW	locus	(Extended	Data	Fig.	6d	and	Supplementary	Table	6).		171	
	172	
We	focused	our	more	detailed	investigation	of	the	mechanistic	links	between	early	growth	and	adult	173	
traits	on	two	phenotypic	areas:	arterial	BP	and	T2D/glycaemia.	Across	both	the	overall	GWAS	and	174	
specifically	among	the	60	significant	BW	loci,	most	BW-raising	alleles	were	associated	with	reduced	175	
BP	(Figs	1,	2):	the	strongest	inverse	associations	were	seen	for	the	loci	near	NT5C2,	FES,	NRIP1,	EBF1	176	
and	PTH1R.	However,	we	also	observed	locus-specific	heterogeneity	in	the	genetic	relationships	177	
between	BP	and	BW:	the	SBP-raising	allele	at	ADRB113	is	associated	with	higher,	rather	than	lower,	178	
BW	(Extended	Data	Fig.	8a).	When	we	considered	the	reciprocal	relationship,	i.e.	the	effects	on	BW	179	
of	BP-raising	alleles	at	30	reported	loci	for	SBP13,14,	there	was	an	excess	of	associations	(5/30	with	180	
lower	BW	at	P<0.05;	P=0.0026;	Extended	Data	Fig.	8a).	To	dissect	maternal	and	foetal	genotype	181	
effects	at	these	loci,	we	tested	the	impact	on	BW	of	a	risk	score	generated	from	the	30	SBP	SNPs,	182	
restricted	to	the	untransmitted	maternal	haplotype	score15	in	a	set	of	5,201	mother-child	pairs.	183	
Analysis	of	these	loci	indicated	that	maternal	genotype	effects	on	the	intrauterine	environment	are	184	
likely	to	contribute	to	the	inverse	genetic	correlation	between	SBP	and	BW	(Methods;	185	
Supplementary	Table	18),	and	was	consistent	with	the	results	of	a	wider	study	of	>30,000	women	186	
which	demonstrated	associations	between	a	maternal	genetic	score	for	SBP	(conditional	on	foetal	187	
genotype)	and	lower	offspring	BW16.				188	
	189	
The	BP-raising	allele	with	the	largest	BW-lowering	effect	maps	to	the	NT5C2	locus	(index	variant	for	190	
BW,	rs74233809,	r2=0.98	with	index	variant	for	BP,	rs1119154814)	and	is	also	associated	with	lower	191	
adult	BMI	(r2=0.99	with	rs1119156017).	The	BW-lowering	allele	at	rs74233809	is	a	proxy	for	a	192	
recently-described	functional	variant	in	the	nearby	CYP17A1	gene	(r2=0.92	with	rs138009835)18.	The	193	
CYP17A1	gene	encodes	the	cytochrome	P450c17α	enzyme,	CYP1719,	which	catalyses	key	steps	in	194	
steroidogenesis	that	determine	the	balance	between	mineralocorticoid,	glucocorticoid	and	195	
androgen	synthesis.	This	variant	is	known	to	alter	transcriptional	efficiency	in	vitro	and	is	associated	196	
with	higher	urinary	tetrahydroaldosterone	excretion18.	CYP17A1	is	expressed	in	foetal	adrenal	glands	197	
and	testes	from	early	gestation20	as	well	as	in	the	placenta21.	These	data	implicate	variation	in	198	
CYP17A1	expression	as	a	contributor	to	the	observational	association	between	low	BW	and	adult	199	
hypertension22.		200	
	201	
When	we	examined	45	loci	associated	with	CAD23,	the	inverse	genetic	correlation	between	CAD	and	202	
BW	was	concentrated	amongst	the	five	CAD	loci	with	primary	BP	associations.	This	suggests	that	203	
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genetic	determinants	of	BP	play	a	leading	role	in	mediating	the	lifecourse	associations	between	BW	204	
and	CAD	(Extended	Data	Figs	8b,	e).		205	
	206	
LD	score	regression	analyses	demonstrated	overall	inverse	genetic	correlation	between	lower	BW	207	
and	elevated	risk	of	T2D	(Fig.	1).	However,	the	locus	specific	heatmap	indicates	a	heterogeneous	208	
pattern	across	individual	loci	(Fig.	2).	To	explore	this	further,	we	tested	the	84	reported	T2D	loci24	for	209	
association	with	BW.	Some	T2D	risk	alleles	(such	as	at	ADCY5,	CDKAL1	and	HHEX-IDE)	were	strongly	210	
associated	with	lower	BW,	whilst	others	(e.g.	ANK1	and	MTNR1B)	were	associated	with	higher	BW	211	
(Extended	Data	Fig.	8c).	This	was	in	contrast	with	the	BW	effects	of	422	known	height	loci25	212	
(Extended	Data	Fig.	8d),	which	showed	a	strong	positive	correlation	consistent	with	the	overall	213	
genetic	correlation	between	height	and	BW,	indicating	that	the	growth	effects	of	many	height	loci	214	
start	prenatally	and	persist	into	adulthood.		215	
	216	
The	contrasting	associations	of	T2D	risk-alleles	with	both	higher	and	lower	BW	are	likely	to	reflect	217	
the	differential	impacts	across	loci	of	variation	in	the	maternal	and	foetal	genomes.	Observational	218	
data	link	paternal	diabetes	with	lower	offspring	BW4	indicating	that	the	inheritance	of	T2D	risk	219	
alleles	by	the	foetus	tends,	in	line	with	the	LD	score	regression	analysis,	to	reduce	growth.	These	220	
relationships	are	consistent	with	the	precepts	of	the	“foetal	insulin	hypothesis”26	and	reflect	the	221	
potential	for	reduced	insulin	secretion	and/or	signalling	to	lead	to	both	reduced	foetal	growth	and,	222	
many	decades	later,	enhanced	predisposition	to	T2D.	In	line	with	this,	the	inferred	paternal	223	
transmitted	haplotype	score	generated	from	the	84	T2D	risk	variants	was	associated	with	lower	BW	224	
(P=0.045)	in	5,201	mother-child	pairs	(Methods;	Supplementary	Table	18).	In	contrast,	maternal	225	
diabetes	is	observationally	associated	with	higher	offspring	BW4,	reflecting	the	impact	of	maternal	226	
hyperglycaemia	to	stimulate	foetal	insulin	secretion.	The	contribution	of	genotype-dependent	227	
maternal	hyperglycaemia	to	BW	is	in	line	with	the	evidence,	from	a	recent	study,	that	maternal	228	
genotype	scores	for	fasting	glucose	and	T2D	(conditional	on	foetal	genotype)	were	causally	229	
associated	with	higher	offspring	BW16.	It	is	also	consistent	with	the	observation	that	a	subset	of	230	
glucose-raising	alleles	is	associated	with	higher	BW7.	For	example,	the	T2D-risk	variant	at	MTNR1B	231	
(which	also	has	a	particularly	marked	effect	on	fasting	glucose	levels	in	non-diabetic	indivudals27,28)	232	
was	amongst	the	subset	of	BW	loci	(5/60)	for	which	the	BW	effect	attributable	to	maternal	genotype	233	
exceeded	that	associated	with	the	foetal	genotype	(maternal:	β=0.048,	P=5.1x10-15;	foetal:	β=0.023,	234	
P=2.9x10-8)	(Supplementary	Table	10,	Extended	Data	Figs	4,	5).	Thus,	both	maternal	and	foetal	235	
genetic	effects	connect	BW	to	later	T2D	risk,	albeit	acting	in	opposing	directions.	When	we	236	
categorised	T2D	loci	using	a	classification	of	physiological	function	derived	from	their	effects	on	237	
related	glycaemic	and	anthropometric	traits27,	we	found	that	T2D-risk	alleles	associated	with	lower	238	
BW	were	those	typically	characterised	by	reduced	insulin	processing	and	secretion	without	239	
detectable	changes	in	fasting	glucose	(the	“Beta	Cell”	cluster	in	Extended	Data	Fig.	8f).		240	
	241	
The	YTK6	signal	at	rs138715366	is	notable,	not	only	because	the	genetic	data	indicates	that	a	single	242	
low-frequency	non-coding	variant	is	driving	the	association	signal	(see	above)	but	because	of	the	243	
proximity	of	this	signal	to	GCK.	Rare	coding	variants	in	glucokinase	are	causal	for	a	form	of	244	
monogenic	hyperglycaemia	and	lead	to	large	reductions	in	BW	when	parental	alleles	are	passed	to	245	
their	offspring29.	In	addition,	common	non-coding	variants	nearby	are	implicated	in	T2D-risk	and	246	
fasting	hyperglycaemia28.	However,	the	latter	variants	are	conditionally	independent	of	rs138715366	247	
(Supplementary	Table	19)	and	show	no	comparable	association	with	lower	BW.	Either	rs138715366	248	
acts	through	effector	transcripts	other	than	GCK,	or	the	impact	of	the	low-frequency	SNP	near	YKT6	249	
on	GCK	expression	involves	tissue-	and/or	temporal-specific	variation	in	regulatory	impact.	250	
	251	
In	conclusion,	we	have	identified	60	genetic	loci	associated	with	BW	and	used	these	to	gain	insights	252	
into	the	aetiology	of	foetal	growth	and	into	well-established,	but	until	now	poorly	understood,	253	
lifecourse	disease	associations.	The	evidence	that	the	relationship	between	early	growth	and	later	254	
	 11	
metabolic	disease	has	an	appreciable	genetic	component	contrasts	with,	but	is	not	necessarily 255	
incompatible	with,	the	emphasis	on	adverse	early	environmental	events	highlighted	by	the	Foetal	256	
Origins	Hypothesis1.	As	we	have	shown,	these	genetic	effects	reflect	variation	in	both	the	foetal	and	257	
the	maternal	genome:	the	impact	of	the	latter	on	the	offspring’s	predisposition	to	adult	disease	258	
could	be	mediated,	at	least	in	part,	through	perturbation	of	the	antenatal	and	early	life	259	
environment.	Future	mechanistic	and	genetic	studies	should	support	reconciliation	between	these	260	
alternative,	but	complementary,	explanations	for	the	far-reaching	lifecourse	associations	that	exist	261	
between	events	in	early	life	and	predisposition	to	cardiometabolic	disease	several	decades	later.		262	
	263	
	264	
	265	
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FIGURE	LEGENDS	348	
	349	
Figure	1	|	Genome-wide	genetic	correlation	between	birth	weight	and	a	range	of	traits	and	350	
diseases	in	later	life.	Genetic	correlation	(rg)	and	corresponding	standard	error	between	BW	and	the	351	
traits	displayed	on	the	x	axis	are	estimated	using	LD	Score	regression8.	The	genetic	correlation	352	
estimates	(rg)	are	colour	coded	according	to	their	intensity	and	direction	(red	for	positive	and	blue	353	
for	inverse	correlation).	WHRadjBMI=waist-hip	ratio	adjusted	for	body	mass	index,	HOMA-354	
B/IR=homeostatic	model	assessment	of	beta-cell	function/insulin	resistance,	HbA1c=Hemoglobin	355	
A1c,	BMD=bone	mineral	density,	ADHD=attention	deficit	hyperactivity	disorder.	See	Supplementary	356	
Table	12	for	references	for	each	of	the	traits	and	diseases	displayed.		357	
	358	
Figure	2	|	Hierarchical	clustering	of	birth	weight	loci	based	on	similarity	of	overlap	with	adult	359	
diseases,	metabolic	and	anthropometric	traits.	For	the	lead	SNP	at	each	BW	locus	(x-axis),	z-scores	360	
(aligned	to	BW-raising	allele)	were	obtained	from	publicly	available	GWAS	for	various	traits	(y-axis;	361	
see	Supplementary	Table	17).	A	positive	z-score	(red)	indicates	a	positive	association	between	the	362	
BW-raising	allele	and	the	outcome	trait,	while	a	negative	z-score	(blue)	indicates	an	inverse	363	
association.	BW	loci	and	traits	are	clustered	according	to	the	Euclidean	distance	amongst	z-scores	364	
(see	Methods).	Squares	are	outlined	with	a	solid	black	line	if	the	BW	locus	is	significantly	(P<5x10-8)	365	
associated	with	the	trait	in	publicly	available	GWAS,	or	with	a	dashed	line	if	reported	significant	366	
elsewhere.	WHRadjBMI=waist-hip	ratio	adjusted	for	body	mass	index.		367	
	368	
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METHODS	369	
	370	
Ethics	statement.	All	human	research	was	approved	by	the	relevant	institutional	review	boards	and	371	
conducted	according	to	the	Declaration	of	Helsinki.	All	participants	provided	written	informed	372	
consent.	Ethical	approval	for	the	study	was	obtained	from	the	ALSPAC	Ethics	and	Law	Committee	373	
and	the	Local	Research	Ethics	Committees.	374	
	375	
Study-level	analyses.	Within	each	study,	BW	was	collected	from	a	variety	of	sources,	including	376	
measurements	at	birth	by	medical	practitioners,	obstetric	records,	medical	registers,	interviews	with	377	
the	mother	and	self-report	as	adults	(Supplementary	Table	1).	BW	was	z-score	transformed,	378	
separately	in	males	and	females.	Individuals	with	extreme	BW	(>5	SD	from	the	sex-specific	study	379	
mean),	monozygotic	or	polyzygotic	siblings,	or	preterm	births	(gestational	age	<37	weeks,	where	this	380	
information	was	available)	were	excluded	from	downstream	association	analyses	(Supplementary	381	
Table	1).	382	
Within	each	study,	stringent	quality	control	of	the	GWAS	genotype	scaffold	was	undertaken,	383	
prior	to	imputation	(Supplementary	Table	2).	Each	scaffold	was	then	pre-phased	and	imputed30,31		384	
up	to	reference	panels	from	the	1000G2	or	1000G	and	UK10K	Project3	(Supplementary	Table	2).	385	
Association	of	BW	with	each	variant	passing	established	GWAS	quality	control	filters32	was	tested	in	386	
a	linear	regression	framework,	under	an	additive	model	for	the	allelic	effect,	after	adjustment	for	387	
study-specific	covariates,	including	gestational	age,	where	available	(Supplementary	Table	2).	388	
Where	necessary,	population	structure	was	accounted	for	by	adjustment	for	axes	of	genetic	389	
variation	from	principal	components	analysis33	and	subsequent	genomic	control	correction34,	or	390	
inclusion	of	a	genetic	relationship	matrix	in	a	mixed	model35	(Supplementary	Table	2). We	calculated	391	
the	genomic	control	inflation	factor	(λ)	in	each	study	to	confirm	that	study-level	population	structure	392	
was	accounted	for	prior	to	meta-analysis.	393	
	394	
Preparation,	quality	control	and	genetic	analysis	in	UK	Biobank	samples.	UK	Biobank	phenotype	395	
data	were	available	for	502,655	participants36.	All	participants	in	the	UK	Biobank	were	asked	to	recall	396	
their	BW,	of	which	279,971	did	so	at	either	the	baseline	or	follow-up	assessment	visit.	Of	these,	397	
7,686	participants	reported	being	part	of	multiple	births	and	were	excluded	from	downstream	398	
analyses.	Ancestry	checks,	based	on	self-reported	ancestry,	resulted	in	the	exclusion	of	8,998	399	
additional	participants	reported	not	to	be	white	European.	Of	those	individuals	reporting	BW	at	400	
baseline	and	follow-up	assessments,	393	were	excluded	because	the	two	reported	values	differed	by	401	
more	than	0.5	kg.	For	those	reporting	different	values	(≤0.5	kg)	between	baseline	and	follow-up,	we	402	
took	the	baseline	measure	forward	for	downstream	analyses.	We	then	excluded	36,716	individuals	403	
reporting	values	<2.5	kg	or	>4.5	kg	as	implausible	for	live	term	births	before	1970.	In	total	226,178	404	
participants	had	data	relating	to	BW	that	matched	these	inclusion	criteria.		405	
Genotype	data	from	the	May	2015	release	were	available	for	a	subset	of	152,249	406	
participants	from	UK	Biobank.	In	addition	to	the	quality	control	metrics	performed	centrally	by	UK	407	
Biobank,	we	defined	a	subset	of	“white	European”	ancestry	samples	using	a	K-means	(K=4)	408	
clustering	approach	based	on	the	first	four	genetically	determined	principal	components.	A	409	
maximum	of	67,786	individuals	(40,425	females	and	27,361	males)	with	genotype	and	valid	BW	410	
measures	were	available	for	downstream	analyses.	We	tested	for	association	with	BW,	assuming	an	411	
additive	allelic	effect,	in	a	linear	mixed	model	implemented	in	BOLT-LMM37	to	account	for	cryptic	412	
population	structure	and	relatedness.	Genotyping	array	was	included	as	a	binary	covariate	in	all	413	
models.	Total	chip	heritability	(i.e.	the	variance	explained	by	all	autosomal	polymorphic	genotyped	414	
SNPs	passing	quality	control)	was	calculated	using	Restricted	Maximum	Likelihood	(REML)	415	
implemented	in	BOLT-LMM37.	We	additionally	analysed	the	association	between	BW	and	directly	416	
genotyped	SNPs	on	the	X	chromosome:	for	this	analysis,	we	used	57,715	unrelated	individuals	with	417	
BW	available	and	identified	by	UK	Biobank	as	white	British.	We	excluded	SNPs	with	evidence	of	418	
deviation	from	Hardy-Weinberg	Equilibrium	(P<1x10-6),	MAF<0.01	or	overall	missing	rate	>0.015,	419	
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resulting	in	19,423	SNPs	for	analysis	in	Plink	v1.07	(http://pngu.mgh.harvard.edu/purcell/plink/)38,	420	
with	the	first	five	ancestry	principal	components	as	covariates.		421	
In	both	the	full	UK	Biobank	sample	and	our	refined	sample,	we	observed	that	BW	was	422	
associated	with	sex,	year	of	birth	and	maternal	smoking	(P<0.0015,	all	in	the	expected	directions),	423	
confirming	more	comprehensive	previous	validation	of	self-reported	BW4.	We	additionally	verified	424	
that	BW	associations	with	lead	SNPs	at	seven	established	loci5	based	on	self-report	in	UK	Biobank	425	
were	consistent	with	those	previously	published.	426	
	427	
European	ancestry	meta-analysis.	The	European	ancestry	meta-analysis	consisted	of	two	428	
components:	(i)	75,891	individuals	from	30	GWAS	from	Europe,	USA	and	Australia;	and	(ii)	67,786	429	
individuals	of	white	European	origin	from	UK	Biobank.	In	the	first	component,	we	combined	sex-430	
specific	BW	association	summary	statistics	across	studies	in	a	fixed-effects	meta-analysis,	431	
implemented	in	GWAMA39	and	applied	a	second	round	of	genomic	control34	(λGC=	1.001).	432	
Subsequently,	we	combined	association	summary	statistics	from	this	component	with	UK	Biobank	in	433	
a	European	ancestry	fixed-effects	meta-analysis,	implemented	in	GWAMA39.	Variants	failing	GWAS	434	
quality	control	filters	in	UK	Biobank,	reported	in	less	than	50%	of	the	total	sample	size	in	the	first	435	
component,	or	with	MAF<0.1%,	were	excluded	from	the	European	ancestry	meta-analysis.	We	436	
aggregated	X-Chromosome	association	summary	statistics	from	UK	Biobank	(19,423	SNPs)	with	437	
corresponding	statistics	from	the	European	GWAS	component	using	fixed	effects	P-value	based	438	
meta-analysis	in	METAL40	(max	N=99,152).		439	
We	were	concerned	that	self-reported	BW	as	adults	in	UK	Biobank	would	not	be	comparable	440	
with	that	obtained	from	more	stringent	collection	methods	used	in	other	European	ancestry	GWAS.	441	
In	addition,	UK	Biobank	lacked	information	on	gestational	age	for	adjustment,	which	could	have	an	442	
impact	on	difference	in	strength	of	association	compared	to	the	results	obtained	from	other	443	
European	ancestry	GWAS.	However,	we	observed	no	evidence	of	heterogeneity	in	BW	allelic	effects	444	
at	lead	SNPs	between	the	two	components	of	European	ancestry	meta-analysis,	using	Cochran’s	Q	445	
statistic41,	implemented	in	GWAMA39,	after	Bonferroni	correction	(P>0.00083)	(Supplementary	446	
Table	3).	We	tested	for	heterogeneity	in	allelic	effects	between	studies	within	the	European	447	
component	using	Cochran’s	Q.	At	loci	demonstrating	evidence	of	heterogeneity,	we	confirmed	that	448	
association	signals	were	not	being	driven	by	outlying	studies by	visual	inspection	of	forest	plots.	We	449	
performed	sensitivity	analyses	to	assess	the	impact	of	covariate	adjustment	(gestational	age	and	450	
population	structure)	on	heterogeneity.		451	
We	were	also	concerned	that	overlap	of	individuals	(duplicated	or	related)	between	the	two	452	
components	of	the	European	ancestry	meta-analysis	might	lead	to	false	positive	association	signals.	453	
We	performed	bivariate	LD	Score	regression8	using	the	two	components	of	the	European	ancestry	454	
meta-analysis	and	observed	a	genetic	covariance	intercept	of	0.0156	(SE	0.0058),	indicating	a	455	
maximum	of	1,119	duplicate	individuals.	Univariate	LD	Score	regression8	of	the	European	ancestry	456	
meta-analysis	estimated	the	intercept	as	1.0426,	which	may	indicate	population	structure	or	457	
relatedness	that	is	not	adequately	accounted	for	in	the	analysis.	To	assess	the	impact	of	this	inflation	458	
on	the	European	ancestry	meta-analysis,	we	expanded	the	standard	errors	of	BW	allelic	effect	size	459	
estimates	and	re-calculated	association	P-values.	On	the	basis	of	this	adjusted	analysis,	the	lead	SNP	460	
only	at	MTNR1B	dropped	below	genome-wide	significance	(rs10830963,	P=5.5x10-8).	461	
	462	
Trans-ancestry	meta-analysis.	The	trans-ancestry	meta-analysis	combined	the	two	European	463	
ancestry	components	with	an	additional	10,104	individuals	from	six	GWAS	from	diverse	ancestry	464	
groups:	African	American,	Chinese,	Filipino,	Surinamese,	Turkish	and	Moroccan.	Within	each	GWAS,	465	
we	first	combined	sex-specific	BW	association	summary	statistics	in	a	fixed-effects	meta-analysis,	466	
implemented	in	GWAMA39	and	applied	a	second	round	of	genomic	control34.	Subsequently,	we	467	
combined	association	summary	statistics	from	the	six	non-European	GWAS	and	the	two	European	468	
ancestry	components	in	a	trans-ancestry	fixed-effects	meta-analysis,	implemented	in	GWAMA39.	469	
Variants	failing	GWAS	quality	control	filters	in	UK	Biobank,	reported	in	less	than	50%	of	the	total	470	
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sample	size	in	the	first	component,	or	with	MAF<0.1%,	were	excluded	from	the	trans-ancestry	meta-471	
analysis.	We	tested	for	heterogeneity	in	allelic	effects	between	ancestries	using	Cochran’s	Q41.					472	
	473	
Approximate	conditional	analysis.	We	searched	for	multiple	distinct	BW	association	signals	in	each	474	
of	the	established	and	novel	loci,	defined	as	1Mb	up-	and	down-stream	of	the	lead	SNP	from	the	475	
trans-ancestry	meta-analysis,	through	approximate	conditional	analysis.	We	applied	GCTA42	to	476	
identify	“index	SNPs”	for	distinct	association	signals	attaining	genome-wide	significance	(P<5x10-8)	in	477	
the	European	ancestry	meta-analysis	using	a	reference	sample	of	5,000	individuals	of	white	British	478	
origin,	randomly	selected	from	UK	Biobank,	to	approximate	patterns	of	linkage	disequilibrium	(LD)	479	
between	variants	in	these	regions.	Note	that	we	performed	approximate	conditioning	on	the	basis	of	480	
only	the	European	ancestry	meta-analysis	because	GCTA	cannot	accommodate	LD	variation	between	481	
diverse	populations.	482	
	483	
Prioritising	candidate	genes	in	each	BW	locus.	We	combined	a	number	of	approaches	to	prioritise	484	
the	most	likely	candidate	gene(s)	in	each	BW	locus.	Expression	quantitative	trait	loci	(eQTLs)	were	485	
obtained	from	the	Genotype	Tissue	Expression	(GTEx)	Project43,	the	GEUVADIS	Project44	and	eleven	486	
other	studies45-55	using	HaploReg	v456.	We	interrogated	coding	variants	for	each	BW	lead	SNP	and	its	487	
proxies	(EUR	r2>0.8)	using	Ensembl57	and	HaploReg.	Their	likely	functional	consequences	were	488	
predicted	by	SIFT58	and	PolyPhen259.	Biological	candidacy	was	assessed	by	presence	in	significantly	489	
enriched	gene	set	pathways	from	MAGENTA	analyses	(see	below	for	details).	We	extracted	all	genes	490	
within	300	kb	of	all	lead	BW	SNPs	and	searched	for	connectivity	between	any	genes	using	STRING60.	491	
If	two	or	more	genes	between	two	separate	BW	loci	were	connected,	they	were	given	an	increased	492	
prior	for	both	being	plausible	candidates.	We	also	applied	protein-protein	interaction	(PPI)	analysis	493	
(see	below	for	details)	to	all	genes	within	300	kb	of	each	lead	BW	SNPs	and	ranked	the	genes	based	494	
on	the	score	for	connectivity	with	the	surrounding	genes.			495	
	496	
Evaluation	of	imputation	quality	of	low-frequency	variant	at	the	YKT6-GCK	locus.	At	the	YKT6-GCK	497	
locus,	the	lead	SNP	(rs138715366)	is	of	low-frequency	in	European	ancestry	populations	498	
(MAF=0.92%)	and	even	rarer	in	other	ancestry	groups	(MAF=0.23%	in	African	Americans,	otherwise	499	
monomorphic)	and	is	not	present	in	the	HapMap	reference	panel61.	To	assess	the	accuracy	of	500	
imputation	for	this	low-frequent	variant,	we	genotyped	rs138715366	in	the	Northern	Finland	Birth	501	
Cohort	(NFBC)	1966	(Supplementary	Table	1).	Of	the	5,009	samples	in	the	study,	4,704	were	502	
successfully	imputed	and	genotyped	(or	sequenced)	for	rs138715366.	The	overall	concordance	rate	503	
between	imputed	and	directly	assayed	genotypes	was	99.8%	and	for	directly	assayed	heterozygote	504	
calls	was	75.0%.		505	
	506	
Fine-mapping	analyses.	We	sought	to	leverage	LD	differences	between	populations	contributing	to	507	
the	trans-ancestry	meta-analysis	and	to	take	advantage	of	the	improved	coverage	of	common	and	508	
low-frequency	variation	offered	by	1000G	or	1000G	and	UK10K	combined	imputation	to	localise	509	
variants	driving	each	distinct	association	signal	achieving	locus-wide	significance.	For	each	distinct	510	
signal,	we	used	MANTRA62	to	construct	99%	credible	sets	of	variants63	that	together	account	for	99%	511	
of	the	posterior	probability	of	driving	the	association.	MANTRA	incorporates	a	prior	model	of	512	
relatedness	between	studies,	based	on	mean	pair-wise	allele	frequency	differences	across	loci,	to	513	
account	for	heterogeneity	in	allelic	effects	(Supplementary	Table	3).	MANTRA	has	been	514	
demonstrated,	by	simulation,	to	improve	localisation	of	causal	variants	compared	with	either	a	515	
fixed-	or	random-effects	trans-ancestry	meta-analysis62,64.			516	
For	loci	with	only	one	signal	of	association,	we	used	MANTRA	to	combine	summary	statistics	517	
from	the	six	non-European	GWAS	and	the	two	European	ancestry	components.	However,	for	loci	518	
with	multiple	distinct	association	signals,	we	used	MANTRA	to	combine	summary	statistics	from	519	
approximate	conditioning	for	the	two	European	components,	separately	for	each	signal.	520	
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For	each	distinct	signal,	we	calculated	the	posterior	probability	that	the	jth	variant,	πCj,	is	521	
driving	the	association,	given	by	522	
	523	 𝜋!! = !!!!! ,	524	
	525	
where	the	summation	is	over	all	variants	mapping	within	the	(conditional)	meta-analysis	across	the	526	
locus.	In	this	expression,	Λj	is	the	Bayes’	factor	(BF)	in	favour	of	association	from	the	MANTRA	527	
analysis.	A	99%	credible	set63	was	then	constructed	by:	(i)	ranking	all	variants	according	to	their	BF,	528	
Λj;	and	(ii)	including	ranked	variants	until	their	cumulative	posterior	probability	exceeds	0.99.	529	
	530	
Genomic	annotation.	We	used	genomic	annotations	of	DNaseI	hypersensitive	sites	(DHS)	from	the	531	
ENCODE65	project	and	protein	coding	genes	from	GENCODE66.	We	filtered	cell	types	that	are	cancer	532	
cell	lines	(karyotype	‘cancer’	from	https://genome.ucsc.edu/ENCODE/cellTypes.html),	and	merged	533	
data	from	multiple	samples	from	the	same	cell	type.	This	resulted	in	128	DHS	cell-type	annotations,	534	
as	well	as	4	gene-based	annotations	(coding	exon,	5UTR,	3UTR	and	1kb	upstream	of	TSS).	First,	we	535	
tested	for	the	effect	of	each	cell	type	DHS	and	gene	annotation	individually	using	the	Bayes’	factors	536	
for	all	variants	in	the	62	credible	sets	using	fgwas67.	Second,	we	categorised	the	annotations	into	537	
‘genic’,	‘foetal	DHS’,	‘embryonic	DHS’,	‘stem	cell	DHS’,	‘neonatal	DHS’	and	‘adult	DHS’	based	on	the	538	
description	fields	from	ENCODE,	and	tested	for	the	effect	of	each	category	individually	as	described	539	
above	using	fgwas.	Third,	we	then	tested	the	effect	of	each	category	by	including	all	categories	in	a	540	
joint	model	using	fgwas.	For	each	of	the	three	analyses,	we	obtained	the	estimated	effects	and	95%	541	
confidence	intervals	(CI)	for	each	annotation,	and	considered	an	annotation	enriched	if	the	95%	CI	542	
did	not	overlap	zero.		543	
	544	
Estimation	of	genetic	variance	explained.	Variance	explained	was	calculated	using	the	REML	545	
method	implemented	in	GCTA68.	We	considered	the	variance	explained	by	two	sets	of	SNPs:	(i)	lead	546	
SNPs	of	all	62	distinct	association	signals	at	the	59	established	and	novel	autosomal	BW	loci	547	
identified	in	the	European-specific	or	trans-ancestry	meta-analyses;	(ii)	lead	SNPs	of	55	distinct	548	
association	signals	at	the	52	novel	autosomal	BW	loci	(Extended	Data	Table	1a	and	Supplementary	549	
Table	7).	Variance	explained	was	calculated	in	samples	of	European	ancestry	in	the	Hyperglycemia	550	
and	Adverse	Pregnancy	Outcome	(HAPO)	study69	(independent	of	the	meta-analysis)	and	two	studies	551	
that	were	part	of	the	European	ancestry	meta-analysis:	NFBC1966	and	Generation	R	552	
(Supplementary	Table	1).	In	each	study,	the	genetic	relationship	matrix	was	estimated	for	each	set	553	
of	SNPs	and	was	tested	individually	against	BW	(males	and	females	combined)	with	study	specific	554	
covariates.	These	analyses	provided	an	estimate	and	standard	error	for	the	variance	explained	by	555	
each	of	the	given	sets	of	SNPs.	556	
	557	
Examining	the	relative	effects	on	BW	of	maternal	and	foetal	genotype	at	the	60	identified	loci.	We	558	
performed	four	sets	of	analyses.		559	
First,	we	used	GWAS	data	from	4,382	mother-child	pairs	in	the	Avon	Longitudinal	Study	of	560	
Parents	and	Children	(ALSPAC)	study	to	fit	a	“maternal-GCTA	model”6	to	estimate	the	extent	to	561	
which	the	maternal	genome	might	influence	offspring	BW	independent	of	the	foetal	genome.	The	562	
m-GCTA	model	uses	genome-wide	genetic	similarity	between	mothers	and	offspring	to	partition	the	563	
phenotypic	variance	in	BW	into	components	due	to	the	maternal	genotype,	the	child’s	genotype,	the	564	
covariance	between	the	two	and	environmental	sources	of	variation.		565	
Second,	we	compared	associations	with	BW	of	the	foetal	versus	maternal	genotype	at	each	566	
of	the	60	BW	loci.	The	maternal	allelic	effect	on	offspring	BW	was	obtained	from	a	maternal	GWAS	567	
meta-analysis	of	68,254	European	mothers	from	the	EGG	Consortium	(n=19,626)7	and	the	UK	568	
Biobank	(n=48,628).	In	the	UK	Biobank,	mothers	were	asked	to	report	the	BW	of	their	first	child.	569	
Women	of	European	ancestry	with	genotype	data	available	in	the	May	2015	data	release	were	570	
included,	and	those	with	reported	BW	equivalent	to	<2.5	kg	or	>4.5	kg	were	excluded.	No	571	
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information	on	gestational	age	or	gender	of	child	was	available.	BW	of	first	child	was	associated	with	572	
maternal	factors	such	as	smoking	status,	BMI	and	height	in	the	expected	directions.	Of	the	68,254	573	
women	included	in	the	maternal	GWAS,	13%	were	mothers	of	individuals	included	in	the	current	574	
foetal	European	ancestry	GWAS,	and	a	further	approximately	45%	were	themselves	(with	their	own	575	
BW)	included	in	the	foetal	GWAS.		576	
Third,	we	additionally	conducted	analyses	in	12,909	mother-child	pairs	from	nine	577	
contributing	studies:	at	each	of	the	60	loci,	we	compared	the	effect	of	the	foetal	genotype	on	BW	578	
adjusted	for	sex	and	gestational	age,	with	and	without	adjustment	for	maternal	genotype.	We	579	
reciprocally	compared	the	association	between	the	maternal	genotype	and	BW	with	and	without	580	
adjustment	for	foetal	genotype.		581	
Fourth,	we	used	the	method	of	Zhang	et	al15	to	test	associations	between	BW	and	the	582	
maternal	untransmitted,	maternal	transmitted	and	inferred	paternal	transmitted	haplotype	score	of	583	
422	height	SNPs25,	30	SBP	SNPs13,14	and	84	T2D	SNPs24	in	5,201	mother-child	pairs	from	the	ALSPAC	584	
study.	585	
	586	
LD	Score	Regression.	The	use	of	LD	Score	regression	to	estimate	the	genetic	correlation	between	587	
two	traits/diseases	has	been	described	in	detail	elsewhere70.	Briefly,	“LD	Score”	is	a	measure	of	how	588	
much	genetic	variation	each	variant	tags;	if	a	variant	has	a	high	LD	Score	then	it	is	in	high	LD	with	589	
many	nearby	polymorphisms.	Variants	with	high	LD	Scores	are	more	likely	to	contain	more	true	590	
signals	and	hence	provide	more	chance	of	overlap	with	genuine	signals	between	GWAS.	The	LD	591	
score	regression	method	uses	summary	statistics	from	the	GWAS	meta-analysis	of	BW	and	the	other	592	
traits	of	interest,	calculates	the	cross-product	of	test	statistics	at	each	SNP,	and	then	regresses	the	593	
cross-product	on	the	LD	Score.	Bulik-Sullivan	et	al70	show	that	the	slope	of	the	regression	is	a	594	
function	of	the	genetic	covariance	between	traits:	595	
	596	
𝐸 𝑧!!𝑧!! = 𝑁!𝑁!𝜌!𝑀 𝑙! + 𝜌𝑁!𝑁!𝑁!	
where	Ni	is	the	sample	size	for	study	i,	ρg	is	the	genetic	covariance,	M	is	the	number	of	SNPs	in	the	597	
reference	panel	with	MAF	between	5%	and	50%,	lj	is	the	LD	score	for	SNP	j,	Ns	quantifies	the	number	598	
of	individuals	that	overlap	both	studies,	and	ρ	is	the	phenotypic	correlation	amongst	the	Ns	599	
overlapping	samples.	Thus,	if	there	is	sample	overlap	(or	cryptic	relatedness	between	samples),	it	600	
will	only	affect	the	intercept	from	the	regression	(i.e.	the	term	 !!!!!!!)	and	not	the	slope,	and	hence	601	
estimates	of	the	genetic	covariance	will	not	be	biased	by	sample	overlap.	Likewise,	population	602	
stratification	will	affect	the	intercept	but	will	have	minimal	impact	on	the	slope	(i.e.	intuitively	since	603	
population	stratification	does	not	correlate	with	linkage	disequilibrium	between	nearby	markers).	604	
Summary	statistics	from	the	GWAS	meta-analysis	for	traits	and	diseases	of	interest	were	605	
downloaded	from	the	relevant	consortium	website.	The	summary	statistics	files	were	reformatted	606	
for	LD	Score	regression	analysis	using	the	munge_sumstats.py	python	script	provided	on	the	607	
developer’s	website	(https://github.com/bulik/ldsc).	For	each	trait,	we	filtered	the	summary	608	
statistics	to	the	subset	of	HapMap	3	SNPs71,	as	advised	by	the	developers,	to	ensure	that	no	bias	was	609	
introduced	due	to	poor	imputation	quality.	Summary	statistics	from	the	European-specific	BW	meta-610	
analysis	were	used	because	of	the	variable	LD	structure	between	ancestry	groups.	Where	the	sample	611	
size	for	each	SNP	was	included	in	the	results	file	this	was	flagged	using	--N-col;	if	no	sample	size	was	612	
available	then	the	maximum	sample	size	reported	in	the	reference	for	the	GWAS	meta-analysis	was	613	
used.	SNPs	were	excluded	for	the	following	reasons:	MAF<0.01;	ambiguous	strand;	duplicate	rsID;	614	
non-autosomal	SNPs;	reported	sample	size	less	than	60%	of	the	total	available.	Once	all	files	were	615	
reformatted,	we	used	the	ldsc.py	python	script,	also	on	the	developers’	website,	to	calculate	the	616	
genetic	correlation	between	BW	and	each	of	the	traits	and	diseases.	The	European	LD	Score	files	617	
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that	were	calculated	from	the	1000G	reference	panel	and	provided	by	the	developers	were	used	for	618	
the	analysis.	Where	multiple	GWAS	meta-analyses	had	been	conducted	on	the	same	phenotype	(i.e.	619	
over	a	period	of	years),	the	genetic	correlation	with	BW	was	estimated	using	each	set	of	summary	620	
statistics	and	presented	in	Supplementary	Table	12.	The	phenotypes	with	multiple	GWAS	included	621	
height,	BMI,	waist-hip	ratio	(adjusted	for	BMI),	total	cholesterol,	triglycerides,	high	density	622	
lipoprotein	(HDL)	and	low	density	lipoprotein	(LDL).	The	estimate	of	the	genetic	correlation	between	623	
the	multiple	GWAS	meta-analyses	on	the	same	phenotype	were	comparable	and	the	later	GWAS	624	
had	a	smaller	standard	error	due	to	the	increased	sample	size,	so	only	the	genetic	correlation	625	
between	BW	and	the	most	recent	meta-analyses	were	presented	in	Fig.	2.	626	
In	the	published	GWAS	for	BP14	the	phenotype	was	adjusted	for	BMI.	Caution	is	needed	627	
when	interpreting	the	genetic	correlation	between	BW	and	BMI-adjusted	SBP	due	to	the	potential	628	
for	collider	bias72.	Since	BMI	is	associated	with	both	BP	and	BW,	it	is	possible	that	the	use	of	a	BP	629	
genetic	score	adjusted	for	BMI	might	bias	the	genetic	correlation	estimate	towards	a	more	negative	630	
value.	To	verify	that	the	inverse	genetic	correlation	with	BW	(rg=-0.26,	SE=0.05,	P=6.5x10-9)	was	not	631	
due	to	collider	bias	caused	by	the	BMI	adjustment	of	the	phenotype,	we	obtained	an	alternative	632	
estimate	using	UK	Biobank	GWAS	data	for	SBP	that	was	unadjusted	for	BMI	and	obtained	a	similar	633	
result	(rg=-0.22,	SE=0.03,	P=5.5x10-13).	The	SBP	phenotype	in	UK	Biobank	was	prepared	as	follows.	634	
Two	BP	readings	were	taken	at	assessment,	approximately	5	minutes	apart.	We	included	all	635	
individuals	with	an	automated	BP	reading	(taken	using	an	automated	Omron	BP	monitor).	Two	valid	636	
measurements	were	available	for	most	participants	(averaged	to	create	a	BP	variable,	or	637	
alternatively	a	single	reading	was	used	if	only	one	was	available).	Individuals	were	excluded	if	the	638	
two	readings	differed	by	more	than	4.56	SD.	BP	measurements	more	than	4.56	SD	away	from	the	639	
mean	were	excluded.	We	accounted	for	BP	medication	use	by	adding	15	mmHg	to	the	SBP	measure.	640	
BP	was	adjusted	for	age,	sex	and	centre	location	and	then	inverse	rank	normalised.	We	performed	641	
the	GWAS	on	127,698	individuals	of	British	descent	using	BOLT-LMM37,	with	genotyping	array	as	642	
covariate.	643	
	644	
Estimating	the	proportion	of	the	BW-adult	traits	covariance	attributable	to	genotyped	SNPs.	We	645	
estimated	the	phenotypic,	genetic	and	residual	correlations	as	well	as	the	genetic	and	residual	646	
covariance	between	BW	and	several	quantitative	traits/disease	outcomes	in	UK	Biobank	using	647	
directly	genotyped	SNPs	and	the	REML	method	implemented	in	BOLT-LMM37.	The	traits	examined	648	
included	T2D,	SBP,	diastolic	BP,	CAD,	height,	BMI,	weight,	waist-hip	ratio,	hip	circumference,	waist	649	
circumference,	obesity,	overweight,	age	at	menarche,	asthma,	and	smoking.	Where	phenotypes	650	
were	not	available	(e.g.	serum	blood	measures	are	not	currently	available	in	UK	Biobank),	we	651	
obtained	estimates	using	the	NFBC1966	study	(for	correlations/covariance	between	BW	and	652	
triglycerides,	total	cholesterol,	HDL,	LDL,	fasting	glucose	and	fasting	insulin).	In	the	UK	Biobank	653	
analysis,	we	used	57,715	unrelated	individuals	with	BW	available	and	identified	by	UK	Biobank	as	654	
white	British.	SNPs	with	evidence	of	deviation	from	Hardy-Weinberg	Equilibrium	(P<1x10-6),	655	
MAF<0.05	or	overall	missing	rate	>0.015	were	excluded,	resulting	in	328,928	SNPs	for	analysis.	We	656	
included	the	first	five	ancestry	principal	components	as	covariates.	In	the	NFBC1966	analysis,	5,009	657	
individuals	with	BW	were	enrolled.	Genotyped	SNPs	that	passed	quality	control	(Supplementary	658	
Table	2)	were	included,	resulting	in	324,895	SNPs	for	analysis.	The	first	three	ancestry	principal	659	
components	and	sex	were	included	as	covariates.	660	
	661	
Gene	set	enrichment	analysis.	Meta-Analysis	Gene-set	Enrichment	of	variaNT	Associations	662	
(MAGENTA)	was	used	to	explore	pathway-based	associations	using	summary	statistics	from	the	663	
trans-ancestry	meta-analysis.	MAGENTA	implements	a	gene	set	enrichment	analysis	(GSEA)	based	664	
approach,	as	previously	described9.	Briefly,	each	gene	in	the	genome	is	mapped	to	a	single	index	SNP	665	
with	the	lowest	P-value	within	a	110	kb	upstream	and	40	kb	downstream	window.	This	P-value,	666	
representing	a	gene	score,	is	then	corrected	for	confounding	factors	such	as	gene	size,	SNP	density	667	
and	LD-related	properties	in	a	regression	model.	Genes	within	the	HLA-region	were	excluded	from	668	
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analysis	due	to	difficulties	in	accounting	for	gene	density	and	LD	patterns.	Each	mapped	gene	in	the	669	
genome	is	then	ranked	by	its	adjusted	gene	score.	At	a	given	significance	threshold	(95th	and	75th	670	
percentiles	of	all	gene	scores),	the	observed	number	of	gene	scores	in	a	given	pathway,	with	a	671	
ranked	score	above	the	specified	threshold	percentile,	is	calculated.	This	observed	statistic	is	then	672	
compared	to	1,000,000	randomly	permuted	pathways	of	identical	size.	This	generates	an	empirical	673	
GSEA	P-value	for	each	pathway.	Significance	was	attained	when	an	individual	pathway	reached	a	674	
false	discovery	rate	(FDR)	<0.05	in	either	analysis.	In	total,	3,216	pre-defined	biological	pathways	675	
from	Gene	Ontology,	PANTHER,	KEGG	and	Ingenuity	were	tested	for	enrichment	of	multiple	modest	676	
associations	with	BW.	The	MAGENTA	software	was	also	used	for	enrichment	testing	of	custom	gene	677	
sets.	678	
	679	
Protein-Protein	interaction	network	analyses.	We	used	the	integrative	Protein-Interaction-680	
Network-Based	Pathway	Analysis	(iPINBPA)	method73.	Briefly,	we	generated	gene-wise	P-values	681	
from	the	trans-ancestry	meta-analysis	using	VEGAS274,	which	map	the	SNPs	to	genes	and	account	for	682	
possible	cofounders,	such	as	LD	between	markers.	The	empirical	gene-wise	P-values	are	calculated	683	
using	simulations	from	the	multivariate	normal	distribution.	Those	that	were	nominally	significant	684	
(P≤0.01)	were	selected	as	“seed	genes”,	and	were	collated	within	high	confidence	version	of	685	
inweb375,	to	weight	the	nodes	in	the	network	following	a	guilt-by-association	approach.	In	a	second	686	
step,	a	network	score	was	defined	by	the	combination	of	the	z-scores	derived	from	the	gene-wise	P-687	
values	with	node	weights	using	the	Liptak-Stouffer	method76.	A	heuristic	algorithm	was	then	applied	688	
to	extensively	search	for	modules	enriched	in	genes	with	low	P-values.	The	modules	were	further	689	
normalised	using	a	null	distribution	of	10,000	random	networks.	Only	those	modules	with	z-score	>5	690	
were	selected.	Finally,	the	union	of	all	modules	constructed	a	BW-overall	PPI	network.	Both	the	691	
proteins	on	the	individual	modules	and	on	the	overall	BW-PPI	were	interrogated	for	enrichment	in	692	
Gene	Ontology	Terms	(Biological	Processes)	using	a	Hypergeometric	test.	Terms	were	considered	as	693	
significant	when	adjusted	P-value,	following	Benjamini-Hochberg	procedure,	was	below	0.05.	694	
	695	
Point	of	contact	(PoC)	analyses.	The	same	methodology	described	above	was	applied	to	16	different	696	
adult	traits	resulting	in	a	number	of	enriched	modules	per	trait.	Different	modules	for	each	trait	697	
were	combined	in	a	single	component	and	the	intersection	between	these	trait-specific	components	698	
and	the	BW	component	was	calculated.	This	intersection	is	defined	as	the	PoC	network.	We	used	the	699	
resulting	PoC	networks	in	downstream	analyses	to	interrogate	which	set	of	proteins	connects	BW	700	
variation	and	adult	trait	variation	via	pathways	enriched	in	the	overall	BW	analysis.	701	
	702	
Parent-of-origin	specific	associations.	We	first	searched	for	evidence	of	parent	of	origin	effects	in	703	
the	UK	Biobank	samples	by	comparing	variance	between	heterozygotes	and	homozygotes	using	704	
Quicktest77.	In	this	analysis,	we	used	only	unrelated	individuals	identified	genetically	as	of	white	705	
British	origin	(n=57,715).	Principal	components	were	generated	using	these	individuals	and	the	first	706	
five	were	used	to	adjust	for	population	structure	as	covariates	in	the	analysis,	in	addition	to	a	binary	707	
indicator	for	genotyping	array.	708	
We	also	examined	4,908	mother-child	pairs	in	ALSPAC	and	determined	the	parental	origin	of	709	
the	alleles	where	possible78.	Briefly,	the	method	uses	mother-child	pairs	to	determine	the	parent	of	710	
origin	of	each	allele.	For	example,	if	the	mother/child	genotypes	are	AA/Aa,	the	child’s	711	
maternal/paternal	allele	combination	is	A/a.	For	the	situation	where	both	mother	and	child	are	712	
heterozygous,	the	child’s	maternal/paternal	alleles	cannot	be	directly	specified.	However,	the	713	
parental	origin	of	the	alleles	can	be	determined	by	phasing	the	genotype	data	and	comparing	714	
maternal	and	child	haplotypes.	We	then	tested	these	alleles	for	association	with	BW	adjusting	for	715	
sex	and	gestational	age.		716	
Statistical	power	in	these	currently	available	sample	sizes	is	insufficient	to	rule	out	717	
widespread	parent-of-origin	effects	across	the	regions	tested.	Using	the	mean	beta	(0.034	SD)	and	718	
MAF	(0.28)	of	the	identified	loci,	we	estimate	that	we	would	need	at	least	200,000	unrelated	719	
	 22	
individuals	or	70,000	mother-child	pairs	for	80%	power	to	detect	parent-of-origin	effects	at	720	
P<0.00085.	721	
	722	
Hierarchical	clustering	of	BW	loci.	To	explore	the	different	patterns	of	association	between	BW	and	723	
other	anthropometric/metabolic/endocrine	traits	and	diseases,	we	performed	hierarchical	clustering	724	
analysis.	The	lead	SNP	(or	proxy,	EUR	r2>0.6)	at	the	60	BW	loci	was	queried	in	publicly	available	725	
GWAS	meta-analysis	datasets	or	in	GWAS	result	obtained	through	collaboration79.	Results	were	726	
available	for	53	of	those	loci	and	the	extracted	z-score	(allelic	effect/SE,	Supplementary	Table	17)	727	
was	aligned	to	the	BW-raising	allele.	We	performed	two	dimensional	clustering	by	trait	and	by	locus.	728	
We	computed	the	Euclidean	distance	amongst	z-scores	of	the	extracted	traits/loci	and	performed	729	
complete	hierarchical	clustering	implemented	in	the	pvclust	package	(http://www.sigmath.es.osaka-730	
u.ac.jp/shimo-lab/prog/pvclust/)	in	R	v3.2.0	(http://www.R-project.org/).	Clustering	uncertainty	was	731	
measured	by	multiscale	bootstrap	resampling	estimated	from	1,000	replicates.	We	used	α=0.05	to	732	
define	distinct	clusters	and,	based	on	the	bootstrap	analysis,	calculated	the	Calinski	index	to	identify	733	
the	number	of	well-supported	clusters	(cascadeKM	function,	Vegan	package,	http://CRAN.R-734	
project.org/package=vegan).	Clustering	was	visualised	by	constructing	dendrograms	and	a	heatmap.	735	
	 Separately	from	the	hierarchical	clustering	analysis,	we	queried	the	lead	SNP	at	EPAS1	in	a	736	
GWAS	of	haematological	traits80	because	variation	at	that	locus	has	previously	been	implicated	in	737	
BW	and	adaptation	to	hypoxia	at	high	altitudes	in	Tibetans81,82	(Supplementary	Table	17).	738	
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EXTENDED	DATA	LEGENDS	
	
Extended	Data	Figure	1	|	Flow	chart	of	the	study	design.	
	
Extended	Data	Figure	2	|	Manhattan	and	quantile-quantile	(QQ)	plots	of	the	trans-ancestry	meta-
analysis	for	birth	weight.	a,	Manhattan	(main	panel)	and	QQ	(top	right)	plots	of	genome-wide	
association	results	for	BW	from	trans-ancestry	meta-analysis	of	up	to	153,781	individuals.	The	
association	P-value	(on	-log10	scale)	for	each	of	up	to	22,434,434	SNPs	(y	axis)	is	plotted	against	the	
genomic	position	(NCBI	Build	37;	x	axis).	Association	signals	that	reached	genome-wide	significance	
(P<5x10-8)	are	shown	in	green	if	novel	and	pink	if	previously	reported.	In	the	QQ	plot,	the	black	dots	
represent	observed	P-values	and	the	grey	line	represents	expected	P-values	under	the	null	
distribution.	The	red	dots	represent	observed	P-values	after	excluding	the	previously	identified	
signals5.	b,	Manhattan	(main	panel)	and	QQ	(top	right)	plots	of	trans-ethnic	GWAS	meta-analysis	for	
BW	highlighting	the	reported	imprinted	regions	described	in	Supplementary	Table	14.	Novel	
association	signals	that	reached	genome-wide	significance	(P<5x10-8)	and	mapped	to	imprinted	
regions	are	shown	in	green.	Genomic	regions	outside	imprinted	regions	are	shaded	in	grey.	SNPs	in	
the	imprinted	regions	are	shown	in	light	blue	or	dark	blue,	depending	on	chromosome	number	(odd	
or	even).	In	the	QQ	plot,	the	black	dots	represent	observed	P	values	and	the	grey	lines	represent	
expected	P-values	and	their	95%	confidence	intervals	under	the	null	distribution	for	the	SNPs	within	
the	imprinted	regions.	
	
Extended	Data	Figure	3	|	Regional	plots	for	multiple	distinct	signals	at	three	birth	weight	loci,	
ZBTB7B	(a),	HMGA1	(b)	and	PTCH1	(c).	Regional	plots	for	each	locus	are	displayed	from:	the	
unconditional	European-specific	meta-analysis	of	up	to	143,677	individuals	(left);	the	approximate	
conditional	meta-analysis	for	the	primary	signal	after	adjustment	for	the	index	variant	for	the	
secondary	signal	(middle);	and	the	approximate	conditional	meta-analysis	for	the	secondary	signal	
after	adjustment	for	the	index	variant	for	the	primary	signal	(right).	Directly	genotyped	or	imputed	
SNPs	are	plotted	with	their	association	P-values	(on	a	-log10	scale)	as	a	function	of	genomic	position	
(NCBI	Build	37).	Estimated	recombination	rates	(blue	lines)	are	plotted	to	reflect	the	local	LD	
structure	around	the	index	SNPs	and	their	correlated	proxies.	SNPs	are	coloured	in	reference	to	LD	
with	the	particular	index	SNP	according	to	a	blue	to	red	scale	from	r2	=	0	to	1,	based	on	pairwise	r2	
values	estimated	from	a	reference	of	5,000	individuals	of	white	British	origin,	randomly	selected	
from	the	UK	Biobank.				
	
Extended	Data	Figure	4	|	Comparison	of	foetal	effect	sizes	and	maternal	effect	sizes	at	60	known	
and	novel	birth	weight	loci	(continues	to	Extended	Data	Figure	5).	For	each	BW	locus,	the	following	
six	effect	sizes	(with	95%	CI)	are	shown,	all	aligned	to	the	same	BW-raising	allele:	foetal_GWAS	=	
foetal	allelic	effect	on	BW	(from	European	ancestry	meta-analysis	of	up	to	n=143,677	individuals);	
foetal_unadjusted	=	foetal	allelic	effect	on	BW	(unconditioned	in	n=12,909	mother-child	pairs);	
foetal_adjusted	=	foetal	effect	(conditioned	on	maternal	genotype,	n=12,909);	maternal_GWAS	=	
maternal	allelic	effect	on	offspring	BW	(from	meta-analysis	of	up	to	n=68,254	European	mothers)7;	
maternal_unadjusted	=	maternal	allelic	effect	on	offspring	BW	(unconditioned,	n=12,909);	
maternal_adjusted	=	maternal	effect	(conditioned	on	foetal	genotype,	n=12,909).	The	60	BW	loci	
are	ordered	by	chromosome	and	position	(Supplementary	Tables	10,	11).	These	plots	illustrate	that	
in	large	GWAS	of	BW,	foetal	effect	size	estimates	are	larger	than	those	of	maternal	at	55/60	
identified	loci	(binomial	P=1x10-11),	suggesting	that	most	of	the	associations	are	driven	by	the	foetal	
genotype.	In	conditional	analyses	that	modelled	the	effects	of	both	maternal	and	foetal	genotypes	
(n=12,909	mother-child	pairs),	confidence	intervals	around	the	estimates	were	wide,	precluding	
inference	about	the	likely	contribution	of	maternal	vs.	foetal	genotype	at	individual	loci.		
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Extended	Data	Figure	5	|	Comparison	of	foetal	effect	sizes	and	maternal	effect	sizes	at	60	known	
and	novel	birth	weight	loci.	a,	Continued	from	Extended	Data	Figure	4.	b,	The	scatterplot	illustrates	
the	difference	between	the	foetal	(x	axis)	and	maternal	(y	axis)	effect	sizes	in	the	overall	maternal	vs.	
foetal	GWAS	results.	
	
Extended	Data	Figure	6	|	Protein-Protein	Interaction	(PPI)	Network	analysis.	a,	Illustrates	the	
largest	global	component	of	birth	weight	(BW)	PPI	network	containing	13	modules.	b,	The	histogram	
shows	the	null	distribution	of	z-scores	of	BW	PPI	networks	based	on	10,000	random	networks,	and	
where	the	z-scores	for	the	13	BW	modules	(M1-13)	lie.	For	each	module,	the	two	most	significant	
GO	terms	are	depicted.	c,	Illustrates	a	heatmap	which	takes	the	top	50	biological	processes	over-
represented	in	the	global	BW	PPI	network	(listed	at	the	right	of	the	plot),	and	displays	extent	of	
enrichment	for	the	various	trait-specific	“point	of	contact“	(PoC)	PPI	networks.	d-e,	Trait-specific	PoC	
PPI	networks	composed	of	proteins	that	are	shared	in	both	the	global	BW	PPI	network	and	networks	
generated	using	the	same	pipeline	for	each	of	the	adult	traits:	d,	canonical	Wnt	signalling	pathway	
enriched	for	PoC	PPI	between	BW	and	blood	pressure	(BP)-related	phenotypes;	and	e,	regulation	of	
insulin	secretion	pathway	enriched	for	PoC	between	BW	and	type	2	diabetes	(T2D)/fasting	glucose	
(FG).	Red	nodes	are	those	that	are	present	in	PoC	for	BW	and	traits	of	interest;	blue	nodes	
correspond	to	the	pathway	nodes;	purple	nodes	are	those	present	in	both	the	pathway	and	PoC;	
orange	nodes	are	genes	in	BW	loci	that	overlap	with	both	the	pathway	and	PoC.	Large	nodes	
correspond	to	genes	in	BW	loci	(within	300kb	from	the	lead	SNP),	and	have	black	border	if	they,	
amongst	all	BW	loci,	have	a	stronger	(top	5)	association	with	at	least	one	of	the	pairing	adult	traits.		
	
Extended	Data	Figure	7	|	Quantile-Quantile	(QQ)	plots	of	(a)	variance	comparison	between	
heterozygotes	and	homozygotes	analysis	in	57,715	UK	Biobank	samples	and	(b)	parent-of-origin	
specific	analysis	in	4,908	ALSPAC	mother-child	pairs	at	59	autosomal	birth	weight	loci	plus	DLK1.	a,	
QQ	plot	from	the	Quicktest77	analysis	comparing	the	BW	variance	of	heterozygotes	with	
homozygotes	in	57,715	UK	Biobank	samples.	b,	QQ	plot	from	the	parent-of-origin	specific	analysis	
testing	the	association	between	BW	and	maternally	transmitted	vs.	paternally	transmitted	alleles	in	
4,908	mother-child	pairs	from	the	ALSPAC	study	(Methods,	Supplementary	Tables	15,	16).	In	both	
panels,	the	black	dots	represent	lead	SNPs	at	59	identified	autosomal	BW	loci	and	a	further	sub-
genome-wide	significant	signal	for	BW	near	DLK1	(rs6575803;	P=5.6x10-8).	The	grey	lines	represent	
expected	P	values	and	their	95%	confidence	intervals	under	the	null	distribution	for	the	60	SNPs.	
Both	results	show	trends	in	favour	of	imprinting	effects	at	BW	loci:	however,	despite	the	large	
sample	size,	these	analyses	were	underpowered	(see	Methods)	and	much	larger	sample	sizes	are	
required	for	definitive	analysis.	
	
Extended	Data	Figure	8	|	Summary	of	previously	reported	loci	for	systolic	blood	pressure	(SBP,	a),	
coronary	artery	disease	(CAD,	b,	e),	type	2	diabetes	(T2D,	c,	f)	and	adult	height	(d)	and	their	effect	
on	birth	weight.	a-d,	Effect	sizes	(left	y	axis)	of	previously	reported	30	SBP	loci13,14,	45	CAD	loci23,	84	
T2D	loci24	and	422	adult	height	loci25	are	plotted	against	effects	on	BW	(x	axis).	Effect	sizes	are	
aligned	to	the	adult	trait-raising	allele.	The	colour	of	each	dot	indicates	BW	association	P	value:	red,	
P<5×10−8;	orange,	5×10−8≤P<0.001;	yellow,	0.001≤P<0.01;	white,	P≥0.01.	The	superimposed	grey	
frequency	histogram	shows	the	number	of	SNPs	(right	y	axis)	in	each	category	of	BW	effect	size.	e,	
Effect	sizes	(with	95%	CI)	on	BW	of	45	known	CAD	loci	are	plotted	arranged	in	the	order	of	CAD	
effect	size	from	highest	to	lowest,	separating	out	the	known	SBP	loci.	CAD	loci	with	a	larger	effect	on	
BW	concentrated	amongst	loci	with	primary	BP	association.	f,	Effect	sizes	(with	95%	CI)	on	BW	of	32	
known	T2D	loci	are	plotted,	subdivided	by	previously	reported	categories	derived	from	detailed	
adult	physiological	data27.	Heterogeneity	in	BW	effect	sizes	between	five	T2D	loci	groups	with	
different	mechanistic	categories	was	substantial	(Phet=1.2x10-9).	In	pairwise	comparisons,	the	“beta	
cell”	group	of	variants	differed	from	the	other	four	groups:	fasting	hyperglycaemia	(Phet	=3x10-11),	
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insulin	resistance	(Phet	=0.002),	proinsulin	(Phet	=0.78)	and	unclassified	(Phet	=0.02)	groups.	All	of	the	
BW	effect	sizes	plotted	in	the	forest	plots	are	aligned	to	the	trait	(or	risk)-raising	allele.	
	
Extended	Data	Table	1	|	Sixty	loci	associated	with	birth	weight	(P<5x10-8)	in	European	ancestry	
meta-analysis	of	up	to	143,677	individuals	and/or	trans-ancestry	meta-analysis	of	up	to	153,781	
individuals.	a,	Effects	(beta	values)	are	aligned	to	the	BW-raising	allele.	EAF	was	obtained	from	the	
trans-ancestry	meta-analysis,	except	for	PLAC1,	for	which	the	EAF	was	obtained	from	the	European	
ancestry	meta-analysis	due	to	lack	of	X	chromosome	data	from	the	non-European	studies.	Chr.,	
chromosome;	bp,	base	pair;	EAF,	effect	allele	frequency;	SE,	standard	error.	b,	The	effect	of	the	lead	
SNP	(absolute	value	of	beta,	y	axis)	is	given	as	a	function	of	minor	allele	frequency	(x	axis)	for	60	
known	(pink)	and	novel	(green)	BW	loci	from	the	trans-ancestry	meta-analysis.	Error	bars	are	
proportional	to	the	standard	error	of	the	effect	size.	The	dashed	line	indicates	80%	power	to	detect	
association	at	genome-wide	significance	level	for	the	sample	size	in	trans-ancestry	meta-analysis.	
	
Extended	Data	Table	2	|	Gene	set	enrichment	analysis	and	protein-protein	interaction	(PPI)	
analysis.	Two	complementary	analyses	of	the	overall	GWAS	summary	data	identified	enrichment	of	
BW	associations	in	biological	pathways	related	to	metabolism,	growth	and	development.	a,	The	top	
results	(FDR<0.05	at	the	95th	percentile	enrichment	threshold)	from	a	total	of	3,216	biological	
pathways	tested	for	enrichment	of	multiple	modest	associations	with	BW.	Additionally,	results	are	
presented	for	custom	sets	of	imprinted	genes.	b,	The	results	of	a	complementary	analysis	of	
empirical	PPI	data,	displaying	the	top	10	most	significant	pathways	enriched	for	BW-association	
scores.		
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Supplementary Table 1. Description of studies contributing to trans-ancestry meta-analysis: ancestry group and country of origin, sample 
size, data collection methods, and birth weight summaries and exclusions. 
 
(a) Component 1: European ancestry GWAS 
 
Study Ancestry 
group 
Country of 
origin 
Year(s) of 
birth 
Sample size 
(M/F) 
Data collection Phenotype 
exclusions 
Mean (SD) birth weight (grams) Median (IQR) 
GA (week) at 
delivery 
Males Females Combined 
1958 British 
Birth Cohort 
European UK 1958 4,595 
(2,320/2,275) 
Measured by midwives; supplemented 
with obstetric records and interviews 
with mothers 
Multiple births, GA 
<37 weeks 
3439 
(484) 
3277 
(468) 
3359 
(483) 
40 (39-41) 
ALSPACa,b European UK ~1992 7,285 
(3,722/3,563) 
Identified from obstetric data, records 
from the ALSPAC measurers, and birth 
notification 
Multiple births,  GA 
<37 weeks, 5 SD 
winsorisation 
3553 
(491) 
3423 
(450) 
3490 
(476) 
40 (40-41) 
CHOP-Caucasian European USA 1988-present 9,405 
(5,040/4,365) 
Questionnaire and medical records Multiple births, GA 
<37 weeks (when 
available) 
3447 
(582) 
3343 
(549) 
3398  
(569) 
N/A 
CoLaus European Switzerland 1928-1970 2,089 
(892/1,197) 
Self-reported as adults N/A 3490 
(668) 
3250 
(661) 
3352 
(675) 
N/A 
COPSAC-2000 European Denmark 1998-2001 352 
(173/179) 
Medical records Multiple births, GA 
<37 weeks 
N/A N/A 3555 
(485) 
40 (39-41) 
COPSAC-2010 European Denmark 2008-2011 589 
(306/283) 
Medical records Multiple births, GA 
<37 weeks 
3635 
(483) 
3536 
(474) 
3588 
(481) 
40 (39-41) 
COPSAC-
REGISTRY 
European Denmark 1987-1999 1,210 
(804/406) 
Medical Records Multiple births, GA 
<37 weeks 
3609 
(498) 
3443 
(447) 
3553 
(488) 
40 (39-41) 
DNBC European Denmark 1996-2003 915 
(475/440) 
Danish Medical Birth Register Multiple births, GA 
<37 weeks, 
congenital 
abnormalities 
3767 
(480) 
3625 
(443) 
3699 
(468) 
40 (40-41) 
ERF European Netherlands Various 459 
(187/272) 
Interview GA <37 weeks 3161 
(680) 
2955 
(608) 
3039 
(644) 
N/A 
EPIC European UK 1993-1997 8,939 
(3,448/5,491) 
Self-reported N/A 3505 
(786) 
3266 
(750) 
3358 
(772) 
N/A 
Fenland (GA+) European UK 1950-1975 5,188 
(2,088/3,100) 
Self-reported as adults  GA described as 
"very pre-term" or 
"pre-term" 
3433 
(638) 
3260 
(594) 
3394  
(555) 
N/A 
Fenland (GA-) European UK 1950-1975 833 
(509/324) 
Self-reported as adults  None 3465 
(593) 
3154 
(608) 
3354 
(624) 
N/A 
Generation R European Netherlands 2002-2006 2,701 
(1,378/1,323) 
Hospital records and community 
midwives 
Multiple births, GA 
<37 weeks 
3628 
(494) 
3518 
(475) 
3574 
(488) 
40 (39-41) 
GINIplus & 
LISAplus (GA+) 
European Germany 1996-1999 656 
(360/296) 
Parental report of medical records  Multiple births, GA 
<37 weeks, <2500g 
3498 
(406) 
3376 
(417) 
3443 
(415) 
40 (39-41) 
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Study Ancestry 
group 
Country of 
origin 
Year(s) of 
birth 
Sample size 
(M/F) 
Data collection Phenotype 
exclusions 
Mean (SD) birth weight (grams) Median (IQR) 
GA (week) at 
delivery 
Males Females Combined 
GINIplus & 
LISAplus (GA-) 
European Germany 1996-1999 790 
(391/399) 
Parental report of medical records  Multiple births, GA 
<37 weeks, <2500g 
3499 
(429) 
3348 
(423) 
3423 
(433) 
N/A 
GOYA European Denmark 1943-1952 149/0 (obese), 
141/0 (control) 
School health records N/A N/A N/A 3553 
(711) 
N/A 
HBCS European Finland 1934-1944 1472 
(639/833) 
Birth records Multiple births, GA 
<37 weeks 
3536 
(460) 
3375 
(439) 
3444 
(454) 
40 (39-41) 
INMA European Spain 1997-2006 1,021 
(527/494) 
Well-trained midwives and nurses  None 3362 
(406) 
3188 
(422) 
3278  
(423) 
40 (39-41) 
INTER99 European Denmark 1939-1969 4,243 
(1,981/2,262) 
Measured by midwives and obtained 
from obstetric record registry 
Multiple births, GA 
<37 weeks 
3505 
(493) 
3370 
(469) 
3433 
(485) 
N/A 
Leipzig European Germany 1985 - 2010 597 (304/293) Questionnaire to mothers, 
documentation of medical screening 
examination if available 
 GA <37 weeks 
3573 
(531) 
3480 
(538) 
3527 
(536) 
40 (39-40) 
NEO European Netherlands  1943-1963 504 (exact; 
200/304), 3215 
(range; 
1,450/1,765) 
Questionnaire N/A 3669 
(1068) 
3236 
(973) 
3514  
(1271) 
N/A 
NFBC1966 European Finland 1966 5,009 
(2,393/2,616) 
Measured in hospitals Multiple births, GA 
<37 weeks or 
unknown 
3607 
(506) 
3480 
(466) 
3541 
(489) 
40 (39-41) 
NFBC1986 European Finland 1986 4,680 
(2,306/2,374) 
Measured in hospitals Multiple births, GA 
<37 weeks or 
unknown 
3626 
(543) 
3519 
(521) 
3572 
(535) 
40 (39-40) 
NTR European Netherlands 1926-1998 1,265 
(447/818) 
Parental report or self-reported Multiple births, GA 
<37 weeks 
3414 
(619) 
3544 
(630) 
3343 
(601) 
40 (40-40) 
ORCADES European Scotland 1920-1991 960 
(330/630) 
Self-reported as adults N/A 3401 
(607) 
3654 
(685) 
3488 
(640) 
N/A 
PANIC European Finland 1999-2002 436 
(231/205) 
Medical records and parental 
questionnaire  
Multiple births, GA 
<37 weeks 
3646 
(488) 
3528 
(444) 
3588  
(474) 
40 (39-41) 
RAINE European Australia 1989-1991 1,347 
(693/654) 
Recorded at delivery by study personnel 
or obtained from hospital reports  
Multiple births, GA 
<37 weeks 
3505 
(471) 
3390 
(462) 
3449 
(470) 
40 (39-41) 
SORBS European Germany 1925-1988 298 
(113/185) 
Interview at recruitment N/A N/A N/A 3393 
(673) 
N/A 
STRIP European Finland 1989-1991 599 
(311/288) 
Medical records Multiple births, GA 
<37 weeks 
3696 
(471) 
3535 
(443) 
3619 
(465) 
40 (39-40) 
TEENAGE (GA+) European Greece 1993-1998 279 
(126/153)  
Measured by midwives or paediatricians; 
supplemented with data from mothers’ 
interviews 
GA <37 weeks 3403 
(467) 
3280 
(421) 
3336 
(445) 
40 (38-40) 
TEENAGE (GA-) European Greece 1993-1998 551 
(234/317) 
Measured by midwives or paediatricians; 
supplemented with data from mothers’ 
interviews 
N/A 3398 
(459) 
3298 
(438) 
3341 
(449) 
N/A 
TDCOB-cases European Denmark 1987-2007 669 Measured by midwives and registered in Multiple births 3682 3629 3660 40 (39-41) 
 5 
(391/278) Danish Civil Registry (536) (545) (540) 
TDCOB-controls European Denmark 1991-2006 560 
(211/349) 
Measured by midwives and registered in 
Danish Civil Registry 
Multiple births 3627 
(517) 
3483 
(485) 
3540 
(502) 
40 (39-41) 
YFS European Finland 1962-1977 1,915 
(861/1,054) 
Mothers’ interview Multiple births, GA 
>3 weeks pre-term 
3648 
(491) 
3510 
(451) 
3572 
(475) 
N/A 
 
(b) Component 2: UK BioBank 
 
Study Ancestry 
group 
Country of 
origin 
Year(s) of 
birth 
Sample size 
(M/F) 
Data collection Phenotype exclusions Mean (SD) birth weight (grams) Median (IQR) 
GA (weeks) at 
delivery 
Males Females Combine
d 
UK BioBank European UK 2006-2010 67,786 
(40,425/27,361) 
Self-reported as adults Multiple births, birth 
weight <2500g or >4000g 
3452 
(416) 
3349 
(417) 
3391 
(420) 
N/A 
 
(c) Component 3: Non-European ancestry GWAS 
 
Study Ancestry 
group 
Country of 
origin 
Year(s) of 
birth 
Sample size 
(M/F) 
Data collection Phenotype exclusions Mean (SD) birth weight (grams) Median (IQR) 
GA (weeks) at 
delivery 
Males Females Combined 
CHOP-AA African 
American 
USA 1988-present 6,635 
(3,343/3,292) 
Questionnaire and medical records Multiple births, GA 
<37 weeks (when 
available) 
3276 
(554) 
3184 
(535) 
3231 
(546) 
N/A 
CLHNS Filipino Philippines 1983-84 1,449 
(755/694) 
Local birth attendants Multiple births, GA 
<37 weeks 
3067 
(401) 
3018 
(403) 
3043 
(403) 
40 (38-40) 
Generation R 
Turkish 
Turkish Netherlands 2002-2006 420 
(215/205) 
Hospital records and community 
midwives 
Multiple births, GA 
<37 weeks 
3477 
(500) 
3369 
(415) 
3424 
(463) 
40 (39-41) 
Generation R 
Moroccan 
Moroccan Netherlands 2002-2006 365 
(188/177) 
Hospital records and community 
midwives 
Multiple births, GA 
<37 weeks 
3642 
(447) 
3417 
(344) 
3533 
(416) 
41 (40-41) 
Generation R 
Surinamese 
Surinamese Netherlands 2002-2006 395 
(215/180) 
Hospital records and community 
midwives 
Multiple births, GA 
<37 weeks 
3288 
(556) 
3130 
(490) 
3216 
(532) 
40 (39-41) 
SCORM Chinese Singapore 1992-1995 840 
(420/420) 
Documented medical record booklet GA <37 weeks 3229 
(422) 
3182 
(475) 
3205 
(450) 
39 (38-40) 
 
M, Males; F, Females; GA, gestational age; IQR, interquartile range; N/A, not applicable; SD, standard deviation. 
aBoyd A, Golding J, Macleod J, Lawlor DA, Fraser A, et al. Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and 
Children. Int J Epidemiol 42, 111-127 (2013).  
bThe study website contains details of all the data that is available through a fully searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-access/data-
dictionary/). 
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Supplementary Table 2. Description of studies contributing to trans-ancestry meta-analysis: genotyping, quality control, pre-phasing, 
imputation, and association analysis. 
(a) Component 1: European ancestry GWAS 
Study Genotyping 
array(s)a 
Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
(M/F) Call rate Additional filters Call rate HWE 
P-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
1958 British 
Birth Cohort 
I550, I610 None Relatedness, ancestry outliers, 
sex discrepancy, identity, 
channel contrast  
95% 1x10-4 MAF<1% MaCH Minimac 1000G   
Mar 2012 
ProbABEL GA 1.01/1.00 
ALSPAC I550 97% Heterozygosity, relatedness, 
ancestry outliers 
95% 5×10-7 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC7 1.02/1.01 
CHOP-
Caucasian 
I550, I610 95% Relatedness, ancestry outliers, 
sex discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-3 0.96/0.96 
CoLaus A5 90% Relatedness, ancestry outliers 90% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
In-house None 0.99/1.00 
COPSAC-2000 I550  97.5% Heterozygosity, relatedness, 
ancestry outliers 
98% 1x10-6 MAF<0.1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA 1.00/1.01 
COPSAC-2010 IOEE 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
QuickTest GA, PC1-5 1.01/1.00 
COPSAC-
REGISTRY 
IOEE 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
97.5% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
QuickTest GA, PC1-5 1.00/1.00 
DNBC I660 96% Heterozygosity, ancestry 
outliers, sex discrepancy 
98% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 1.00/1.00 
ERF Various 98% Relatedness, ancestry outliers, 
sex discrepancy 
98% 5x10-8 MAF<0.5% MaCH Minimac 1000G   
Mar 2012 
ProbABEL Kinship 
matrix 
1.02/0.95 
EPIC AUKBB 97% Heterozygosity, relatedness, 
sex discrepancy, singletons, 
channel contrast 
95% 1x10-6 MAC<1 SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-10 1.00/1.01 
Fenland (GA+) AUKBB 95% Sex discrepancy, identity 95% 1x10-6 MAC<2 SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-10 1.00/1.01 
Fenland (GA-) AUKBB 95% Sex discrepancy, identity 95% 1x10-6 MAC<2 SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-10 0.99/1.00 
Generation R I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
98% 1x10-6 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1-4 1.03/1.01 
GINIplus & 
LISAplus 
A5, A6 95% Heterozygosity, ancestry 
outliers, sex discrepancy 
95% 1x10-5 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 0.99/1.00 
GOYA I610 95% Heterozygosity, ancestry 
outliers, sex discrepancy 
95% 1x10-7 MAF<1% MaCH MaCH 1000G   
Mar 2012 
QuickTest None 1.00/0.99 
 
HBCS I670 95% Heterozygosity, relatedness, 
ancestry outliers 
95% 1x10-6 MAF<1% MaCH MaCH 1000G   
Mar 2012 
mach2qtl GA 1.02/1.02 
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Study Genotyping 
array(s)a 
Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
(M/F) Call rate Additional filters Call rate HWE     
p-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
INMA IOQ 98% Heterozygosity, relatedness, 
ancestry outliers, duplicates 
95% 1.1x10-6 MAF<1% IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 1.00/0.99 
INTER99 ICM 95% Relatedness, ancestry outliers, 
sex discrepancy 
95% 1x10-4 MAF<1% IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1 0.97/1.02 
Leipzig ICM 95% Duplicates, ancestry outliers, 
sex discrepancy 
95% 
(99% if 
MAF<5%) 
1x10-4 MAF<1% IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 0.95/0.96 
NEO ICE 98% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
98% 1x10-6 None IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-5 0.99/0.99 
NFBC1966 I370 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy, duplicates, 
withdrawn consent 
95% 
(99% if 
MAF<5%) 
5.7x10-7 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-3 1.00/0.99 
NFBC1986 ICM 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy, duplicates, 
withdrawn consent 
95% 
(99% if 
MAF<5%) 
5.7x10-7 
(1x10-4 if 
MAF<5%) 
MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-3 1.00/1.10 
NTR A6, I370, I660, 
IOQ 
90% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 1x10-5 MAF<1% MaCH Minimac 1000G   
Mar 2012 
PLINK GA, array, 
PC1-6 
(global), PC1-
3 (local) 
1.08/1.04 
ORCADES I300, IOQ, IOE 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy, duplicates 
95% 
(99% if 
MAF<5%) 
1x10-6 MAF<1% SHAPEIT IMPUTE2 1000G Mar 
2012 
ProbABEL array, PC1-3 1.00/0.99 
PANIC ICM, ICE 90 % Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-4 1.01/1.01 
RAINE I660 97% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy, chromosomal 
abnormalities 
95% 5.7x10-7 MAF<1% MaCH MaCH 1000G   
Mar 2012 
ProbABEL GA, PC1-2 1.01/0.99 
SORBS I660 94% Relatedness, ancestry outliers, 
sex discrepancy, duplicates 
95% 1x10-4 MAF<1% MaCH Minimac 1000G   
Mar 2012 
ProbABEL Kinship 
matrix 
1.01/1.01 
STRIP A5, A6 95% Heterozygosity, ancestry 
outliers, twins 
95% 1x10-6 MAF<0.1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-4 1.01/1.01 
TEENAGE (GA+) ICM 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 
(99% if 
MAF<5%) 
1x10-4 MAF<1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 1.02/1.00 
TEENAGE (GA-) IOE  95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 
(99% if 
MAF<5%) 
1x10-4 MAF<1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST None 1.02/0.98 
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TDCOB-cases IOE 95% Heterozygosity, relatedness, 
ancestry outliers 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1 1.02/1.01 
TDCOB-
controls 
ICE 95% Heterozygosity, relatedness, 
ancestry outliers 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1 1.02/1.05 
YFS I670 95% Heterozygosity, relatedness, 
sex discrepancy, duplicates 
95% 1x10-6 MAF<1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-4 0.99/1.01 
 
(b) Component 2: UK BioBank 
 
Study Genotyping 
array(s)a 
Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
Call rate Additional filters Call rate HWE 
P-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
UK BioBank AUKBB 98% Heterozygosity, relatedness, 
ancestry outliers 
95% N/A MAF<1% SHAPEIT2 IMPUTE2 1000G    
Oct 2014 & 
UK10K 
BOLT-LMM Sex, genotype 
array 
N/A 
 
(c) Component 3: Non-European ancestry GWAS. 
 
Study Genotyping 
array(s)a 
Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
(M/F) Call rate Additional filters Call rate HWE 
P-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
CHOP-AA I550, I610 95% Relatedness, ancestry outliers, 
sex discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-3 0.98/0.98 
CLHNS ICM 98.6% Relatedness, sex discrepancy 97% 1×10-6 N/A MaCH MaCH 1000G   
Mar 2012 
mach2qtl GA 1.02/1.02 
Generation R 
Turkish 
I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
95% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1-4 1.01/1.02 
Generation R 
Moroccan 
I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
90% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1-4 1.01/0.98 
Generation R 
Surinamese 
I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
98% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1 0.99/0.95 
SCORM I550 95% Heterozygosity, relatedness, 
sex discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 0.98/0.99 
 
HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; MAC, minor allele count; GA, gestational age; PC, principal component. 
aGenotype array codes: Affymetrix 5.0 (A5); Affymetrix 6.0 (A6); Affymetrix Axiom UK BiLEVE (AUKBL); Affymetrix Axiom UK BioBank (AUKBB); Illumina Human370CNV 
(I370); Illumina HumanHap550 (I550); Illumina HumanHap610 (I610); Illumina HumanHap660 (I660); Illumina HumanHap670 (I670); Illumina CardioMetabochip (ICM); 
Illumina OmniQuad (IOQ); Illumina OmniExpress (IOE); Illumina CoreExome (ICE); Illumina OmniExpressExome (IOEE).   
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Supplementary Table 3. BW association summary statistics for each component of the 
trans-ancestry meta-analysis of 153,781 individuals for lead SNPs at loci attaining genome-
wide significance (P<5x10-8).  
 
Locus: WNT4-ZBTB40.  Lead SNP: rs2473248.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.86 0.039 0.008 5.0x10-7 71,642 0.66 
Component 2: UKBB 0.88 0.025 0.008 0.0032 67,786 N/A 
European ancestry meta-analysis 0.87 0.033 0.006 1.1x10-8 139,428 0.21 
Component 3: non-European ancestry 0.78 0.039 0.018 0.034 8,653 0.43 
Trans-ancestry meta-analysis 0.87 0.033 0.005 1.1x10-9 148,081 0.72 
 
Locus: ZBTB7B.  Lead SNP: rs3753639.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.23 0.038 0.006 3.9x10-9 70,376 0.60 
Component 2: UKBB 0.25 0.024 0.006 0.00017 67,786 N/A 
European ancestry meta-analysis 0.24 0.031 0.004 7.3x10-12 138,162 0.12 
Component 3: non-European ancestry 0.18 0.037 0.020 0.061 8,655 0.40 
Trans-ancestry meta-analysis 0.23 0.031 0.004 1.3x10-12 146,817 0.72 
 
Locus: FCGR2B.  Lead SNP: rs72480273.  Effect/other alleles: C/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.16 0.029 0.007 8.7x10-5 70,594 0.14 
Component 2: UKBB 0.19 0.033 0.007 2.3x10-6 67,786 N/A 
European ancestry meta-analysis 0.17 0.031 0.005 8.0x10-10 138,380 0.69 
Component 3: non-European ancestry 0.15 0.005 0.023 0.84 8,655 0.71 
Trans-ancestry meta-analysis 0.17 0.030 0.005 1.5x10-9 147,035 0.86 
 
Locus: DTL.  Lead SNP: rs61830764.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.38 0.031 0.006 1.0x10-7 70,372 0.12 
Component 2: UKBB 0.38 0.013 0.006 0.019 67,786 N/A 
European ancestry meta-analysis 0.38 0.022 0.004 5.6x10-8 138,158 0.029 
Component 3: non-European ancestry 0.15 0.016 0.024 0.50 8,655 0.30 
Trans-ancestry meta-analysis 0.36 0.022 0.004 4.5x10-8 146,813 0.18 
 
Locus: ATAD2B.  Lead SNP: rs7575873.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.88 0.040 0.008 4.9x10-7 71,639 0.98 
Component 2: UKBB 0.87 0.036 0.008 6.3x10-6 67,786 N/A 
European ancestry meta-analysis 0.88 0.038 0.006 1.3x10-11 139,425 0.71 
Component 3: non-European ancestry 0.93 -0.011 0.027 0.67 10,104 0.61 
Trans-ancestry meta-analysis 0.88 0.036 0.006 6.2x10-11 149,529 0.35 
 
Locus: EPAS1.  Lead SNP: rs1374204.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.70 0.050 0.006 1.0x10-16 66,667 0.94 
Component 2: UKBB 0.70 0.044 0.006 9.7x10-14 67,786 N/A 
European ancestry meta-analysis 0.70 0.047 0.004 6.2x10-29 134,453 0.42 
Component 3: non-European ancestry 0.63 0.031 0.016 0.049 8,654 0.14 
Trans-ancestry meta-analysis 0.70 0.046 0.004 1.5x10-29 143,107 0.82 
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Locus: PTH1R.  Lead SNP: rs2242116.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.38 0.018 0.005 0.00048 75,884 0.48 
Component 2: UKBB 0.38 0.025 0.006 5.5x10-6 67,786 N/A 
European ancestry meta-analysis 0.38 0.022 0.004 1.4x10-8 143,670 0.37 
Component 3: non-European ancestry 0.57 0.012 0.014 0.41 10,103 0.92 
Trans-ancestry meta-analysis 0.39 0.021 0.004 1.2x10-8 153,773 0.94 
 
Locus: ADCY5.  Lead SNP: rs11719201.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.22 0.052 0.006 5.2x10-18 75,884 0.34 
Component 2: UKBB 0.24 0.039 0.006 4.0x10-10 67,786 N/A 
European ancestry meta-analysis 0.23 0.046 0.004 2.4x10-26 143,670 0.14 
Component 3: non-European ancestry 0.13 0.037 0.022 0.095 9,264 0.18 
Trans-ancestry meta-analysis 0.23 0.046 0.004 6.4x10-27 152,934 0.35 
 
Locus: CPA3.  Lead SNP: rs10935733.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.42 0.023 0.005 2.2x10-5 71,640 0.58 
Component 2: UKBB 0.39 0.021 0.005 0.00012 67,786 N/A 
European ancestry meta-analysis 0.41 0.022 0.004 9.2x10-9 139,426 0.80 
Component 3: non-European ancestry 0.60 0.038 0.015 0.013 10,103 0.62 
Trans-ancestry meta-analysis 0.42 0.023 0.004 6.2x10-10 149,529 0.33 
 
Locus: CCNL1-LEKR1.  Lead SNP: rs13322435.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.60 0.063 0.005 1.0x10-30 71,640 0.0091 
Component 2: UKBB 0.60 0.042 0.006 3.4x10-13 67,786 N/A 
European ancestry meta-analysis 0.60 0.053 0.004 3.7x10-41 139,426 0.0080 
Component 3: non-European ancestry 0.45 0.040 0.015 0.0066 10,103 0.66 
Trans-ancestry meta-analysis 0.59 0.052 0.004 1.3x10-42 149,529 0.14 
 
Locus: LCORL.  Lead SNP: rs925098.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.040 0.006 4.8x10-12 71,640 0.46 
Component 2: UKBB 0.26 0.027 0.006 9.0x10-6 67,786 N/A 
European ancestry meta-analysis 0.27 0.034 0.004 5.4x10-16 139,426 0.11 
Component 3: non-European ancestry 0.34 0.011 0.015 0.44 10,102 0.28 
Trans-ancestry meta-analysis 0.28 0.032 0.004 1.3x10-15 149,528 0.060 
 
Locus: HHIP.  Lead SNP: rs6537307.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.023 0.005 1.5x10-5 71,645 0.35 
Component 2: UKBB 0.49 0.029 0.005 1.1x10-7 67,786 N/A 
European ancestry meta-analysis 0.50 0.025 0.004 9.5x10-12 139,431 0.41 
Component 3: non-European ancestry 0.21 0.038 0.018 0.036 9,557 0.92 
Trans-ancestry meta-analysis 0.48 0.026 0.004 1.3x10-12 148,988 0.80 
 
Locus: 5q11.2.  Lead SNP: rs854037.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.81 0.038 0.007 7.8x10-9 71,643 0.021 
Component 2: UKBB 0.82 0.014 0.007 0.045 67,786 N/A 
European ancestry meta-analysis 0.81 0.027 0.005 2.2x10-8 139,429 0.011 
Component 3: non-European ancestry 0.53 0.009 0.014 0.52 10,103 0.29 
Trans-ancestry meta-analysis 0.80 0.025 0.005 3.5x10-8 149,532 0.010 
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Locus: EBF1.  Lead SNP: rs7729301.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.72 0.021 0.006 0.00035 75,883 0.23 
Component 2: UKBB 0.74 0.027 0.006 1.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.73 0.024 0.004 1.6x10-8 143,669 0.48 
Component 3: non-European ancestry 0.58 0.033 0.014 0.022 10,104 0.64 
Trans-ancestry meta-analysis 0.72 0.025 0.004 1.3x10-9 153,773 0.78 
 
Locus: CDKAL1.  Lead SNP: rs35261542.  Effect/other alleles: C/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.72 0.047 0.006 6.1x10-17 75,881 0.94 
Component 2: UKBB 0.74 0.041 0.006 1.4x10-11 67,786 N/A 
European ancestry meta-analysis 0.73 0.044 0.004 4.4x10-27 143,667 0.49 
Component 3: non-European ancestry 0.75 0.044 0.016 0.0059 10,102 0.35 
Trans-ancestry meta-analysis 0.73 0.044 0.004 9.7x10-29 153,769 0.42 
 
Locus: HIST1H2BE.  Lead SNP: rs9379832.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.67 0.029 0.006 7.2x10-7 70,375 1.0 
Component 2: UKBB 0.73 0.016 0.006 0.011 67,786 N/A 
European ancestry meta-analysis 0.70 0.023 0.004 6.6x10-8 138,161 0.13 
Component 3: non-European ancestry 0.77 0.044 0.021 0.038 10,103 0.70 
Trans-ancestry meta-analysis 0.71 0.024 0.004 1.2x10-8 148,264 0.42 
 
Locus: HMGA1.  Lead SNP: rs7742369.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.17 0.027 0.007 0.0011 69,259 0.90 
Component 2: UKBB 0.18 0.030 0.007 2.4x10-5 67,786 N/A 
European ancestry meta-analysis 0.18 0.028 0.005 1.0x10-8 137,045 0.77 
Component 3: non-European ancestry 0.44 0.013 0.016 0.41 9,561 0.18 
Trans-ancestry meta-analysis 0.19 0.027 0.005 1.1x10-8 146,606 0.16 
 
Locus: L3MBTL3.  Lead SNP: rs1415701.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.75 0.025 0.006 2.3x10-5 75,880 0.69 
Component 2: UKBB 0.73 0.025 0.006 3.2x10-5 67,786 N/A 
European ancestry meta-analysis 0.74 0.025 0.004 2.6x10-9 143,666 1.00 
Component 3: non-European ancestry 0.63 0.048 0.015 0.0013 10,102 0.64 
Trans-ancestry meta-analysis 0.73 0.027 0.004 4.0x10-11 153,768 0.40 
 
Locus: ESR1.  Lead SNP: rs1101081.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.72 0.044 0.006 5.4x10-14 71,641 0.95 
Component 2: UKBB 0.73 0.031 0.006 2.7x10-7 67,786 N/A 
European ancestry meta-analysis 0.72 0.038 0.004 1.6x10-19 139,427 0.14 
Component 3: non-European ancestry 0.79 0.027 0.017 0.13 10,103 0.47 
Trans-ancestry meta-analysis 0.73 0.037 0.004 6.1x10-20 149,530 0.28 
 
Locus: GNA12.  Lead SNP: rs798489.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.73 0.020 0.006 0.00040 75,884 0.75 
Component 2: UKBB 0.73 0.027 0.006 1.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.73 0.023 0.004 2.0x10-8 143,670 0.44 
Component 3: non-European ancestry 0.92 0.053 0.027 0.048 9,708 0.14 
Trans-ancestry meta-analysis 0.74 0.024 0.004 5.0x10-9 153,378 0.84 
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Locus: IGF2BP3.  Lead SNP: rs11765649.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.76 0.021 0.006 0.00049 71,642 0.80 
Component 2: UKBB 0.74 0.032 0.006 1.3x10-7 67,786 N/A 
European ancestry meta-analysis 0.75 0.027 0.004 5.8x10-10 139,428 0.19 
Component 3: non-European ancestry 0.87 0.003 0.022 0.88 10,103 0.37 
Trans-ancestry meta-analysis 0.76 0.026 0.004 1.0x10-9 149,531 0.60 
 
Locus: TBX20.  Lead SNP: rs6959887.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.61 0.031 0.005 1.4x10-9 75,873 0.58 
Component 2: UKBB 0.61 0.013 0.006 0.021 67,786 N/A 
European ancestry meta-analysis 0.61 0.023 0.004 1.5x10-9 143,659 0.013 
Component 3: non-European ancestry 0.63 -0.007 0.014 0.65 10,098 0.62 
Trans-ancestry meta-analysis 0.61 0.021 0.004 1.0x10-8 153,757 0.054 
 
Locus: YKT6-GCK.  Lead SNP: rs138715366.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.9908 0.227 0.034 1.7x10-11 64,557 0.86 
Component 2: UKBB 0.9915 0.253 0.031 7.1x10-16 67,786 N/A 
European ancestry meta-analysis 0.9911 0.241 0.023 7.2x10-26 132,343 0.57 
Component 3: non-European ancestry 0.9977 0.855 0.333 0.010 3,292 1.00 
Trans-ancestry meta-analysis 0.9913 0.244 0.023 1.4x10-26 135,635 0.16 
 
Locus: MLXIPL.  Lead SNP: rs62466330.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.06 0.052 0.011 1.9x10-6 74,414 0.24 
Component 2: UKBB 0.07 0.046 0.011 1.5x10-5 67,786 N/A 
European ancestry meta-analysis 0.07 0.049 0.008 1.2x10-10 142,200 0.70 
Component 3: non-European ancestry 0.04 0.142 0.045 0.0015 7,815 0.52 
Trans-ancestry meta-analysis 0.07 0.051 0.007 5.9x10-12 150,015 0.23 
 
Locus: ANK1-NKX6-3.  Lead SNP: rs13266210.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.78 0.023 0.006 0.00034 71,643 0.19 
Component 2: UKBB 0.79 0.040 0.007 1.5x10-9 67,786 N/A 
European ancestry meta-analysis 0.79 0.031 0.005 1.3x10-11 139,429 0.054 
Component 3: non-European ancestry 0.81 0.013 0.019 0.48 9,562 0.30 
Trans-ancestry meta-analysis 0.79 0.030 0.004 1.6x10-11 148,991 0.32 
 
Locus: TRIB1.  Lead SNP: rs6989280.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.73 0.026 0.006 5.6x10-6 75,885 0.34 
Component 2: UKBB 0.73 0.017 0.006 0.0069 67,786 N/A 
European ancestry meta-analysis 0.73 0.022 0.004 2.2x10-7 143,671 0.25 
Component 3: non-European ancestry 0.32 0.027 0.016 0.085 10,104 0.85 
Trans-ancestry meta-analysis 0.70 0.022 0.004 5.0x10-8 153,775 0.92 
 
Locus: SLC45A4.  Lead SNP: rs12543725.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.59 0.023 0.005 1.1x10-5 71,645 0.39 
Component 2: UKBB 0.59 0.023 0.005 3.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.59 0.023 0.004 1.2x10-9 139,431 0.94 
Component 3: non-European ancestry 0.78 0.005 0.018 0.78 8,653 0.42 
Trans-ancestry meta-analysis 0.60 0.022 0.004 1.9x10-9 148,084 0.65 
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Locus: PTCH1.  Lead SNP: rs28510415.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.09 0.041 0.009 1.4x10-5 66,960 0.40 
Component 2: UKBB 0.10 0.070 0.009 1.7x10-14 67,786 N/A 
European ancestry meta-analysis 0.09 0.056 0.007 1.5x10-17 134,746 0.023 
Component 3: non-European ancestry 0.03 -0.086 0.043 0.049 8,654 0.79 
Trans-ancestry meta-analysis 0.09 0.053 0.006 4.0x10-16 143,400 0.0055 
 
Locus: LPAR1.  Lead SNP: rs2150052.  Effect/other alleles: T/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.021 0.005 8.6x10-5 71,638 0.23 
Component 2: UKBB 0.51 0.021 0.005 7.5x10-5 67,786 N/A 
European ancestry meta-analysis 0.50 0.021 0.004 2.2x10-8 139,424 0.95 
Component 3: non-European ancestry 0.46 0.008 0.015 0.61 8,655 0.71 
Trans-ancestry meta-analysis 0.50 0.020 0.004 2.8x10-8 148,079 0.99 
 
Locus: PHF19.  Lead SNP: rs7847628.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.68 0.028 0.006 1.1x10-6 71,638 0.47 
Component 2: UKBB 0.68 0.018 0.006 0.0014 67,786 N/A 
European ancestry meta-analysis 0.68 0.023 0.004 1.0x10-8 139,424 0.23 
Component 3: non-European ancestry 0.57 0.017 0.015 0.25 10,104 0.30 
Trans-ancestry meta-analysis 0.67 0.023 0.004 5.4x10-9 149,528 0.17 
 
Locus: STRBP.  Lead SNP: rs700059.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.15 0.027 0.007 0.00028 71,641 0.090 
Component 2: UKBB 0.14 0.040 0.008 2.1x10-7 67,786 N/A 
European ancestry meta-analysis 0.14 0.033 0.005 4.7x10-10 139,427 0.22 
Component 3: non-European ancestry 0.43 0.059 0.016 0.00018 8,653 0.34 
Trans-ancestry meta-analysis 0.16 0.036 0.005 1.2x10-12 148,080 0.21 
 
Locus: HHEX-IDE.  Lead SNP: rs61862780.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.51 0.027 0.005 9.2x10-8 75,884 0.37 
Component 2: UKBB 0.51 0.029 0.005 7.6x10-8 67,786 N/A 
European ancestry meta-analysis 0.51 0.028 0.004 3.0x10-14 143,670 0.81 
Component 3: non-European ancestry 0.77 0.025 0.017 0.13 10,103 0.12 
Trans-ancestry meta-analysis 0.52 0.028 0.004 9.5x10-15 153,773 0.80 
 
Locus: NT5C2.  Lead SNP: rs74233809.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.08 0.032 0.009 0.00039 75,881 0.88 
Component 2: UKBB 0.08 0.042 0.010 3.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.08 0.037 0.007 5.2x10-8 143,667 0.49 
Component 3: non-European ancestry 0.12 0.061 0.022 0.0057 10,104 0.39 
Trans-ancestry meta-analysis 0.08 0.039 0.006 1.8x10-9 153,771 0.14 
 
Locus: ADRB1.  Lead SNP: rs7076938.  Effect/other alleles: T/C. 
Analysis EAF Β SE P-value N Q P-value 
Component 1: European ancestry 0.73 0.046 0.006 1.3x10-15 75,885 0.79 
Component 2: UKBB 0.73 0.025 0.006 4.5x10-5 67,786 N/A 
European ancestry meta-analysis 0.73 0.036 0.004 4.7x10-18 143,671 0.011 
Component 3: non-European ancestry 0.64 0.018 0.015 0.22 10,103 0.56 
Trans-ancestry meta-analysis 0.73 0.035 0.004 4.7x10-18 153,774 0.19 
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Locus: PLEKHA1.  Lead SNP: rs2421016.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.022 0.005 1.0x10-5 75,873 0.25 
Component 2: UKBB 0.47 0.019 0.005 0.00047 67,786 N/A 
European ancestry meta-analysis 0.49 0.021 0.004 1.8x10-8 143,659 0.62 
Component 3: non-European ancestry 0.40 0.021 0.014 0.15 10,100 0.28 
Trans-ancestry meta-analysis 0.48 0.021 0.004 6.1x10-9 153,759 0.83 
 
Locus: INS-IGF2.  Lead SNP: rs72851023.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.07 0.055 0.011 6.7x10-7 67,990 0.014 
Component 2: UKBB 0.08 0.041 0.010 8.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.07 0.048 0.008 2.9x10-10 135,776 0.35 
Component 3: non-European ancestry 0.02 -0.048 0.064 0.45 7,815 1.00 
Trans-ancestry meta-analysis 0.07 0.046 0.007 6.8x10-10 143,591 0.64 
 
Locus: MTNR1B.  Lead SNP: rs10830963.  Effect/other alleles: G/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.029 0.006 5.1x10-7 75,877 0.20 
Component 2: UKBB 0.28 0.017 0.006 0.0059 67,786 N/A 
European ancestry meta-analysis 0.28 0.023 0.004 2.9x10-8 143,663 0.12 
Component 3: non-European ancestry 0.20 -0.013 0.021 0.54 10,102 0.76 
Trans-ancestry meta-analysis 0.27 0.022 0.004 1.0x10-7 153,765 0.23 
 
Locus: APOLD1.  Lead SNP: rs11055034.  Effect/other alleles: C/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.74 0.028 0.006 2.1x10-6 75,867 0.91 
Component 2: UKBB 0.72 0.016 0.006 0.0099 67,786 N/A 
European ancestry meta-analysis 0.73 0.022 0.004 1.8x10-7 143,653 0.13 
Component 3: non-European ancestry 0.81 0.046 0.020 0.019 9,942 0.67 
Trans-ancestry meta-analysis 0.73 0.023 0.004 2.3x10-8 153,595 0.32 
 
Locus: ABCC9.  Lead SNP: rs139975827.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.61 0.027 0.007 4.9x10-5 55,417 0.72 
Component 2: UKBB 0.63 0.023 0.006 5.8x10-5 67,786 N/A 
European ancestry meta-analysis 0.62 0.025 0.004 1.1x10-8 123,203 0.72 
Component 3: non-European ancestry 0.70 -0.018 0.018 0.32 8,655 0.68 
Trans-ancestry meta-analysis 0.63 0.022 0.004 1.0x10-7 131,858 0.22 
 
Locus: ITPR2.  Lead SNP: rs12823128.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.54 0.017 0.005 0.00086 71,645 0.59 
Component 2: UKBB 0.53 0.025 0.005 3.8x10-6 67,786 N/A 
European ancestry meta-analysis 0.54 0.021 0.004 1.9x10-8 139,431 0.32 
Component 3: non-European ancestry 0.86 0.000 0.021 1.0 10,103 0.054 
Trans-ancestry meta-analysis 0.56 0.020 0.004 3.2x10-8 149,534 0.65 
 
Locus: HMGA2.  Lead SNP: rs1351394.  Effect/other alleles: T/C. 
Analysis EAF Β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.048 0.005 7.6x10-21 75,885 0.40 
Component 2: UKBB 0.49 0.039 0.005 3.1x10-13 67,786 N/A 
European ancestry meta-analysis 0.49 0.044 0.004 1.9x10-32 143,671 0.24 
Component 3: non-European ancestry 0.34 0.033 0.015 0.028 10,102 0.75 
Trans-ancestry meta-analysis 0.48 0.043 0.004 2.0x10-33 153,773 0.72 
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Locus: IGF1.  Lead SNP: rs7964361.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.08 0.038 0.009 5.6x10-5 71,642 0.63 
Component 2: UKBB 0.09 0.040 0.010 2.3x10-5 67,786 N/A 
European ancestry meta-analysis 0.09 0.039 0.007 4.7x10-9 139,428 0.86 
Component 3: non-European ancestry 0.03 -0.010 0.040 0.81 9,264 0.21 
Trans-ancestry meta-analysis 0.08 0.038 0.007 9.7x10-9 148,692 0.20 
 
Locus: LINC00332.  Lead SNP: rs2324499.  Effect/other alleles: G/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.68 0.026 0.006 7.9x10-6 71,639 0.25 
Component 2: UKBB 0.67 0.018 0.006 0.0019 67,786 N/A 
European ancestry meta-analysis 0.68 0.022 0.004 7.3x10-8 139,425 0.34 
Component 3: non-European ancestry 0.60 0.034 0.016 0.027 8,655 0.41 
Trans-ancestry meta-analysis 0.67 0.023 0.004 8.3x10-9 148,080 0.64 
 
Locus: RB1.  Lead SNP: rs2854355.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.024 0.006 0.00012 69,775 0.036 
Component 2: UKBB 0.26 0.023 0.006 0.00024 67,786 N/A 
European ancestry meta-analysis 0.27 0.023 0.004 9.8x10-8 137,561 0.91 
Component 3: non-European ancestry 0.19 0.037 0.020 0.066 8,654 0.86 
Trans-ancestry meta-analysis 0.26 0.024 0.004 2.2x10-8 146,215 0.63 
 
Locus: RNF219-AS1.  Lead SNP: rs1819436.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.86 0.041 0.008 2.4x10-7 71,193 0.19 
Component 2: UKBB 0.88 0.024 0.008 0.0030 67,786 N/A 
European ancestry meta-analysis 0.87 0.033 0.006 6.3x10-9 138,979 0.14 
Component 3: non-European ancestry 0.84 0.033 0.021 0.12 8,654 0.96 
Trans-ancestry meta-analysis 0.87 0.033 0.005 1.8x10-9 147,633 0.80 
 
Locus: FES.  Lead SNP: rs12906125.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.69 0.020 0.006 0.00036 73,495 0.92 
Component 2: UKBB 0.67 0.025 0.006 1.1x10-5 67,786 N/A 
European ancestry meta-analysis 0.68 0.023 0.004 1.7x10-8 141,281 0.55 
Component 3: non-European ancestry 0.75 0.018 0.017 0.30 10,103 0.87 
Trans-ancestry meta-analysis 0.69 0.023 0.004 1.0x10-8 151,384 0.75 
 
Locus: IGF1R.  Lead SNP: rs7402982.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.43 0.022 0.005 4.9x10-5 71,637 0.24 
Component 2: UKBB 0.41 0.024 0.006 1.3x10-5 67,786 N/A 
European ancestry meta-analysis 0.43 0.023 0.004 2.3x10-9 139,423 0.83 
Component 3: non-European ancestry 0.35 0.020 0.017 0.23 10,103 0.61 
Trans-ancestry meta-analysis 0.42 0.023 0.004 1.1x10-9 149,526 0.61 
 
Locus: GPR139.  Lead SNP: rs1011939.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.31 0.022 0.006 0.00013 75,818 0.93 
Component 2: UKBB 0.28 0.022 0.006 0.00030 67,786 N/A 
European ancestry meta-analysis 0.30 0.022 0.004 1.3x10-7 143,604 0.97 
Component 3: non-European ancestry 0.57 0.047 0.015 0.0013 10,098 0.52 
Trans-ancestry meta-analysis 0.31 0.024 0.004 2.7x10-9 153,702 0.66 
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Locus: CLDN7.  Lead SNP: rs113086489.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.57 0.033 0.005 7.1x10-10 71,640 0.10 
Component 2: UKBB 0.55 0.028 0.005 2.6x10-7 67,786 N/A 
European ancestry meta-analysis 0.56 0.031 0.004 9.1x10-16 139,426 0.51 
Component 3: non-European ancestry 0.40 0.012 0.015 0.40 10,104 0.29 
Trans-ancestry meta-analysis 0.55 0.030 0.004 1.3x10-15 149,530 0.77 
 
Locus: SUZ12P1-CRLF3.  Lead SNP: rs144843919.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.97 0.036 0.018 0.0048 53,571 0.13 
Component 2: UKBB 0.96 0.087 0.015 1.0x10-8 67,786 N/A 
European ancestry meta-analysis 0.96 0.066 0.012 1.4x10-8 121,357 0.033 
Component 3: non-European ancestry 0.96 0.112 0.049 0.022 6,635 0.056 
Trans-ancestry meta-analysis 0.96 0.068 0.011 1.5x10-9 127,992 0.068 
 
Locus: SP6-SP2.  Lead SNP: rs12942207.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.31 0.025 0.006 2.2x10-5 71,635 0.85 
Component 2: UKBB 0.30 0.020 0.006 0.00063 67,786 N/A 
European ancestry meta-analysis 0.30 0.022 0.004 5.1x10-8 139,421 0.59 
Component 3: non-European ancestry 0.26 0.050 0.018 0.0053 8,654 0.98 
Trans-ancestry meta-analysis 0.30 0.024 0.004 3.0x10-9 148,075 0.75 
 
Locus: ACTL9.  Lead SNP: rs61154119.  Effect/other alleles: T/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.84 0.030 0.007 6.4x10-5 63,412 0.00014 
Component 2: UKBB 0.85 0.026 0.007 0.00050 67,786 N/A 
European ancestry meta-analysis 0.84 0.028 0.005 1.1x10-7 131,198 0.70 
Component 3: non-European ancestry 0.79 0.033 0.018 0.077 8,655 0.64 
Trans-ancestry meta-analysis 0.84 0.028 0.005 2.3x10-8 139,853 0.98 
 
Locus: PEPD.  Lead SNP: rs10402712.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.25 0.021 0.006 0.00033 71,642 0.23 
Component 2: UKBB 0.26 0.022 0.006 0.00042 67,786 N/A 
European ancestry meta-analysis 0.26 0.022 0.004 4.4x10-7 139,428 0.98 
Component 3: non-European ancestry 0.40 0.038 0.014 0.0086 10,102 0.89 
Trans-ancestry meta-analysis 0.27 0.023 0.004 2.3x10-8 149,530 0.72 
 
Locus: JAG1.  Lead SNP: rs6040076.  Effect/other alleles: C/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.48 0.023 0.005 3.1x10-5 71,638 0.82 
Component 2: UKBB 0.51 0.023 0.005 1.8x10-5 67,786 N/A 
European ancestry meta-analysis 0.49 0.023 0.004 2.0x10-9 139,424 0.96 
Component 3: non-European ancestry 0.69 -0.006 0.018 0.73 8,655 0.026 
Trans-ancestry meta-analysis 0.51 0.022 0.004 7.2x10-9 148,079 0.24 
 
Locus: C20orf203.  Lead SNP: rs28530618.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.032 0.005 5.0x10-9 70,376 0.45 
Component 2: UKBB 0.47 0.020 0.005 0.00015 67,786 N/A 
European ancestry meta-analysis 0.49 0.026 0.004 7.7x10-12 138,162 0.14 
Component 3: non-European ancestry 0.63 -0.011 0.016 0.50 10,102 0.25 
Trans-ancestry meta-analysis 0.50 0.024 0.004 8.4x10-11 148,264 0.18 
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Locus: MAFB.  Lead SNP: rs6016377.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.41 0.028 0.005 3.8x10-7 71,639 0.10 
Component 2: UKBB 0.45 0.020 0.006 0.00043 67,786 N/A 
European ancestry meta-analysis 0.43 0.024 0.004 9.5x10-10 139,425 0.29 
Component 3: non-European ancestry 0.74 0.025 0.018 0.17 10,103 0.26 
Trans-ancestry meta-analysis 0.45 0.024 0.004 3.7x10-10 149,528 0.27 
 
Locus: NRIP1.  Lead SNP: rs2229742.  Effect/other alleles: G/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.85 0.037 0.008 6.6x10-6 75,886 0.66 
Component 2: UKBB 0.90 0.034 0.009 9.1x10-5 67,786 N/A 
European ancestry meta-analysis 0.87 0.036 0.006 2.2x10-9 143,672 0.82 
Component 3: non-European ancestry 0.82 -0.085 0.044 0.052 9,264 0.72 
Trans-ancestry meta-analysis 0.87 0.034 0.006 1.5x10-8 152,936 0.092 
 
Locus: KREMEN1.  Lead SNP: rs134594.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.35 0.022 0.006 8.9x10-5 69,554 0.36 
Component 2: UKBB 0.35 0.023 0.006 3.2x10-5 67,786 N/A 
European ancestry meta-analysis 0.35 0.023 0.004 1.0x10-8 137,340 0.84 
Component 3: non-European ancestry 0.33 0.002 0.016 0.90 8,655 0.59 
Trans-ancestry meta-analysis 0.35 0.022 0.004 2.2x10-8 145,995 0.25 
 
Locus: SREBF2.  Lead SNP: rs62240962.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.91 0.054 0.010 2.6x10-8 68,286 0.69 
Component 2: UKBB 0.92 0.040 0.010 6.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.91 0.047 0.007 9.7x10-12 136,072 0.30 
Component 3: non-European ancestry 0.97 0.07 0.048 0.15 7,815 0.028 
Trans-ancestry meta-analysis 0.92 0.047 0.007 3.7x10-12 143,887 0.69 
 
Locus: PLAC1.  Lead SNP: rs11096402.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.027 0.007 2.0x10-4 37,417 0.73 
Component 2: UKBB 0.24 0.028 0.006 1.8x10-6 57,620 N/A 
European ancestry meta-analysis 0.25 0.028 0.005 1.3x10-9 95,037 0.31 
Component 3: non-European ancestry N/A N/A N/A N/A N/A N/A 
Trans-ancestry meta-analysis N/A N/A N/A N/A N/A N/A 
PLAC1 result (on X chromosome) was not available in non-European ancestry studies. 
EAF, effect allele frequency; SE, standard error. 
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Supplementary Table 4. Summary statistics for lead SNPs attaining genome-wide significant evidence (P<5x10-8) of association with BW in 
European ancestry meta-analysis of up to 143,677 individuals and/or trans-ancestry meta-analysis of up to 153,781 individuals. 
 
Locus SNP Chr Position 
(b37, bp) 
Alleles EAF European ancestry Trans-ancestry Statusa EUR r2 with 
lead TA 
Present in 
HapMap? 
Best proxy in HapMap 
Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 
WNT4-ZBTB40  rs2473248 1 22,536,643 C T 0.87 0.033 
(0.006) 
1.1x10-8 0.033 
(0.005) 
1.1x10-9 TA/EUR  No rs2744726 0.99 
ZBTB7B  rs3753639 1 154,986,091 C T 0.24 0.031 
(0.004) 
7.3x10-12 0.031 
(0.004) 
1.3x10-12 TA/EUR  No rs905938 0.77 
FCGR2B  rs72480273 1 161,644,871 C A 0.17 0.031 
(0.005) 
8.0x10-10 0.030 
(0.005) 
1.5x10-9 TA/EUR  No rs17413015 0.97 
DTL rs61830764 1 212,289,976 A G 0.38 0.022 
(0.004) 
5.6x10-8 0.022 
(0.004) 
4.5x10-8 TA  No rs1387815 0.51 
ATAD2B   rs7575873 2 23,962,647 A G 0.88 0.038 
(0.006) 
1.3x10-11 0.036 
(0.006) 
6.2x10-11 TA  No rs718139 0.98 
rs181211713 2 23,965,445 G A 0.87 0.038 
(0.006) 
1.2x10-11 0.036 
(0.005) 
7.3x10-11 EUR 0.94 No   
EPAS1  rs1374204 2 46,484,205 T C 0.70 0.047 
(0.004) 
6.2x10-29 0.046 
(0.004) 
1.5x10-29 TA  Yes   
rs17034876 2 46,484,310 T C 0.70 0.047 
(0.004) 
2.6x10-29 0.046 
(0.004) 
1.9x10-29 EUR 0.99 Yes   
PTH1R  rs2242116 3 46,941,116 A G 0.38 0.022 
(0.004) 
1.4x10-8 0.021 
(0.004) 
1.2x10-8 TA  Yes   
rs2168443 3 46,947,087 T A 0.38 0.023 
(0.004) 
3.5x10-9 0.021 
(0.004) 
1.3x10-8 EUR 0.99 Yes   
ADCY5   rs11719201 3 123,068,744 T C 0.23 0.046 
(0.004) 
2.4x10-26 0.046 
(0.004) 
6.4x10-27 TA/EUR  No rs7613951 0.97 
rs9883204 3 123,096,820 T C 0.25 0.041 
(0.004) 
8.4x10-22 0.040 
(0.004) 
6.1x10-22 Previous 0.85 Yes   
CPA3  rs10935733 3 148,622,968 T C 0.41 0.022 
(0.004) 
9.2x10-9 0.023 
(0.004) 
6.2x10-10 TA/EUR  No rs12496367 0.81 
CCNL1-LEKR1   rs13322435 3 156,795,468 A G 0.60 0.053 
(0.004) 
3.7x10-41 0.052 
(0.004) 
1.3x10-42 TA  Yes   
rs900399 3 156,798,732 A G 0.61 0.052 
(0.004) 
2.2x10-41 0.051 
(0.004) 
2.9x10-41 EUR 0.92 Yes   
rs900400 3 156,798,775 T C 0.61 0.053 
(0.004) 
1.1x10-40 0.051 
(0.004) 
8.4x10-41 Previous 0.92 Yes   
LCORL   rs925098 4 17,919,811 G A 0.27 0.034 
(0.004) 
5.4x10-16 0.032 
(0.004) 
1.3x10-15 TA  Yes   
rs2724475 4 17,946,432 T C 0.27 0.034 
(0.004) 
5.3x10-16 0.032 
(0.004) 
1.3x10-15 EUR 0.97 Yes   
rs724577 4 17,993,410 A C 0.27 0.033 
(0.004) 
1.7x10-15 0.031 
(0.004) 
1.5x10-14 Previous 0.98 Yes   
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Locus SNP Chr
  
Position 
(b37, bp) 
Alleles  EAF 
  
European ancestry Trans-ancestry Statusa EUR r2 with 
lead TA 
Present in 
HapMap? 
Best proxy in HapMap 
Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 
HHIP   rs6537307 4 145,601,863 G A 0.50 0.025 
(0.004) 
9.5x10-12 0.026 
(0.004) 
1.3x10-12 TA  Yes   
rs2131354 4 145,599,908 A G 0.53 0.026 
(0.004) 
4.1x10-12 0.026 
(0.004) 
2.3x10-12 EUR 0.88 No   
5q11.2  rs854037 5 57,091,783 A G 0.81 0.027 
(0.005) 
2.2x10-8 0.025 
(0.005) 
3.5x10-8 TA/EUR  Yes   
rs4432842 5 57,172,078 T C 0.70 0.021 
(0.004) 
3.4x10-7 0.019 
(0.004) 
7.0x10-7 Previous 0.47 Yes   
EBF1  rs7729301 5 157,886,953 A G 0.73 0.024 
(0.004) 
1.6x10-8 0.025 
(0.004) 
1.3x10-9 TA  No rs2946164 0.97 
rs2946179 5 157,886,627 C T 0.73 0.024 
(0.004) 
1.3x10-8 0.024 
(0.004) 
1.5x10-9 EUR 0.98 No   
CDKAL1   rs35261542 6 20,675,792 C A 0.73 0.044 
(0.004) 
4.4x10-27 0.044 
(0.004) 
9.7x10-29 TA/EUR  No rs7756992 0.97 
rs6931514 6 20,703,952 A G 0.73 0.043 
(0.004) 
6.2x10-26 0.043 
(0.004) 
1.0x10-26 Previous 0.94 Yes   
HIST1H2BE rs9379832 6 26,186,200 A G 0.70 0.023 
(0.004) 
6.6x10-8 0.024 
(0.004) 
1.2x10-8 TA  No rs806794 0.62 
HMGA1  rs7742369 6 34,165,721 G A 0.18 0.028 
(0.005) 
1.0x10-8 0.027 
(0.005) 
1.1x10-8 TA  Yes   
rs1187118 6 34,169,020 A T 0.17 0.030 
(0.005) 
3.6x10-9 0.027 
(0.005) 
1.4x10-8 EUR 0.95 No   
L3MBTL3  rs1415701 6 130,345,835 G A 0.74 0.025 
(0.004) 
2.6x10-9 0.027 
(0.004) 
4.0x10-11 TA/EUR  Yes   
ESR1  
 
rs1101081 6 152,032,917 C T 0.72 0.038 
(0.004) 
1.6x10-19 0.037 
(0.004) 
6.1x10-20 TA  No rs851977 0.99 
rs10872678 6 152,039,964 T C 0.72 0.038 
(0.004) 
6.9x10-20 0.036 
(0.004) 
1.3x10-19 EUR 0.98 Yes   
GNA12   rs798489 7 2,801,803 C T 0.73 0.023 
(0.004) 
2.0x10-8 0.024 
(0.004) 
5.0x10-9 TA  Yes   
rs798498 7 2,795,882 T G 0.69 0.023 
(0.004) 
1.3x10-8 0.022 
(0.004) 
3.8x10-8 EUR 0.83 Yes   
IGF2BP3  rs11765649 7 23,479,013 T C 0.75 0.027 
(0.004) 
5.8x10-10 0.026 
(0.004) 
1.0x10-9 TA/EUR  No rs12540730 0.86 
TBX20  rs6959887 7 35,295,365 A G 0.61 0.023 
(0.004) 
1.5x10-9 0.021 
(0.004) 
1.0x10-8 TA/EUR  Yes   
YKT6-GCK rs138715366 7 44,246,271 C T 0.99 0.241 
(0.023) 
7.2x10-26 0.244 
(0.023) 
1.4x10-26 TA/EUR  No rs2908277 0.096 
MLXIPL  rs62466330 7 73,056,805 C T 0.07 0.049 
(0.008) 
1.2x10-10 0.051 
(0.007) 
5.9x10-12 TA  No rs17401675 1 
rs111778406 7 72,957,570 G A 0.07 0.049 
(0.008) 
5.8x10-11 0.050 
(0.007) 
1.3x10-11 EUR 0.78 No   
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Locus SNP Chr Position Alleles EAF European ancestry Trans-ancestry Statusa EUR r2 with 
lead TA 
Present in 
HapMap? 
Best proxy in HapMap 
(b37, bp) Effect Other  β (SE) P-value β (SE) P-value SNP EUR r2 
ANK1-NKX6.3  rs13266210 8 41,533,514 A G 0.79 0.031 
(0.005) 
1.3x10-11 0.030 
(0.004) 
1.6x10-11 TA/EUR  Yes   
TRIB1 rs6989280 8 126,508,746 G A 0.73 0.022 
(0.004) 
2.2x10-7 0.022 
(0.004) 
5.0x10-8 TA  Yes   
SLC45A4  rs12543725 8 142,247,979 G A 0.59 0.023 
(0.004) 
1.2x10-9 0.022 
(0.004) 
1.9x10-9 TA/EUR  Yes   
PTCH1   rs28510415 9 98,245,026 G A 0.09 0.056 
(0.007) 
1.5x10-17 0.053 
(0.006) 
4.0x10-16 TA  No rs3824488 1 
rs3780573 9 98,239,503 A G 0.10 0.055 
(0.006) 
7.0x10-18 0.050 
(0.006) 
1.1x10-15 EUR 1.00 No   
LPAR1  rs2150052 9 113,945,067 T A 0.50 0.021 
(0.004) 
2.2x10-8 0.020 
(0.004) 
2.8x10-8 TA  Yes   
rs1411424 9 113,892,963 A G 0.52 0.021 
(0.004) 
2.2x10-8 0.020 
(0.004) 
4.1x10-8 EUR 0.86 Yes   
PHF19   rs7847628 9 123,631,225 G A 0.68 0.023 
(0.004) 
1.0x10-8 0.023 
(0.004) 
5.4x10-9 TA  Yes rs1056567 0.87 
rs4836833 9 123,632,829 C G 0.67 0.023 
(0.004) 
8.6x10-9 0.022 
(0.004) 
1.5x10-8 EUR 0.88 Yes   
STRBP  rs700059 9 125,824,055 G A 0.14 0.033 
(0.005) 
4.7x10-10 0.036 
(0.005) 
1.2x10-12 TA  Yes   
rs10818797 9 126,020,405 C T 0.14 0.035 
(0.005) 
1.2x10-10 0.035 
(0.005) 
1.5x10-11 EUR 0.91 Yes   
HHEX-IDE   rs61862780 10 94,468,643 T C 0.51 0.028 
(0.004) 
3.0x10-14 0.028 
(0.004) 
9.5x10-15 TA  No rs2497306 0.97 
rs2497304 10 94,492,716 C T 0.52 0.028 
(0.004) 
2.6x10-14 0.028 
(0.004) 
1.4x10-14 EUR 0.90 Yes   
NT5C2 rs74233809 10 104,913,940 C T 0.08 0.037 
(0.007) 
5.2x10-8 0.039 
(0.006) 
1.8x10-9 TA  No rs11191582 1 
rs79237883 10 104,940,946 C T 0.08 0.037 
(0.007) 
3.6x10-8 0.038 
(0.006) 
5.6x10-9 EUR 1.00 No   
ADRB1 rs7076938 10 115,789,375 T C 0.73 0.036 
(0.004) 
4.7x10-18 0.035 
(0.004) 
4.7x10-18 TA  Yes   
rs740746 10 115,792,787 A G 0.73 0.036 
(0.004) 
3.8x10-18 0.035 
(0.004) 
6.4x10-18 EUR 0.99 Yes   
rs1801253  10 115,805,056 C G 0.71 0.032 
(0.004) 
3.0x10-14 0.031 
(0.004) 
2.6x10-14 Previous 0.99 Yes   
PLEKHA1  rs2421016 10 124,167,512 T C 0.49 0.021 
(0.004) 
1.8x10-8 0.021 
(0.004) 
6.1x10-9 TA/EUR  Yes   
INS-IGF2  rs72851023 11 2,130,620 T C 0.07 0.048 
(0.008) 
2.9x10-10 0.046 
(0.007) 
6.8x10-10 TA/EUR  No rs868332 0.49 
MTNR1B  rs10830963 11 92,708,710 G C 0.28 0.023 
(0.004) 
2.9x10-8 0.022 
(0.004) 
1.0x10-7 EUR  Yes   
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Locus 
  
SNP 
  
Chr Position Alleles EAF 
  
European ancestry Trans-ancestry Statusa EUR r2 with 
lead TA 
Present in 
HapMap? 
Best proxy in HapMap 
(b37, bp) Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 
APOLD1 rs11055034 12 12,890,626 C A 0.73 0.022 
(0.004) 
1.8x10-7 0.023 
(0.004) 
2.3x10-8 TA  Yes   
ABCC9  rs139975827 12 22,068,161 G A 0.62 0.025 
(0.004) 
1.1x10-8 0.022 
(0.004) 
1.0x10-7 EUR  No rs4148656 0.67 
ITPR2  rs12823128 12 26,872,730 T C 0.54 0.021 
(0.004) 
1.9x10-8 0.020 
(0.004) 
3.2x10-8 TA  Yes   
rs2306547 12 26,877,885 C T 0.54 0.021 
(0.004) 
1.8x10-8 0.020 
(0.004) 
3.2x10-8 EUR 0.96 Yes   
HMGA2  rs1351394 12 66,351,826 T C 0.49 0.044 
(0.004) 
1.9x10-32 0.043 
(0.004) 
2.0x10-33 TA/EUR  Yes   
rs1042725 12 66,358,347 C T 0.51 0.043 
(0.004) 
3.1x10-32 0.042 
(0.004) 
7.1x10-32 Previous 0.93 Yes   
IGF1  rs7964361 12 102,994,878 A G 0.09 0.039 
(0.007) 
4.7x10-9 0.038 
(0.007) 
9.7x10-9 TA/EUR  Yes   
LINC00332 rs2324499 13 40,662,001 G C 0.68 0.022 
(0.004) 
7.3x10-8 0.023 
(0.004) 
8.3x10-9 TA  Yes   
rs7998537 13 40,662,742 G A 0.68 0.022 
(0.004) 
3.9x10-8 0.022 
(0.004) 
1.8x10-8 EUR 1.00 Yes   
RB1 rs2854355 13 48,882,363 G A 0.27 0.023 
(0.004) 
9.8x10-8 0.024 
(0.004) 
2.2x10-8 TA  No rs9568028 0.88 
rs34217484 13 48,854,550 A T 0.26 0.024 
(0.004) 
4.8x10-8 0.023 
(0.004) 
5.8x10-8 EUR 0.85 No   
RNF219-AS1  rs1819436 13 78,580,283 C T 0.87 0.033 
(0.006) 
6.3x10-9 0.033 
(0.005) 
1.8x10-9 TA/EUR  No rs944379 0.88 
FES  rs12906125 15 91,427,612 G A 0.68 0.023 
(0.004) 
1.7x10-8 0.023 
(0.004) 
1.0x10-8 TA/EUR  No rs6227 0.87 
IGF1R  rs7402982 15 99,193,269 A G 0.43 0.023 
(0.004) 
2.3x10-9 0.023 
(0.004) 
1.1x10-9 TA/EUR  No rs8028620 0.55 
GPR139 rs1011939 16 19,992,996 G A 0.30 0.022 
(0.004) 
1.3x10-7 0.024 
(0.004) 
2.7x10-9 TA  No rs1858988 0.70 
CLDN7  rs113086489 17 7,171,356 T C 0.56 0.031 
(0.004) 
9.1x10-16 0.030 
(0.004) 
1.3x10-15 TA/EUR  No rs5417 0.80 
SUZ12P1-CRLF3  rs144843919 17 29,037,339 G A 0.97 0.066 
(0.012) 
1.4x10-8 0.068 
(0.011) 
1.5x10-9 TA/EUR  No rs8073965 0.22 
SP6-SP2 rs12942207 17 45,968,294 C T 0.30 0.022 
(0.004) 
5.1x10-8 0.024 
(0.004) 
3.0x10-9 TA  No rs11079800 0.91 
rs72833480 17 45,964,861 A G 0.29 0.023 
(0.004) 
4.6x10-8 0.023 
(0.004) 
2.1x10-8 EUR 0.94 No   
ACTL9 rs61154119 19 8,787,750 T G 0.84 0.028 
(0.005) 
1.1x10-7 0.028 
(0.005) 
2.3x10-8 TA  No rs2967684 1 
PEPD rs10402712 19 33,926,013 A G 0.26 0.022 
(0.004) 
4.4x10-7 0.023 
(0.004) 
2.3x10-8 TA  No rs17833935 0.54 
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Locus SNP Chr Position Alleles EAF European ancestry Trans-ancestry Statusa EUR r2 with 
lead TA 
Present in 
HapMap? 
Best proxy in HapMap 
(b37, bp) Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 
JAG1  rs6040076 20 10,658,882 C G 0.49 0.023 
(0.004) 
2.0x10-9 0.022 
(0.004) 
7.2x10-9 TA/EUR  No rs2206815 0.85 
C20orf203  rs28530618 20 31,275,581 A G 0.49 0.026 
(0.004) 
7.7x10-12 0.024 
(0.004) 
8.4x10-11 TA/EUR  No rs6057610 0.82 
MAFB rs6016377 20 39,172,728 T C 0.43 0.024 
(0.004) 
9.5x10-10 0.024 
(0.004) 
3.7x10-10 TA/EUR  Yes   
NRIP1  rs2229742 21 16,339,172 G C 0.87 0.036 
(0.006) 
2.2x10-9 0.034 
(0.006) 
1.5x10-8 TA/EUR  Yes   
KREMEN1  rs134594 22 29,468,456 C T 0.35 0.023 
(0.004) 
1.0x10-8 0.022 
(0.004) 
2.2x10-8 TA/EUR  Yes   
SREBF2  rs62240962 22 42,259,524 C T 0.91 0.047 
(0.007) 
9.7x10-12 0.047 
(0.007) 
3.7x10-12 TA/EUR  No rs10483213 0.70 
PLAC1 rs11096402 X 133,827,868 G A 0.28 0.028 
(0.005) 
1.3x10-9 N/A N/A EUR  Yes   
Chr, chromosome; bp, base pair; EAF, effect allele frequency; SE, standard error. 
aStatus indicates whether the SNP was lead in European ancestry (EUR) or trans-ancestry (TA) meta-analysis. Previous denotes previously reported lead SNP5 at established 
loci. 
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Supplementary Table 5. Loci with multiple distinct association signals attaining genome-wide significance (P<5x10-8) in approximate 
conditional meta-analysis of 143,677 individuals of European ancestry, using 5,000 white British participants from UK BioBank as a 
reference for linkage disequilibrium. 
 
Locus Index 
variant 
Chr Position 
(b37, bp) 
Alleles EAF Unconditional 
meta-analysis 
Conditional meta-analysis UKBB 
refer
ence 
r2 
Present 
in 
HapMap
? 
Best proxy in 
HapMap 
Effect/
Other 
β (SE) P-value Conditioned 
on 
β (SE) P-value 
SNP EUR r2 
ZBTB7B rs3753639 1 154,986,091 C/T 0.24 0.031 
(0.004) 
7.3x10-12 
rs4330912 
0.034 
(0.005) 
2.2x10-14 0.019 No rs905938 0.77 
rs4330912 1 155,969,428 G/C 0.64 0.021 
(0.004) 
1.8x10-7 
rs3753639 
0.025 
(0.004) 
5.4x10-10 No rs12043212 0.93 
HMGA1 rs9368777 6 33,788,637 C/G 0.58 0.022 
(0.004) 
2.2x10-8 
rs1187118 
0.021 
(0.004) 
3.3x10-8 0.000 No rs4304152 0.57 
rs1187118 6 34,169,020 A/T 0.17 0.030 
(0.005) 
3.6x10-9 
rs9368777 
0.030 
(0.005) 
5.4x10-9 No rs1776877 0.95 
PTCH1 rs12551019 9 96,949,079 C/T 0.68 0.022 
(0.004) 
3.1x10-8 
rs3780573 
0.024 
(0.004) 
5.1x10-9 0.001 Yes   
rs3780573 9 98,239,503 A/G 0.10 0.055 
(0.006) 
7.0x10-18 
rs12551019 
0.057 
(0.006) 
1.2x10-18 No rs3824488 1.00 
Chr, chromosome; bp, base pair; EAF, effect allele frequency; SE, standard error. 
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Supplementary Table 6. Candidate gene(s) at birth weight loci. 
 
Locus Lead SNP Chr 
Position 
(b37) 
Candidate gene(s) 
in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
WNT4-
ZBTB40  
rs2473248 1 22,536,643 
WNT4[P,N], 
CDC42[B] 
WNT4: Cerebellum and temporal cortex 
eQTL; CDC42: Whole blood eQTL (proxy 
SNP) 
 
- 
ZBTB7B  rs3753639 1 154,986,091 SHC1[B], S100A7[P]  
SHC1: The Shc adaptor proteins are key transducers of growth 
promotion and gene expression, and are phosphorylated by all 
known receptor tyrosine.  - 
FCGR2B  rs72480273 1 161,644,871 
ATF6[B], APOA2[P], 
FCGR2B[N] 
ATF6: Cerebellum and temporal cortex 
eQTL; FCGR2B: Whole blood, 
cerebellum and temporal cortex eQTL 
HSPA6: higher expression of HSPA6 in placental vascular disease 
(PVD) vs controls; HSPA6 encodes HSP70 which was found to be 
upregulated in PVD vs control placenta and microvascular 
endothelial cells. HSP70 mRNA and protein expression also 
correlated negatively with infant birth weight (PMID:18372927). - 
DTL rs61830764 1 212,289,976 DTL[N]   - 
ATAD2B  rs7575873 2 23,962,647 
ATAD2B[N], 
FKBP1B[P] 
PFN4: Lymphoblastoid eQTL 
 - 
EPAS1  rs1374204 2 46,484,205 RHOQ[B], SOCS5[P] 
EPAS1, PRKCE: Cerebellum and 
temporal cortex eQTL 
EPAS1: involved in the hypoxic response and is suggested to be 
responsible for the genetic adaptation of high-altitude hypoxia 
in Tibetans. PMID 25501874 found associations of 2 variants 
with BW in small sample-sized Tibetans. - 
PTH1R  rs2242116 3 46,941,116 
PTH1R[B,N], 
CCR1[P] 
CCDC12: Whole blood, cerebellum and 
temporal cortex eQTL  - 
ADCY5 rs11719201 3 123,068,744 
ADCY5[B,N], 
HCLS1[P] 
ADCY5: Cerebellum and temporal 
cortex eQTL (proxy SNP)  - 
CPA3  rs10935733 3 148,622,968 AGTR1[B,P] CPA3,CPB1: eQTL (proxy SNP) 
AGTR1 = angiotensin II receptor gene: good candidate as the 
protein mediates processes important for placentation. Levels 
of protein higher in umbilical cord and maternal peripheral 
blood in preeclampsia than in controls; levels of mRNA higher in 
placenta of preeclampsia than control pregnancies; birth weight 
negatively correlated with levels in cord (PMID 23302726). - 
CCNL1-LEKR1 rs13322435 3 156,795,468 LEKR1[N], IL12A[P] 
LEKR1: Temporal cortex eQTL; CCNL1: 
Whole blood, cerebellum and temporal 
cortex eQTL   - 
LCORL rs925098 4 17,919,811 LCORL[N], SLIT2[P] 
LCORL: Cerebellum and temporal cortex 
eQTL 
Adipose tissue and muscle expression in cattle of NCAPG and 
LCORL associated with feed intake and weight gain in cattle 
(these are in a QTL for body weight in cattle). - 
HHIP  rs6537307 4 145,601,863 
HHIP[N], 
ANAPC10[P] 
HHIP: Cerebellum and temporal cortex 
eQTL  - 
5q11.2 rs854037 5 57,091,783 ACTBL2[N], IL6ST[P]   - 
EBF1  rs7729301 5 157,886,953 EBF1[N,B], FABP6[P]   - 
CDKAL1 rs35261542 6 20,675,792 CDKAL1[B], SOX4[P] 
CDKAL1: Cerebellum and temporal 
cortex eQTL  - 
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Locus Lead SNP Chr 
Position 
(b37) 
Candidate gene(s) 
in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
HIST1H2BE rs9379832 6 26,186,200 
HIST1H2BE[N,B], 
BTN2A2[P] 
 
 - 
HMGA1  rs7742369 6 34,165,721 
HMGA1[N,B], 
GRM4[B], 
MAPK14[P] 
HMGA1: Cerebellum and temporal 
cortex eQTL 
 - 
L3MBTL3  rs1415701 6 130,345,835 
L3MBTL3[E,N], 
SAMD3[E], ENPP1[P] 
L3MBTL3, SAMD3: Whole blood, 
cerebellum and temporal cortex eQTLs  - 
ESR1  rs1101081 6 152,032,917 ESR1[N,B], LATS1[P] 
ESR1: Monocyte, cerebellum and 
temporal cortex eQTL (for proxy SNP)  - 
GNA12  rs798489 7 2,801,803 
GNA12[N,E], 
PDGFA[N] 
GNA12: Nerve tibial, lymphoblastid, 
whole blood, cerebellum and temporal 
cortex eQTL  - 
IGF2BP3  rs11765649 7 23,479,013 
IGF2BP3[N,B], 
NPY[P] 
CCDC126: lymphoblastoid eQTL 
 - 
TBX20  rs6959887 7 35,295,365 TBX20[N], SEPT7[P] 
TBX20: Cerebellum and temporal cortex 
eQTL  - 
YKT6-GCK rs138715366 7 44,246,271 YKT6[N], GCK[B]  
GCK mutations reduce birth weight and increase fasting glucose 
(Hattersley et al 1999, Nat Genet). - 
MLXIPL  rs62466330 7 73,056,805 MLXIPL[N], FZD9[P] 
MLXIPL: Cerebellum and temporal 
cortex eQTL (for proxy SNP)  - 
ANK1-NKX6-3  rs13266210 8 41,533,514 ANK1[N,B], SFRP1[P] 
ANK1: Cerebellum, temporal cortex and 
lung eQTL  - 
TRIB1 rs6989280 8 126,508,746 TRIB1[N], MYC[P] 
TRIB1: Cerebellum and temporal cortex 
eQTL  - 
SLC45A4  rs12543725 8 142,247,979 
SLC45A4[N,E], 
PTK2[B,P] 
SLC45A4: Whole blood, cerebellum and 
temporal cortex eQTL  - 
PTCH1  rs28510415 9 98,245,026 
PTCH1[N,B], 
FOXE1[P] 
PTCH1: Whole blood, cerebellum and 
temporal cortex eQTL (for proxy SNP) 
FANCC: mutations result in Fanconi anaemia (associated with 
low birth weight and shorter stature). - 
LPAR1  rs2150052 9 113,945,067 LPAR1[N,E,B,P] LPAR1: whole blood eQTL  - 
PHF19  rs7847628 9 123,631,225 C5[B], DAB2IP[P] 
C5: naïve monocyte, whole blood, 
cerebellum and temporal cortex eQTL  - 
STRBP  rs700059 9 125,824,055 STRBP[E], C5[P] 
STRBP: Whole blood, cerebellum and 
temporal cortex eQTL  - 
HHEX-IDE  rs61862780 10 94,468,643 IDE[B], PLCE1[P] 
HHEX: monocyte, whole blood, 
cerebellum and temporal cortex eQTL  - 
NT5C2 rs74233809 10 104,913,940 NT5C2[N], CHUK[P]  CYP17A1: mutation in maternal CYP17A1 is associated with 
small for gestational age (SGA) (PMID 14665706) - 
ADRB1 rs7076938 10 115,789,375 
ADRB1[N,C,B], 
AFAP1L2[P] 
ADRB1: cerebellum and temporal cortex 
eQTL  
rs1801253 (G389R, 
r2=0.99, damaging) 
PLEKHA1  rs2421016 10 124,167,512 
PLEKHA1[N,E], 
FGFR2[P] 
PLEKHA1: Whole blood, cerebellum and 
temporal cortex eQTL  - 
INS-IGF2  rs72851023 11 2,130,620 INS-IGF2[N,B,imp]   - 
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Locus Lead SNP Chr 
Position 
(b37) 
Candidate gene(s) 
in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
MTNR1B  rs10830963 11 92,708,710 MTNR1B[N,B,P] 
MTNR1B: Cerebellum and temporal 
cortex eQTL  - 
APOLD1 rs11055034 12 12,890,626 
CDKN1B[B,E,P], 
HEBP1[B] 
CDKN1B: Cerebellum and temporal 
cortex eQTL  - 
ABCC9  rs139975827 12 22,068,161 ABCC9[N], KRAS[P]   - 
ITPR2 rs12823128 12 26,872,730 ITPR2[N,B] 
ITPR2: Cerebellum and temporal cortex 
eQTL  - 
HMGA2 rs1351394 12 66,351,826 
HMGA2[N,B], 
IRAK3[P] 
HMGA2: Cerebellum and temporal 
cortex eQTL 
HMGA2: 12q14 microdeletion syndrome implicates HMGA2 as 
causal to height (PMID: 17220210 and 19298872). - 
IGF1  rs7964361 12 102,994,878 IGF1[N,B,P]   - 
LINC00332 rs2324499 13 40,662,001 
LINC00332[N], 
TNFSF11[P] 
 
 - 
RB1 rs2854355 13 48,882,363 
RB1[N,B,P,imp], 
LPAR6[imp,B] 
RB1: Whole blood, cerebellum and 
temporal cortex eQTL  - 
RNF219-AS1  rs1819436 13 78,580,283 EDNRB[B,P] 
EDNRB: Monocyte, cerebellum and 
temporal cortex eQTL (for proxy SNP)  - 
FES  rs12906125 15 91,427,612 FES[N,E], MESP1[P] 
FES: Thyroid, whole blood, cerebellum, 
temporal cortex and tibial nerve eQTL 
FURIN: a ubiquitous proprotein convertase, the major 
processing enzyme of the secretory pathway. It is involved in 
processing proinsulin to insulin, and in processing proIGF2 
(PMID 9660813). - 
IGF1R  rs7402982 15 99,193,269 IGF1R[B]   - 
GPR139 rs1011939 16 19,992,996 
GPR139[N], 
RPS15A[P] 
 
 - 
CLDN7  rs113086489 17 7,171,356 
SLC2A4[B], 
POLR2A[S], DVL2[P] 
SLC2A4: Cerebellum and temporal 
cortex eQTL; DVL2: monocyte, whole 
blood, cerebellum and temporal cortex 
eQTL (for proxy SNP) 
SLC2A4 (GLUT4): an insulin responsive glucose transporter. 
PMID 24062248 showed lower mRNA in preadipocytes from 
LBW vs NBW. Protein level of SLCA24 was lower in adipose 
tissue of LBW men compared to NMW (PMID 17063325). - 
SUZ12P1-
CRLF3  
rs144843919 17 29,037,339 SUZ12P1[N]  
 - 
SP6-SP2 rs12942207 17 45,968,294 SP2[N], NGFR[P] 
SP2: Whole blood, cerebellum and 
temporal cortex eQTL (for proxy SNP)  - 
ACTL9  rs61154119 19 8,787,750 ACTL9[N], INSR[P]   - 
PEPD rs10402712 19 33,926,013 CEBPA[B]  
CEBPA: an adipogenic transcription factor involved in adipocyte 
differentiation. Expression levels lower in smaller pig fetuses 
(PMID 21354690). - 
JAG1  rs6040076 20 10,658,882 JAG1[N], MKKS[P] 
JAG1: Cerebellum and temporal cortex 
eQTL (proxy SNP) 
JAG1 is a ligand that interacts with receptors in the notch 
signalling pathway. Notch pathway plays an important role 
during placental development; notch pathway downregulation 
is associated with preeclampsia, and specifically JAG1 mRNA 
levels downregulated in preeclampsia placental samples vs 
controls (PMID 25962154). - 
C20orf203  rs28530618 20 31,275,581 
BAK1P1[E], 
FOXS1[P] 
BAK1P1: thyroid eQTL (for proxy SNP)  
 - 
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Locus Lead SNP Chr 
Position 
(b37) 
Candidate gene(s) 
in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
MAFB rs6016377 20 39,172,728 MAFB[N], PLCG1[P] 
MAFB: Cerebellum and temporal cortex 
eQTL (for proxy SNP) 
Lots of literature on importance of MAFB in transcriptional 
regulation in embryonic islets, e.g. analysis of Mafa(-/-) and 
pancreas-specific Mafa(∆panc) deletion mutant mice 
demonstrated a primary role for MafA in adult β-cell activity, 
different from the embryonic importance of MafB (PMID 
24520122). - 
NRIP1 rs2229742 21 16,339,172 
NRIP1[N,C], 
SAMSN1[P] 
NRIP1: Cerebellum and temporal cortex 
eQTL 
 
rs2229742 (R448G, 
lead SNP, damaging) 
KREMEN1  rs134594 22 29,468,456 
KREMEN1[N,E], 
YWHAH[P] 
KREMEN1: Monocyte, heart, whole 
blood, cerebellum and temporal cortex 
eQTL 
 
- 
SREBF2  rs62240962 22 42,259,524 
SREBF2[N,B], 
PDGFB[P] 
  
- 
PLAC1 rs11096402 X 133,827,868 PLAC1[N]  
PLAC1 shows placenta-specific expression in human (PMID: 
10995572). A mutant mouse model showed PLAC1 as a 
paternally imprinted, X-linked gene essential for normal 
placental and embryonic development (PMID: 22729990).  - 
aB = biological candidate, C = coding variant, E = eQTL (from GTEx), N=nearest, P = best ranked gene in PPI network, imp = imprinted gene. 
beQTL reported from GTEx v4, GEUVADIS, and 11 other studies for the lead variant. When there was no eQTL report for the lead variant, eQTL reports for the proxy SNPs (r2>0.8 
with the lead variant) are shown. 
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Supplementary Table 7. Summary of 99% credible sets at 62 distinct autosomal association signals. 
 
Locus Index variant Chr Position 
(b37, bp) 
MANTRA 
log10BF 
99% credible set 
Variants Distance (bp) Interval (bp) 
WNT4-ZBTB40  rs2473248 1 22,536,643 7.68 7 17,534 22,536,643-22,554,176 
ZBTB7B  rs3753639 1 154,986,091 12.19 6 22,088 154,984,363-155,006,450 
 rs4330912 1 155,969,428 7.93 45 403,839 155,612,197-156,016,035 
FCGR2B  rs72480273 1 161,644,871 7.48 37 173,221 161,500,712-161,673,932 
DTL rs61830764 1 212,289,976 6.02 56 702,234 211,830,044-212,532,277 
ATAD2B  rs7575873 2 23,962,647 8.87 234 477,824 23,887,437-24,365,260 
EPAS1  rs1374204 2 46,484,205 27.22 4 695 46,484,188-46,484,882 
PTH1R  rs2242116 3 46,941,116 6.65 54 243,837 46,925,539-47,169,375 
ADCY5  rs11719201 3 123,068,744 24.38 6 16,621 123,065,778-123,082,398 
CPA3  rs10935733 3 148,622,968 7.91 80 33,654 148,591,725-148,625,378 
CCNL1-LEKR1  rs13322435 3 156,795,468 40.24 11 3,265 156,795,468-156,798,732 
LCORL  rs925098 4 17,919,811 13.56 15 123,806 17,901,679-18,025,484 
HHIP  rs6537307 4 145,601,863 10.43 43 137,679 145,520,608-145,658,286 
5q11.2 rs854037 5 57,091,783 5.77 63 276,269 56,906,160-57,182,428 
EBF1  rs7729301 5 157,886,953 7.62 50 77380 157,884,706-157,962,085 
CDKAL1  rs35261542 6 20,675,792 26.41 7 14,242 20,673,880-20,688,121 
HIST1H2BE rs9379832 6 26,186,200 6.64 5 26,542 26,180,634-26,207,175 
HMGA1  rs9368777 6 33,788,637 6.20 91 570,460 33,292,543-33,863,002 
 rs1187118 6 34,169,020 6.94 27 148,294 34,095,696-34,243,989 
L3MBTL3  rs1415701 6 130,345,835 9.03 2 4,601 130,341,235-130,345,835 
ESR1  rs1101081 6 152,032,917 17.69 14 20,968 152,029,556-152,050,523 
GNA12  rs798489 7 2,801,803 7.01 114 160,777 2,752,152-2,912,928 
IGF2BP3  rs11765649 7 23,479,013 7.58 23 111,149 23,474,687-23,585,835 
TBX20  rs6959887 7 35,295,365 6.75 113 109,117 35,196,208-35,305,324 
YKT6-GCK rs138715366 7 44,246,271 24.10 1 1 44,246,271-44,246,271 
MLXIPL  rs62466330 7 73,056,805 9.60 102 221,896 72,836,230-73,058,025 
ANK1-NKX6-3  rs13266210 8 41,533,514 9.22 17 28,742 41,508,577-41,537,318 
TRIB1 rs6989280 8 126,508,746 5.69 39 411,117 126,114,947-126,526,063 
SLC45A4  rs12543725 8 142,247,979 7.18 10 13,200 142,239,381-142,252,580 
PTCH1  rs12551019 9 96,949,079 6.96 40 652,934 96,900,505-97,553,438 
 rs3780573 9 98,239,503 16.44 23 53,294 98,212,608-98,265,901 
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Locus Index variant Chr Position MANTRA 
log10BF 
99% credible set 
(b37, bp) Variants Distance (bp) Interval (bp) 
LPAR1  rs2150052 9 113,945,067 6.29 60 214,738 113,828,811-114,043,548 
PHF19  rs7847628 9 123,631,225 6.95 5 90,924 123,631,225-123,722,148 
STRBP  rs700059 9 125,824,055 10.35 135 432,744 125,605,840-126,038,583 
HHEX-IDE  rs61862780 10 94,468,643 12.40 31 134,694 94,358,023-94,492,716 
NT5C2 rs74233809 10 104,913,940 7.25 98 404,547 104,655,350-105,059,896 
ADRB1  rs7076938 10 115,789,375 15.69 4 9,521 115,789,375-115,798,895 
PLEKHA1  rs2421016 10 124,167,512 6.90 26 70,596 124,127,990-124,198,585 
INS-IGF2  rs72851023 11 2,130,620 7.89 48 145,434 2,078,742-2,224,175 
MTNR1B  rs10830963 11 92,708,710 5.78 52 499,464 92,225,858-92,725,321 
APOLD1 rs11055034 12 12,890,626 6.33 13 42,180 12,849,241-12,891,420 
ABCC9  rs139975827 12 22,068,161 5.64 72 133,773 22,027,182-22,160,954 
ITPR2 rs12823128 12 26,872,730 6.12 114 291,548 26,759,026-27,050,573 
HMGA2  rs1351394 12 66,351,826 30.74 7 32,282 66,343,810-66,376,091 
IGF1  rs7964361 12 102,994,878 6.71 42 213,557 102,867,636-103,081,192 
LINC00332 rs2324499 13 40,662,001 6.83 41 95,318 40,583,503-40,678,820 
RB1 rs2854355 13 48,882,363 6.23 143 403,044 48,797,661-49,200,704 
RNF219-AS1  rs1819436 13 78,580,283 7.44 105 220,228 78,443,297-78,663,524 
FES  rs12906125 15 91,427,612 6.68 24 36,382 91,404,705-91,441,086 
IGF1R  rs7402982 15 99,193,269 7.59 5 15,682 99,177,595-99,193,276 
GPR139 rs1011939 16 19,992,996 7.20 55 53,120 19,992,996-20,461,115 
CLDN7  rs113086489 17 7,171,356 13.41 29 84,570 7,101,292-7,185,861 
SUZ12P1-CRLF3  rs144843919 17 29,037,339 7.60 21 520,396 28,780,178-29,300,573 
SP6-SP2 rs12942207 17 45,968,294 7.04 21 90,685 45,940,310-46,030,994 
ACTL9 rs61154119 19 8,787,750 6.24 21 4,455 8,785,744-8,790,198 
PEPD rs10402712 19 33,926,013 6.40 35 218,599 33,784,657-34,003,255 
JAG1  rs6040076 20 10,658,882 6.72 43 164,577 10,539,775-10,704,351 
C20orf203  rs28530618 20 31,275,581 8.69 63 114,192 31,214,234-31,328,425 
MAFB rs6016377 20 39,172,728 8.15 33 72,001 39,144,286-39,216,286 
NRIP1 rs2229742 21 16,339,172 6.69 4 85,250 16,339,172-16,424,421 
KREMEN1  rs134594 22 29,468,456 6.41 56 52,177 29,461,150-29,513,326 
SREBF2  rs62240962 22 42,259,524 10.01 4 189,151 42,070,374-42,259,524 
Chr, chromosome; bp, base pair; BF, Bayes factor.
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Supplementary Table 8. BW credible set enrichment for DNaseI hypersensitive sites. 
 
(a) 128 cell-type DHS annotation and 4 genic annotation tested for enrichment individually 
Cell type Lower 
95%CIa 
Effecta Upper 
95%CIa 
Tissue Category 
iPS_6_9 -20.00 0.35 1.74 Stem cell Stem cell 
iPS_4_7 -20.00 0.82 2.04 Stem cell Stem cell 
iPS_19_7 -1.22 0.96 2.09 Stem cell Stem cell 
iPS_19_11 -1.40 0.80 1.93 Stem cell Stem cell 
hESCT0 -0.10 1.26 2.16 Stem cell Stem cell 
HESC -20.00 0.21 1.79 Stem cell Stem cell 
NPC 0.94 2.14 2.99 Brain Progenitor cell 
HMVEC_dNeo 0.24 1.62 2.54 Neonatal blood vessel Neonatal 
HMVEC_dLyNeo 0.48 1.71 2.58 Neonatal blood vessel Neonatal 
HMVEC_dBlNeo -0.82 1.00 2.01 Neonatal blood vessel Neonatal 
NHDF_Neo 1.22 2.29 3.12 Skin Neonatal 
fThymus 0.88 1.94 2.75 Foetal thymus Foetal 
fTestes 0.88 1.97 2.79 Foetal testes Foetal 
fStomach 0.40 1.63 2.50 Foetal stomach Foetal 
fSpleen 0.75 1.86 2.68 Foetal spleen Foetal 
fSpinal_cord 0.52 1.58 2.38 Foetal skin Foetal 
fSkin_fibro_upper_back -0.86 1.43 2.44 Foetal skin Foetal 
fSkin_fibro_scalp -4.83 1.03 2.17 Foetal skin Foetal 
fSkin_fibro_leg_R_quad -20.00 0.84 2.11 Foetal skin Foetal 
fSkin_fibro_leg_L_quad -0.89 1.23 2.25 Foetal skin Foetal 
fSkin_fibro_bicep_R -20.00 0.73 2.05 Foetal skin Foetal 
fSkin_fibro_bicep_L -20.00 1.09 2.24 Foetal skin Foetal 
fSkin_fibro_back -20.00 0.04 1.75 Foetal skin Foetal 
fSkin_fibro_abdomen -3.50 1.30 2.41 Foetal skin Foetal 
fSkin -20.00 1.13 2.31 Foetal skin Foetal 
fPlacenta 0.80 1.72 2.49 Foetal placenta Foetal 
fMuscle_upper_trunk 0.70 1.74 2.55 Foetal muscle Foetal 
fMuscle_upper_limb_sk -0.08 1.43 2.35 Foetal muscle Foetal 
fMuscle_upper_back 0.48 1.70 2.54 Foetal muscle Foetal 
fMuscle_trunk 0.63 1.72 2.54 Foetal muscle Foetal 
fMuscle_lower_limb 0.53 1.53 2.33 Foetal muscle Foetal 
fMuscle_leg 0.22 1.60 2.49 Foetal muscle Foetal 
fMuscle_back 0.34 1.37 2.17 Foetal muscle Foetal 
fMuscle_arm 0.46 1.73 2.60 Foetal muscle Foetal 
fLung_R 0.76 1.84 2.65 Foetal lung Foetal 
fLung_L 0.09 1.50 2.41 Foetal lung Foetal 
fLung -1.03 1.34 2.42 Foetal lung Foetal 
fKidney_renal_pelvis_R 1.23 2.12 2.87 Foetal kidney Foetal 
fKidney_renal_pelvis_L 0.51 1.62 2.45 Foetal kidney Foetal 
fKidney_renal_pelvis 0.60 1.69 2.52 Foetal kidney Foetal 
fKidney_renal_cortex_R 0.03 1.44 2.35 Foetal kidney Foetal 
fKidney_renal_cortex_L 0.91 1.88 2.67 Foetal kidney Foetal 
fKidney_R 0.52 1.63 2.45 Foetal kidney Foetal 
fKidney_L 0.70 1.81 2.65 Foetal kidney Foetal 
fKidney 0.42 1.65 2.51 Foetal kidney Foetal 
fIntestine_Sm -0.17 1.29 2.22 Foetal intestine Foetal 
fIntestine_Lg 0.25 1.63 2.55 Foetal intestine Foetal 
fHeart 0.21 1.56 2.45 Foetal heart Foetal 
fBrain 0.65 1.90 2.78 Foetal brain Foetal 
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Cell type Lower 
95%_CIa 
Effecta Upper 
95%_CIa 
Tissue Category 
fAdrenal 0.54 1.69 2.52 Foetal adrenal Foetal 
WI_38_TAM -3.99 0.83 1.95 Embryonic Embryonic 
WI_38 -20.00 0.43 1.87 Embryonic Embryonic 
Trophoblast -20.00 1.21 2.36 Embryonic Embryonic 
Mesendoderm -0.52 1.15 2.15 Embryonic Embryonic 
Skin_Melanocytes -0.05 1.40 2.33 Skin Adult 
Skin_Keratinocytes -20.00 0.84 2.00 Skin Adult 
Skin_Fibroblasts 0.81 1.81 2.64 Skin Adult 
NHEK -20.00 0.57 1.98 Skin Adult 
NHDF_Ad -0.75 1.09 2.09 Skin Adult 
BJ -0.05 1.65 2.64 Skin Adult 
AG10803 -0.12 1.50 2.46 Skin Adult 
AG09309 -20.00 1.03 2.20 Skin Adult 
AG04449 -0.32 1.50 2.47 Skin Adult 
PrEC -20.00 0.83 2.13 Prostate Adult 
LNCap -20.00 1.28 2.42 Prostate Adult 
SkMC -0.82 1.33 2.38 Muscle Adult 
HSMM_D -20.00 0.66 1.83 Muscle Adult 
HSMM -20.00 -1.29 1.31 Muscle Adult 
NHLF -2.24 0.96 2.08 Lung Adult 
IMR90 -20.00 0.61 1.93 Lung Adult 
HPF -1.69 1.00 2.10 Lung Adult 
AG04450 0.03 1.60 2.56 Lung Adult 
HRGEC -0.64 1.57 2.60 Kidney Adult 
HCM -20.00 0.79 1.99 Heart Adult 
HCFaa -0.48 1.25 2.25 Heart Adult 
HCF -2.09 1.13 2.20 Heart Adult 
HGF 0.49 1.88 2.79 Gingival Adult 
AG09319 -0.49 1.54 2.56 Gingival Adult 
HFF_MyC -1.06 1.16 2.21 Foreskin Adult 
HFF 0.51 1.74 2.62 Foreskin Adult 
HConF -20.00 0.94 2.12 Eye Adult 
SAEC -20.00 0.92 2.11 Epithelium Adult 
RPTEC -20.00 -0.11 1.55 Epithelium Adult 
HRPEpiC -20.00 0.20 1.67 Epithelium Adult 
HRE -1.34 1.17 2.20 Epithelium Adult 
HRCE -20.00 0.82 2.02 Epithelium Adult 
HPdLF -20.00 0.55 1.91 Epithelium Adult 
HNPCEpiC -0.11 1.42 2.36 Epithelium Adult 
HIPEpiC -0.16 1.38 2.32 Epithelium Adult 
HEEpiC -0.05 1.51 2.45 Epithelium Adult 
HCPEpiC 0.06 1.53 2.45 Epithelium Adult 
HAEpiC -0.87 1.21 2.23 Epithelium Adult 
HVMF -0.07 1.53 2.49 Connective Adult 
vHMEC -0.13 1.36 2.29 Breast Adult 
HMF -0.37 1.35 2.31 Breast Adult 
HMEC 0.27 1.69 2.60 Breast Adult 
NHA -1.48 1.16 2.22 Brain Adult 
HAsp -20.00 0.63 1.91 Brain Adult 
HAh -20.00 0.59 1.80 Brain Adult 
HAc -20.00 0.63 1.97 Brain Adult 
HUVEC -0.57 1.36 2.38 Blood vessel Adult 
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Cell type Lower 
95%_CIa 
Effecta Upper 
95%_CIa 
Tissue Category 
HPAF -20.00 0.95 2.08 Blood vessel Adult 
HPAEC -1.23 1.34 2.44 Blood vessel Adult 
HMVEC_LLy -0.39 1.32 2.34 Blood vessel Adult 
HMVEC_LBl -4.39 0.70 1.90 Blood vessel Adult 
HMVEC_dLyAd -20.00 1.02 2.24 Blood vessel Adult 
HMVEC_dBlAd 0.03 1.46 2.38 Blood vessel Adult 
HMVEC_dAd -0.79 1.37 2.44 Blood vessel Adult 
HBMEC -1.98 0.88 1.96 Blood vessel Adult 
AoAF -20.00 0.73 1.92 Blood vessel Adult 
hTH2 0.28 1.54 2.43 Blood Adult 
hTH17 -20.00 1.00 2.39 Blood Adult 
hTH1 0.19 1.61 2.53 Blood Adult 
H9_P42 -0.80 1.24 2.27 Blood Adult 
H1_P18 -0.07 1.40 2.35 Blood Adult 
GM12878 -0.72 1.24 2.30 Blood Adult 
GM12865 -20.00 0.73 2.07 Blood Adult 
GM12864 -20.00 0.85 2.10 Blood Adult 
GM06990 -20.00 0.98 2.19 Blood Adult 
CD8 0.34 1.73 2.66 Blood Adult 
CD56 -1.01 1.06 2.13 Blood Adult 
CD4 -0.49 1.28 2.29 Blood Adult 
CD34 -0.15 1.50 2.49 Blood Adult 
CD3_CordBlood -1.52 1.56 2.69 Blood Adult 
CD3 -2.48 1.09 2.30 Blood Adult 
CD20 -2.52 0.90 2.01 Blood Adult 
CD19 0.29 1.71 2.66 Blood Adult 
CD14 -0.70 1.07 2.10 Blood Adult 
TSS -0.87 1.37 2.42 Genic Genic 
3UTR -20.00 1.04 2.47 Genic Genic 
5UTR -47.50 -2.00 2.14 Genic Genic 
CDS -2.08 1.03 2.48 Genic Genic 
 
(b) Six categorical fields from ENCODE tested for enrichment in a joint model 
Annotation Lower 95% CIa Effecta Upper 95% CIa 
Neonatal DHS 0.60 1.59 2.40 
Foetal DHS 0.57 1.43 2.37 
Genic -0.85 0.63 1.61 
Stem_cell DHS -1.35 0.09 1.04 
Adult DHS -1.12 -0.26 0.62 
Embryonic DHS -3.95 -1.49 -0.39 
aEstimated effects of enrichment and 95% CI are natural log transformed. We considered an annotation 
enriched if the 95% CI of the estimated effects of enrichment did not overlap zero.
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Supplementary Table 9. Genetic variance explained.  
 
Study N By 62 known and 
novel SNPs 
By 55 novel SNPs 
Variance 
explained SE 
Variance 
explained SE 
HAPO 1338 0.020 0.011 0.013 0.010 
NFBC1966 5402 0.029 0.007 0.020 0.006 
Generation R 2537 0.049 0.013 0.026 0.009 
SE, standard error. HAPO study is independent of the birth weight meta-analysis whilst NFBC1966 and 
Generation R (European component) are part of the meta-analysis.     
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Supplementary Table 10. Look-up of maternal genotype effect on offspring BW (unadjusted for foetal genotype) in up to 68,254 mothers for 
the 60 BW loci detected in foetal birth weight GWAS. 
 
Locus Lead SNP 
Allele 
Foetal (European 
ancestry) GWAS 
Maternal GWAS 
Foetal Beta 
- Maternal 
Betaa Effect Other β SE EAF β SE P-value N 
WNT4-ZBTB40  rs2473248 C T 0.033 0.006 0.88 0.013 0.010 0.20 48,632 0.020 
ZBTB7B  rs3753639 C T 0.031 0.004 0.25 0.017 0.008 0.03 48,632 0.014 
FCGR2B  rs72480273 C A 0.031 0.005 0.19 0.013 0.008 0.11 48,632 0.018 
DTL rs61830764 A G 0.022 0.004 0.37 -0.002 0.007 0.76 48,632 0.020 
ATAD2B  rs7575873 A G 0.038 0.004 0.87 -0.011 0.010 0.27 48,632 0.028 
EPAS1  rs1374204 T C 0.047 0.004 0.69 0.024 0.006 5.6x10-5 68,252 0.023 
PTH1R  rs2242116 A G 0.022 0.004 0.37 0.019 0.006 9.3x10-4 67,542 0.004 
ADCY5  rs11719201 T C 0.046 0.004 0.25 -0.001 0.008 0.85 48,632 0.045 
CPA3  rs10935733 T C 0.022 0.004 0.40 0.015 0.007 0.02 48,632 0.007 
CCNL1-LEKR1 rs13322435 A G 0.053 0.004 0.59 0.026 0.006 9.5x10-6 68,250 0.027 
LCORL  rs925098 G A 0.034 0.004 0.28 0.025 0.006 2.9x10-5 68,254 0.009 
HHIP  rs6537307 G A 0.025 0.004 0.49 0.019 0.005 4.4x10-4 68,247 0.006 
5q11.2  rs854037 A G 0.027 0.005 0.80 0.009 0.007 0.18 68,219 0.018 
EBF1  rs7729301 A G 0.024 0.004 0.74 0.039 0.007 8.9x10-8 48,632 -0.015 
CDKAL1  rs35261542 C A 0.044 0.004 0.74 0.004 0.007 0.60 48,632 0.040 
HIST1H2BE rs9379832 A G 0.023 0.004 0.73 0.008 0.007 0.30 48,632 0.015 
HMGA1  rs7742369 G A 0.028 0.005 0.19 0.017 0.007 0.01 68,253 0.011 
L3MBTL3  rs1415701 G A 0.025 0.004 0.73 0.037 0.006 3.7x10-9 66,897 -0.012 
ESR1  rs1101081 C T 0.038 0.004 0.72 0.021 0.007 3.8x10-3 48,632 0.017 
GNA12  rs798489 C T 0.023 0.004 0.72 0.023 0.006 1.6x10-4 68,253 0.001 
IGF2BP3  rs11765649 T C 0.027 0.004 0.74 0.015 0.007 0.04 48,632 0.012 
TBX20  rs6959887 A G 0.023 0.004 0.61 0.009 0.006 0.10 68,232 0.014 
YKT6-GCK rs138715366 C T 0.241 0.023 0.99 0.137 0.038 2.8x10-4 48,632 0.104 
MLXIPL rs62466330 C T 0.051 0.011 0.07 0.022 0.013 0.08 48,632 0.029 
ANK1-NKX6-3  rs13266210 A G 0.031 0.005 0.78 0.005 0.007 0.43 68,252 0.026 
TRIB1 rs6989280 G A 0.022 0.004 0.72 0.020 0.006 1.3x10-3 67,520 0.003 
SLC45A4  rs12543725 G A 0.023 0.004 0.58 0.021 0.005 1.4x10-4 68,222 0.002 
PTCH1  rs28510415 G A 0.056 0.007 0.09 0.034 0.011 2.2x10-3 48,632 0.022 
LPAR1  rs2150052 T A 0.021 0.004 0.50 0.017 0.005 1.4x10-3 68,245 0.004 
PHF19  rs7847628 G A 0.023 0.004 0.68 0.009 0.007 0.20 48,632 0.014 
STRBP  rs700059 G A 0.033 0.005 0.16 0.018 0.008 0.02 68,251 0.016 
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Locus Lead SNP 
Allele 
Foetal (European 
ancestry) GWAS 
Maternal GWAS 
Foetal Beta 
- Maternal 
Betaa Effect Other β SE EAF β SE P-value N 
HHEX-IDE  rs61862780 T C 0.028 0.004 0.49 -0.004 0.006 0.55 48,632 0.024 
NT5C2 rs74233809 C T 0.037 0.007 0.08 0.005 0.012 0.70 48,632 0.032 
ADRB1  rs7076938 T C 0.036 0.004 0.73 0.010 0.006 0.09 68,254 0.026 
PLEKHA1  rs2421016 T C 0.021 0.004 0.48 0.016 0.005 3.3x10-3 68,253 0.005 
INS-IGF2  rs72851023 T C 0.048 0.008 0.08 0.015 0.012 0.24 48,632 0.033 
MTNR1B  rs10830963 G C 0.023 0.004 0.29 0.048 0.006 5.1x10-15 67,603 -0.025 
APOLD1 rs11055034 C A 0.022 0.004 0.71 0.002 0.006 0.74 67,597 0.020 
ABCC9  rs139975827 G A 0.027 0.007 0.63 -0.010 0.007 0.13 48,632 0.017 
ITPR2 rs12823128 T C 0.021 0.004 0.53 0.009 0.005 0.08 68,187 0.012 
HMGA2  rs1351394 T C 0.044 0.004 0.49 0.034 0.005 1.4x10-10 68,247 0.010 
IGF1  rs7964361 A G 0.039 0.007 0.10 0.018 0.010 0.06 68,251 0.021 
LINC00332 rs2324499 G C 0.022 0.004 0.68 0.012 0.006 0.05 68,213 0.011 
RB1 rs2854355 G A 0.023 0.004 0.26 0.017 0.007 0.03 48,632 0.007 
RNF219-AS1  rs1819436 C T 0.033 0.006 0.88 0.007 0.010 0.50 48,632 0.026 
FES  rs12906125 G A 0.023 0.004 0.68 0.029 0.007 1.8x10-5 48,632 -0.006 
IGF1R  rs7402982 A G 0.023 0.004 0.41 0.021 0.007 1.7x10-3 48,632 0.002 
GPR139 rs1011939 G A 0.022 0.004 0.28 0.007 0.007 0.34 48,632 0.015 
CLDN7  rs113086489 T C 0.031 0.004 0.54 0.022 0.007 7.7x10-4 48,632 0.009 
SUZ12P1-CRLF3  rs144843919 G A 0.066 0.012 0.96 0.041 0.018 0.02 48,632 0.025 
SP6-SP2 rs12942207 C T 0.022 0.004 0.30 0.010 0.007 0.14 48,632 0.012 
ACTL9 rs61154119 T G 0.028 0.005 0.85 0.047 0.009 1.5x10-7 48,632 -0.019 
PEPD rs10402712 A G 0.022 0.004 0.26 -0.002 0.007 0.76 48,632 0.020 
JAG1  rs6040076 C G 0.023 0.004 0.51 0.015 0.007 0.02 48,632 0.008 
C20orf203  rs28530618 A G 0.026 0.004 0.47 0.003 0.006 0.62 48,632 0.023 
MAFB rs6016377 T C 0.024 0.004 0.45 0.005 0.006 0.35 67,909 0.019 
NRIP1 rs2229742 G C 0.036 0.006 0.88 0.018 0.009 0.04 68,155 0.018 
KREMEN1  rs134594 C T 0.023 0.004 0.36 0.004 0.006 0.53 66,634 0.020 
SREBF2  rs62240962 C T 0.047 0.007 0.92 0.027 0.012 0.02 48,632 0.020 
PLAC1 rs11096402 G A 0.028 0.005 0.24 0.001 0.003 0.82 45,353 0.027 
SE, standard error, EAF, effect allele frequency. The lead SNPs at MTNR1B, HMGA2 and L3MBTL3 attained genome-wide significance in the maternal, as well as the foetal 
GWAS. aFoetal GWAS effect size subtracted from maternal GWAS effect size: 55/60 beta values were more positive in the foetal GWAS (aligned to BW-raising allele) than in 
the maternal GWAS (2-tailed binomial sign test P=1x10-11).  
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Supplementary Table 11. Maternal and foetal conditional analyses in 12,909 mother-child pairs. 
 
Locus Index variant EA/
NEA 
Maternal effect on offspring birth weight Foetal effect on birth weight 
Unadjusted Adjusted for foetal genotype Unadjusted Adjusted for maternal genotype 
β SE P-value β SE P-value β SE P-value β SE P-value 
WNT4-ZBTB40 rs2473248 C/T 0.004 0.018 0.82 -0.006 0.020 0.76 0.033 0.018 0.06 0.039 0.020 0.05 
ZBTB7B rs3753639 C/T 0.022 0.015 0.16 -0.005 0.017 0.79 0.060 0.016 9.8x10-5 0.060 0.018 5.7x10-4 
FCGR2B rs72480273 C/A 0.034 0.017 0.05 0.018 0.019 0.34 0.042 0.017 0.01 0.031 0.019 0.11 
DTL rs61830764 A/G 0.026 0.014 0.06 0.016 0.016 0.31 0.029 0.014 0.04 0.027 0.016 0.09 
ATAD2B rs7575873 A/G 0.018 0.019 0.35 0.007 0.022 0.74 0.042 0.019 0.03 0.047 0.022 0.03 
EPAS1 rs1374204 T/C 0.032 0.013 0.02 0.008 0.015 0.60 0.056 0.013 2.6x10-5 0.047 0.015 1.9x10-3 
PTH1R rs2242116 A/G 0.025 0.013 0.05 0.031 0.015 0.03 0.002 0.013 0.86 -0.013 0.014 0.38 
ADCY5 rs11719201 T/C 0.000 0.015 1.00 -0.025 0.017 0.15 0.057 0.015 2.2x10-4 0.075 0.017 1.5x10-5 
CPA3 rs10935733 T/C -0.004 0.013 0.73 -0.006 0.014 0.66 0.007 0.013 0.57 0.013 0.014 0.36 
CCNL1-LEKR1 rs13322435 A/G 0.028 0.013 0.03 -0.015 0.014 0.31 0.091 0.013 7.9x10-13 0.097 0.014 9.7x10-12 
LCORL rs925098 G/A 0.012 0.014 0.39 -0.017 0.016 0.29 0.057 0.014 3.1x10-5 0.060 0.015 1.0x10-4 
HHIP rs6537307 G/A 0.028 0.013 0.03 0.003 0.014 0.85 0.057 0.013 1.1x10-5 0.057 0.015 7.8x10-5 
5q11.2 rs854037 A/G 0.019 0.015 0.20 0.016 0.017 0.35 0.022 0.015 0.15 0.011 0.017 0.52 
EBF1 rs7729301 A/G 0.036 0.014 8.8x10-3 0.040 0.015 9.6x10-3 0.024 0.014 0.08 0.010 0.016 0.52 
CDKAL1 rs35261542 C/A 0.003 0.014 0.81 -0.028 0.016 0.07 0.057 0.014 4.3x10-5 0.071 0.016 6.1x10-6 
HIST1H2BE rs9379832 A/G -0.005 0.014 0.74 -0.012 0.016 0.45 0.022 0.014 0.12 0.026 0.016 0.10 
HMGA1 rs7742369 G/A 0.027 0.015 0.08 0.006 0.017 0.72 0.043 0.015 4.9x10-3 0.035 0.017 0.04 
L3MBTL3 rs1415701 G/A 0.035 0.014 0.01 0.019 0.016 0.22 0.052 0.014 2.7x10-4 0.041 0.016 0.01 
ESR1 rs1101081 C/T 0.009 0.014 0.51 -0.004 0.016 0.82 0.029 0.014 0.04 0.033 0.016 0.04 
GNA12 rs798489 C/T 0.018 0.015 0.22 0.011 0.017 0.50 0.034 0.015 0.02 0.029 0.017 0.08 
IGF2BP3 rs11765649 T/C 0.007 0.015 0.64 0.006 0.017 0.74 0.017 0.015 0.25 0.013 0.017 0.45 
TBX20 rs6959887 A/G 0.018 0.013 0.15 -0.002 0.014 0.89 0.040 0.013 1.7x10-3 0.036 0.014 0.01 
YKT6-GCK rs138715366 C/T -0.030 0.087 0.73 -0.147 0.097 0.13 0.186 0.087 0.03 0.230 0.098 0.02 
MLXIPL rs62466330 C/T 0.019 0.028 0.50 -0.015 0.031 0.62 0.104 0.028 2.2x10-4 0.129 0.031 3.3x10-5 
ANK1-NKX6-3 rs13266210 A/G 0.013 0.015 0.41 0.009 0.017 0.61 0.018 0.015 0.24 0.023 0.017 0.18 
TRIB1 rs6989280 G/A 0.014 0.014 0.32 0.019 0.016 0.24 -0.003 0.014 0.84 -0.012 0.016 0.46 
SLC45A4 rs12543725 G/A 0.012 0.013 0.36 0.004 0.015 0.79 0.013 0.013 0.31 0.014 0.015 0.34 
PTCH1 rs28510415 G/A 0.037 0.023 0.11 -0.005 0.026 0.84 0.105 0.023 8.0x10-6 0.105 0.027 7.2x10-5 
LPAR1 rs2150052 T/A 0.019 0.013 0.13 0.008 0.014 0.56 0.017 0.013 0.17 0.010 0.014 0.47 
PHF19 rs7847628 G/A 0.020 0.013 0.13 0.018 0.015 0.24 0.022 0.013 0.11 0.017 0.015 0.25 
STRBP rs700059 G/A 0.017 0.016 0.27 -0.006 0.018 0.76 0.053 0.016 8.0x10-4 0.062 0.018 4.5x10-4 
HHEX-IDE rs61862780 T/C 0.012 0.013 0.36 -0.015 0.014 0.29 0.053 0.013 3.0x10-5 0.059 0.014 3.1x10-5 
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Locus 
  
  
Index variant EA/ 
NEA 
  
Maternal effect on offspring birth weight Foetal effect on birth weight 
Unadjusted Adjusted for foetal genotype Unadjusted Adjusted for maternal genotype 
β SE P-value β SE P-value β SE P-value β SE P-value 
NT5C2 rs74233809 C/T -0.002 0.021 0.94 -0.010 0.024 0.67 0.016 0.021 0.44 0.011 0.024 0.64 
ADRB1 rs7076938 T/C 0.045 0.014 8.8x10-4 0.032 0.015 0.03 0.050 0.014 2.6x10-4 0.037 0.015 0.02 
PLEKHA1 rs2421016 T/C 0.017 0.012 0.17 0.018 0.014 0.19 0.006 0.012 0.63 0.001 0.014 0.95 
INS-IGF2 rs72851023 T/C 0.031 0.027 0.26 0.008 0.031 0.79 0.060 0.028 0.03 0.061 0.031 0.05 
MTNR1B rs10830963 G/C 0.047 0.015 1.7x10-3 0.035 0.017 0.04 0.049 0.015 9.8x10-4 0.032 0.017 0.06 
APOLD1 rs11055034 C/A -0.003 0.014 0.83 -0.013 0.016 0.42 0.005 0.014 0.72 0.011 0.016 0.51 
ABCC9 rs139975827 G/A 0.005 0.014 0.72 -0.011 0.015 0.47 0.033 0.014 0.02 0.041 0.015 0.01 
ITPR2 rs12823128 T/C -0.003 0.013 0.83 -0.016 0.015 0.28 0.022 0.013 0.10 0.024 0.015 0.10 
HMGA2 rs1351394 T/C 0.023 0.013 0.07 0.007 0.015 0.65 0.038 0.013 3.0x10-3 0.038 0.014 0.01 
IGF1 rs7964361 A/G -0.005 0.023 0.85 -0.016 0.026 0.55 0.025 0.023 0.28 0.030 0.026 0.25 
LINC00332 rs2324499 G/C 0.006 0.013 0.68 0.001 0.015 0.96 0.019 0.013 0.15 0.019 0.015 0.22 
RB1 rs2854355 G/A -0.013 0.015 0.37 -0.027 0.016 0.10 0.020 0.015 0.18 0.029 0.016 0.07 
RNF219-AS1 rs1819436 C/T 0.040 0.018 0.03 0.013 0.020 0.52 0.057 0.018 1.8x10-3 0.046 0.020 0.02 
FES rs12906125 G/A 0.006 0.014 0.66 -0.004 0.016 0.82 0.016 0.014 0.27 0.012 0.016 0.47 
IGF1R rs7402982 A/G 0.015 0.013 0.24 0.003 0.015 0.83 0.025 0.013 0.06 0.027 0.015 0.07 
GPR139 rs1011939 G/A 0.015 0.014 0.27 0.013 0.015 0.39 0.008 0.014 0.57 0.000 0.015 1.00 
CLDN7 rs113086489 T/C 0.018 0.013 0.16 0.002 0.014 0.89 0.043 0.013 5.7x10-4 0.044 0.014 1.9x10-3 
SUZ12P1-CRLF3 rs144843919 G/A 0.003 0.037 0.93 -0.030 0.041 0.47 0.045 0.038 0.24 0.047 0.043 0.27 
SP6-SP2 rs12942207 C/T -0.001 0.014 0.92 -0.003 0.016 0.82 0.007 0.014 0.63 0.008 0.015 0.59 
ACTL9 rs61154119 T/G -0.005 0.016 0.75 -0.022 0.018 0.23 0.032 0.016 0.05 0.041 0.018 0.02 
PEPD rs10402712 A/G -0.013 0.014 0.36 -0.028 0.016 0.07 0.016 0.014 0.26 0.025 0.016 0.11 
JAG1 rs6040076 C/G 0.000 0.013 0.98 -0.007 0.015 0.64 0.010 0.013 0.43 0.017 0.015 0.24 
C20orf203 rs28530618 A/G 0.015 0.013 0.23 0.013 0.014 0.34 0.006 0.013 0.63 0.003 0.014 0.85 
MAFB rs6016377 T/C 0.000 0.013 0.99 -0.021 0.015 0.16 0.042 0.013 1.4x10-3 0.058 0.015 9.9x10-5 
NRIP1 rs2229742 G/C 0.026 0.023 0.26 0.018 0.026 0.49 0.031 0.023 0.17 0.018 0.026 0.49 
KREMEN1 rs134594 C/T 0.016 0.013 0.22 0.007 0.015 0.64 0.017 0.013 0.20 0.015 0.015 0.30 
SREBF2 rs62240962 C/T 0.019 0.026 0.47 0.005 0.029 0.87 0.049 0.026 0.06 0.049 0.029 0.09 
PLAC1a rs11096402 G/A 0.009 0.022 0.68 -0.004 0.024 0.88 0.013 0.024 0.60 0.014 0.027 0.61 
aFor analysis of the PLAC1 locus on the X chromosome, we used female offsprings only: N = 4,940 mother-child pairs 
EA: Effect Allele. NEA: Non Effect Allele. SE: standard error. Effects (beta values) are aligned to the BW-raising allele as reported in Extended Data Table 1a. 
 38 
Supplementary Table 12. Summary results of LD Score regression analyses between birth weight and various diseases, metabolic and 
anthropometric traits. 
 
(a) Birth weight and other traits 
Phenotype1 Phenotype2 Genetic 
Correlation (rg) 
SE z P-value Sample size of 
phenotype 2 
Number of 
SNPs 
Reference 
(PMID) 
Birth weight  Infant head circumference 0.389 0.073 5.30 1.2x10-7 10,770 1,019,674 22504419 
Birth weight  Birth length 0.805 0.058 13.98 2.0x10-44 28,460 983,823 25281659 
Birth weight  Height (2014) 0.406 0.027 15.18 4.8x10-52 253,300 1,049,262 25282103 
Birth weight  Height (2010) 0.401 0.028 14.09 4.6x10-45 133,900 1,026,905 20881960 
Birth weight  Height (women) 0.400 0.032 12.59 2.4x10-36 73,140 1,028,514 23754948 
Birth weight  Height (men) 0.384 0.035 11.00 3.7x10-28 60,590 1,024,139 23754948 
Birth weight  Extreme height 0.399 0.043 9.20 3.5x10-20 16,200 739,427 23563607 
Birth weight  Body mass index (2015) 0.114 0.025 4.49 7.3x10-6 322,200 1,050,986 25673413 
Birth weight  Body mass index (2010) 0.120 0.033 3.66 3.0x10-4 123,900 1,028,235 20935630 
Birth weight  Extreme Body mass index 0.116 0.048 2.40 0.017 16,070 738,850 23563607 
Birth weight  Body mass index (men) 0.148 0.040 3.67 2.4x10-4 58,670 1,025,063 23754948 
Birth weight  Body mass index (women) 0.096 0.035 2.76 0.006 67,960 1,029,327 23754948 
Birth weight  Weight (men) 0.377 0.039 9.57 1.1x10-21 58,350 1,025,155 23754948 
Birth weight  Weight (women) 0.280 0.036 7.70 1.4x10-14 67,590 1,029,320 23754948 
Birth weight  Waist-hip ratio (2015) -0.052 0.031 -1.66 0.097 212,200 1,048,211 25673412 
Birth weight  Waist-hip ratio (adjusted for BMI - 2015) -0.159 0.032 -4.93 8.3x10-7 210,100 1,051,567 25673412 
Birth weight  Waist-hip ratio (adjusted for BMI - 2010) -0.189 0.041 -4.59 4.4x10-6 77,220 1,027,370 20935629 
Birth weight  Waist-hip ratio (men) -0.080 0.053 -1.51 0.132 34,640 1,025,922 23754948 
Birth weight  Waist-hip ratio (women) -0.060 0.054 -1.11 0.268 42,730 1,029,620 23754948 
Birth weight  Extreme waist-hip ratio -0.254 0.071 -3.57 3.6x10-4 10,260 674,047 23563607 
Birth weight  Hip circumference 0.281 0.030 9.30 1.4x10-20 213,000 1,048,111 25673412 
Birth weight  Hip circumference (adjusted for BMI) 0.314 0.033 9.49 2.3x10-21 211,100 1,049,874 25673412 
Birth weight  Hip circumference (men) 0.339 0.063 5.34 9.3x10-8 32,850 1,030,276 23754948 
Birth weight  Hip circumference (women) 0.260 0.057 4.54 5.6x10-6 40,360 1,031,503 23754948 
Birth weight  Waist circumference 0.177 0.028 6.29 3.9x10-10 232,100 1,048,634 25673412 
Birth weight  Waist circumference (adjusted for BMI) 0.128 0.032 4.03 5.7x10-5 231,400 1,049,871 25673412 
Birth weight  Waist circumference (men) 0.218 0.053 4.11 3.9x10-5 38,310 1,025,680 23754948 
Birth weight  Waist circumference (women) 0.135 0.047 2.86 0.004 47,320 1,027,090 23754948 
Birth weight  Obesity (class 1) 0.102 0.035 2.97 0.003 98,700 965,717 23563607 
Birth weight  Obesity (class 2) 0.099 0.040 2.46 0.014 72,550 890,085 23563607 
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Phenotype1 Phenotype2 Genetic 
Correlation (rg) 
SE z P-value Sample size of 
phenotype 2 
Number of 
SNPs 
Reference 
(PMID) 
Birth weight  Obesity (class 3) 0.136 0.055 2.48 0.013 50,360 621,425 23563607 
Birth weight  Childhood obesity 0.192 0.049 3.95 7.8x10-5 13,850 1,057,303 22484627 
Birth weight  Overweight 0.061 0.033 1.83 0.067 158,900 1,012,975 23563607 
Birth weight  Anorexia nervosa 0.029 0.033 0.91 0.365 17,770 1,042,946 24514567 
Birth weight  Crohn's disease 0.047 0.044 1.07 0.284 20,883 1,066,772 26192919 
Birth weight  Irritable bowel syndrome 0.009 0.052 0.18 0.858 27,432 1,091,971 26192919 
Birth weight  Rheumatoid arthritis -0.004 0.046 -0.08 0.935 25,710 986,060 20453842 
Birth weight  Lumbar spine bone mineral density  -0.027 0.043 -0.63 0.531 31,800 1,061,087 22504420 
Birth weight  Lumbar spine bone mineral density (men) -0.098 0.064 -1.53 0.127 9,980 1,060,919 22504420 
Birth weight  Lumbar spine bone mineral density (women) -0.003 0.044 -0.07 0.943 22,180 1,064,756 22504420 
Birth weight  Femoral neck bone mineral density 0.013 0.039 0.34 0.736 32,960 1,065,335 22504420 
Birth weight  Femoral neck bone mineral density (men) -0.019 0.057 -0.33 0.745 9,971 1,056,535 22504420 
Birth weight  Femoral neck bone mineral density (women) 0.020 0.050 0.40 0.686 22,990 1,069,031 22504420 
Birth weight  Coronary artery disease -0.295 0.051 -5.80 6.5x10-9 84,270 932,642 21378990 
Birth weight  Systolic blood pressure (adjusted for BMI) -0.263 0.039 -6.72 1.8x10-11 69,395 990,423 21909115 
Birth weight Systolic blood pressure (unadjusted for BMI) -0.215 0.030 -7.21 5.5x10-13 127,969 1,186,583 
UK Biobank 
data 
Birth weight  Diastolic blood pressure (adjusted for BMI) -0.224 0.042 -5.35 8.7x10-8 69,395 990,446 21909115 
Birth weight  Triglycerides (2010) -0.167 0.038 -4.41 1.0x10-5 96,600 1,024,575 20686565 
Birth weight  Triglycerides (2013) -0.112 0.031 -3.61 3.0x10-4 177,900 1,026,718 24097068 
Birth weight  Total cholesterol (2010) -0.127 0.040 -3.21 0.001 100,200 1,026,024 20686565 
Birth weight  Total cholesterol (2013) -0.105 0.033 -3.17 0.002 187,400 1,027,605 24097068 
Birth weight  Low density lipoprotein (2010) -0.136 0.047 -2.90 0.004 95,450 1,024,730 20686565 
Birth weight  Low density lipoprotein (2013) -0.102 0.036 -2.87 0.004 173,100 1,026,705 24097068 
Birth weight  High density lipoprotein (2010) 0.087 0.039 2.23 0.026 99,900 1,026,029 20686565 
Birth weight  High density lipoprotein (2013) 0.056 0.029 1.97 0.048 187,200 1,027,731 24097068 
Birth weight  Type 2 diabetes -0.271 0.056 -4.88 1.1x10-6 69,030 976,437 22885922 
Birth weight  Fasting insulin -0.150 0.071 -2.10 0.036 46,190 1,054,692 20081858 
Birth weight  Fasting insulin (adjusting for BMI) -0.178 0.055 -3.26 0.001 51,750 1,121,151 22581228 
Birth weight  HbA1c -0.166 0.060 -2.75 0.006 46,368 1,109,233 20858683 
Birth weight  2hr glucose -0.245 0.094 -2.62 0.009 15,230 1,028,518 20081857 
Birth weight  Fasting glucose -0.073 0.054 -1.35 0.178 46,190 1,056,257 20081858 
Birth weight  Fasting glucose (adjusting for BMI) -0.126 0.048 -2.61 0.009 58,074 1,121,150 22581228 
Birth weight  HOMA-IR -0.133 0.072 -1.84 0.066 46,190 1,053,709 20081858 
Birth weight  HOMA-B -0.065 0.065 -1.00 0.317 46,190 1,053,581 20081858 
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Phenotype1 Phenotype2 Genetic 
Correlation (rg) 
SE z P-value Sample size of 
phenotype 2 
Number of 
SNPs 
Reference 
(PMID) 
Birth weight  Educational attainment (college) 0.111 0.042 2.63 0.009 126,600 1,017,448 25201988 
Birth weight  Educational attainment (years) 0.105 0.043 2.43 0.015 126,600 1,014,207 25201988 
Birth weight  Childhood intelligence 0.123 0.075 1.64 0.100 17,990 800,741 25201988 
Birth weight  Autism -0.089 0.053 -1.69 0.091 10,263 944,654 23453885 
Birth weight  ADHD -0.107 0.103 -1.04 0.300 3,351 1,065,753 20732625 
Birth weight  Major depressive disorder -0.076 0.074 -1.02 0.306 18,760 887,434 22472876 
Birth weight  Bipolar disorder 0.026 0.047 0.56 0.578 16,730 800,584 21926972 
Birth weight  Alzheimer's disease -0.039 0.080 -0.49 0.622 74,050 1,142,332 24162737 
Birth weight  Schizophrenia -0.022 0.044 -0.49 0.624 21,860 846,564 21926974 
Birth weight  
Pubertal growth - height at age 10 in females 
and 12 in males - targets take-off phase of 
growth spurt 0.271 0.051 5.28 1.3x10-7 13,960 1,009,067 23449627 
Birth weight  Pubertal growth - height at age 12 in males 0.305 0.072 4.23 2.3x10-5 6,986 1,017,307 23449627 
Birth weight  Pubertal growth - height at age 10 in females 0.221 0.061 3.63 3.0x10-4 6,974 1,036,441 23449627 
Birth weight  
Pubertal growth - total amount of growth 
across the pubertal growth period 0.162 0.062 2.61 0.009 10,800 1,037,500 23449627 
Birth weight  
Pubertal growth - total amount of growth 
across the pubertal growth period (males) 0.173 0.080 2.15 0.032 5,043 1,039,045 23449627 
Birth weight  
Pubertal growth - total amount of growth 
across the pubertal growth period (females) 0.142 0.083 1.70 0.089 5,756 1,038,734 23449627 
Birth weight  
Pubertal growth - total amount of growth in 
late adolescence, targeting the timing of peak 
height growth velocity 0.109 0.075 1.46 0.145 4,282 1,039,103 23449627 
Birth weight  
Pubertal growth - total amount of growth in 
late adolescence (males) 0.041 0.081 0.51 0.613 4,282 1,039,103 23449627 
Birth weight  
Pubertal growth - total amount of growth in 
late adolescence (females) 0.230 0.112 2.06 0.039 4,946 1,038,829 23449627 
Birth weight  Age at menarche (2014) 0.029 0.031 0.93 0.354 133,000 1,057,631 25231870 
Birth weight  Pubertal growth - Tanner scale -0.137 0.125 -1.10 0.273 9,918 969,224 23449627 
Birth weight  Pubertal growth - Tanner scale (males) -0.453 0.650 -0.97 0.486 3,769 969,224 23449627 
Birth weight  Pubertal growth - Tanner scale (females) -0.037 0.138 -0.27 0.786 6,149 969,224 23449627 
Birth weight  Asthma 0.050 0.069 0.72 0.471 10,770 1,019,674 20860503 
Birth weight  Ever smoked 0.007 0.045 0.15 0.878 28,460 983,823 20418890 
Birth weight  Former smoker 0.097 0.061 1.58 0.114 253,300 1,049,262 20418890 
Birth weight  Cigarettes per day -0.042 0.064 -0.67 0.505 133,900 1,026,905 20418890 
Birth weight  Smoking start age 0.041 0.087 0.47 0.636 73,140 1,028,514 20418890 
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(b) Glucose-Related Phenotypes 
Phenotype1 Phenotype2 Genetic 
Correlation (rg) 
SE z P-value Sample size of 
phenotype 2 
Number of 
SNPs 
Reference 
(PMID) 
Type 2 diabetes Fasting glucose 0.587 0.097 6.07 1.3x10-9 46,190 1,056,257 20081858 
Type 2 diabetes 2hr glucose 0.301 0.12 2.47 0.014 15,230 1,028,518 20081857 
Type 2 diabetes Fasting insulin 0.435 0.12 3.56 4.0x10-4 46,190 1,054,692 20081858 
Type 2 diabetes HOMA-B -0.002 0.11 -0.01 0.989 46,190 1,053,581 20081858 
SE, standard error; BMI, body mass index; ADHD, attention deficit hyperactive disorder; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-B, 
homeostasis model assessment of beta cell function. 
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Supplementary Table 13. Estimating the proportion of the BW-adult phenotype covariance attributable to genotyped SNPs in UK Biobank 
and the Northern Finland Birth Cohort (NFBC) 1966 data. 
 
 
Adult phenotype Na 
Phenotypic 
correlation 
with BW 
Genetic 
correlation 
with BW 
(SE) 
Residual 
correlation 
with BW 
(SE) 
Genetic 
covariance 
with BW, 
gcov (SE) 
Residual 
covariance 
with BW, 
rcov (SE) 
Proportion of covariance 
explained by genetic 
variants directly genotyped: 
gcov/(gcov+rcov)b (95% CI) 
UK Biobank 
Type 2 diabetes  56,654  -0.034 
-0.124 
(0.081) 
-0.001 
(0.010) 
-0.012 
(0.008) 
-0.001 
(0.008) 0.96 (0.36, 1.56) 
Systolic blood pressure (unadjusted for 
BMI)  57,581  -0.072 
-0.201 
(0.037) 
-0.011 
(0.011) 
-0.045 
(0.008) 
-0.008 
(0.008) 0.85 (0.70, 0.99) 
Systolic blood pressure (adjusted for BMI)  57,319  -0.084 
-0.216 
(0.030) 
-0.042 
(0.010) 
-0.052 
(0.007) 
-0.031 
(0.007) 0.62 (0.54, 0.71) 
Diastolic blood pressure (adjusted for BMI)  57,230  -0.072 
-0.156 
(0.030) 
-0.045 
(0.010) 
-0.038 
(0.007) 
-0.033 
(0.007) 0.54 (0.44, 0.64) 
Coronary artery disease  57,715  -0.002 
-0.174 
(0.182) 
0.004 
(0.009) 
-0.008 
(0.007) 
0.003 
(0.008) N/A 
Height  57,638  0.228 
0.332 
(0.026) 
0.194 
(0.015) 
0.106 
(0.008) 
0.091 
(0.007) 0.54 (0.50, 0.58) 
Height (men)  23,385  0.202 
0.343 
(0.060) 
0.214 
(0.041) 
0.108 
(0.019) 
0.090 
(0.018) 0.55 (0.45, 0.64) 
Height (women)  34,253  0.2 
0.367 
(0.037) 
0.174 
(0.029) 
0.131 
(0.013) 
0.072 
(0.012) 0.65 (0.58, 0.71) 
Weight (men)  23,371  0.15 
0.199 
(0.074) 
0.118 
(0.027) 
0.050 
(0.018) 
0.080 
(0.018) 0.38 (0.24, 0.53) 
Weight (women)  34,233  0.094 
0.206 
(0.049) 
0.058 
(0.019) 
0.056 
(0.013) 
0.040 
(0.013) 0.58 (0.45, 0.72) 
Body mass index  57,402  0.043 
0.063 
(0.036) 
0.031 
(0.011) 
0.014 
(0.008) 
0.023 
(0.008) 0.39 (0.17, 0.61) 
Body mass index (men)  34,077  0.045 
0.049 
(0.051) 
0.019 
(0.019) 
0.013 
(0.013) 
0.013 
(0.013) 0.49 (-0.01, 0.98) 
Body mass index (women)  23,325  0.024 
0.072 
(0.087) 
0.037 
(0.025) 
0.015 
(0.018) 
0.028 
(0.018) 0.35 (-0.06, 0.77) 
Obesity (class 1)  33,622  0.048 
0.080 
(0.051) 
0.040 
(0.020) 
0.021 
(0.013) 
0.027 
(0.013) 0.44 (0.17, 0.71) 
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Adult phenotype Na 
Phenotypic 
correlation 
with BW 
Genetic 
correlation 
with BW 
(SE) 
Residual 
correlation 
with BW 
(SE) 
Genetic 
covariance 
with BW, 
gcov (SE) 
Residual 
covariance 
with BW, 
rcov (SE) 
Proportion of covariance 
explained by genetic 
variants directly genotyped: 
gcov/(gcov+rcov)b (95% CI) 
Obesity (class 2)  23,846  0.028 
0.016 
(0.061) 
0.050 
(0.029) 
0.005 
(0.018) 
0.032 
(0.017) 0.13 (-0.37, 0.63) 
Obesity (class 3)  20,966  0.01 
-0.088 
(0.105) 
0.046 
(0.026) 
-0.017 
(0.020) 
0.036 
(0.020) N/A 
Overweight  57,451  0.042 
0.052 
(0.045) 
0.035 
(0.010) 
0.009 
(0.008) 
0.028 
(0.008) 0.25 (0.04, 0.46) 
Waist-hip ratio  57,590  0.077 
-0.049 
(0.041) 
0.015 
(0.010) 
-0.010 
(0.008) 
0.012 
(0.008) N/A 
Waist-hip ratio (adjusted for BMI)  57,388  0.065 
-0.115 
(0.042) 
0.007 
(0.010) 
-0.022 
(0.008) 
0.005 
(0.008) N/A 
Waist-hip ratio (men)  23,387  0.004 
-0.081 
(0.110) 
0.026 
(0.022) 
-0.013 
(0.018) 
0.022 
(0.018) N/A 
Waist-hip ratio (women)  34,203  -0.011 
-0.023 
(0.055) 
-0.002 
(0.018) 
-0.006 
(0.013) 
-0.001 
(0.013) 0.80 (-1.07, 2.68) 
Waist circumference  57,641  0.103 
0.084 
(0.041) 
0.091 
(0.010) 
0.017 
(0.008) 
0.072 
(0.008) 0.19 (0.10, 0.28) 
Waist circumference (adjusted for BMI)  57,435  0.129 
0.147 
(0.041) 
0.008 
(0.011) 
0.029 
(0.008) 
0.006 
(0.008) 0.83 (0.60, 1.05) 
Waist circumference (men)  23,318  0.072 
0.090 
(0.089) 
0.047 
(0.025) 
0.019 
(0.018) 
0.035 
(0.018) 0.35 (0.01, 0.68) 
Waist circumference (women)  34,252  0.014 
0.083 
(0.052) 
0.017 
(0.018) 
0.021 
(0.013) 
0.012 
(0.013) 0.63 (0.25, 1.01) 
Hip circumference  57,559  0.066 
0.173 
(0.036) 
0.033 
(0.011) 
0.039 
(0.008) 
0.025 
(0.008) 0.61 (0.48, 0.73) 
Hip circumference (adjusted for BMI)  57,359  0.070 
0.292 
(0.037) 
0.015 
(0.011) 
0.065 
(0.008) 
0.011 
(0.008) 0.85 (0.75, 0.96) 
Hip circumference (men)  23,376  0.102 
0.193 
(0.082) 
0.058 
(0.026) 
0.044 
(0.018) 
0.041 
(0.018) 0.51 (0.30, 0.73) 
Hip circumference (women)  34,183  0.046 
0.146 
(0.053) 
0.026 
(0.018) 
0.037 
(0.013) 
0.019 
(0.013) 0.66 (0.43, 0.89) 
Age at menarche  33,518  0.022 
0.021 
(0.054) 
0.008 
(0.019) 
0.005 
(0.013) 
0.006 
(0.013) 0.49 (-0.72, 1.71) 
Asthma  57,715  -0.019 
-0.014 
(0.054) 
-0.007 
(0.010) 
-0.002 
(0.008) 
-0.006 
(0.008) 0.25 (-0.67, 1.16) 
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Adult phenotype Na 
Phenotypic 
correlation 
with BW 
Genetic 
correlation 
with BW 
(SE) 
Residual 
correlation 
with BW 
(SE) 
Genetic 
covariance 
with BW, 
gcov (SE) 
Residual 
covariance 
with BW, 
rcov (SE) 
Proportion of covariance 
explained by genetic 
variants directly genotyped: 
gcov/(gcov+rcov)b (95% CI) 
Ever smoked  56,960  0.042 
-0.011 
(0.049) 
0.043 
(0.010) 
-0.002 
(0.008) 
0.035 
(0.008) N/A 
Former smoker  50,907  0.046 
-0.038 
(0.059) 
0.048 
(0.011) 
-0.006 
(0.009) 
0.040 
(0.009) N/A 
Cigarettes per day  50,641  0.044 
-0.053 
(0.052) 
0.049 
(0.011) 
-0.009 
(0.009) 
0.040 
(0.009) N/A 
Smoking start age  19,639  -0.024 
0.465 
(0.239) 
-0.054 
(0.024) 
0.043 
(0.020) 
-0.048 
(0.020) N/A 
NFBC1966 
Triglycerides 4,954 -0.065 
-0.448 
(0.224) 
0.022 
(0.049) 
-0.083 
(0.038) 
0.018 
(0.039) N/A 
Total cholesterol 4,970 -0.021 
-0.271 
(0.137) 
0.080 
(0.054) 
-0.078 
(0.039) 
0.057 
(0.038) N/A 
High density lipoprotein 4,972 0.020 
0.101 
(0.125) 
-0.017 
(0.055) 
0.031 
(0.039) 
-0.011 
(0.038) N/A 
Low density lipoprotein 4,970 -0.013 
-0.223 
(0.119) 
0.093 
(0.058) 
-0.074 
(0.039) 
0.062 
(0.038) N/A 
Fasting glucose 4,465 -0.042 
-0.184 
(0.173) 
0.006 
(0.058) 
-0.045 
(0.042) 
0.005 
(0.042) N/A 
Fasting insulin 4,441 -0.100 
-0.180 
(0.214) 
-0.087 
(0.056) 
-0.036 
(0.043) 
-0.067 
(0.043) 0.35 (-0.07, 1.28) 
aThe number of case/control was T2D: 1,488/55,166, CAD: 1,959/55,756, obesity1: 19,820/13,802, obesity2: 4,026/13,802, obesity3: 1,146/13,802, overweight: 
37,631/19,820, asthma: 7,131/50,584, ever smoker: 24,774/32,186, and former smoker: 18,721/32,186  The covariance for these traits were on the observed scale. 
bWe have put N/A (not applicable) when the genetic and residual covariances are in the opposite direction and it is not relevant to calculate gcov/(gcov + rcov). Although 
genetic covariance is subject to high uncertainty, there is a general pattern across both UK Biobank and the NFBC1966 that the phenotypic covariation between low BW 
and future cardiometabolic risk is at least in part genetically mediated. 
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Supplementary Table 14. List of 77 reported imprinted regions used in the current analysis.  
 
Gene Type Entrez ID Chr Gene Start site 
(bp, b37) 
Gene End site 
(bp, b37) 
CPA4 GTEX Primary 51200 7  129,932,973   129,964,020  
CST1 GTEX Primary 1469 20  23,728,189   23,731,574  
DIRAS3 GTEX Primary 9077 1  68,511,644   68,516,460  
DLK1 GTEX Primary 8788 14  101,193,201   101,201,467  
FAM50B GTEX Primary 26240 6  3,849,631   3,851,551  
GRB10 GTEX Primary 2887 7  50,657,759   50,861,159  
H19 GTEX Primary 283120 11  2,016,405   2,019,065  
IGF2 GTEX Primary 3481 11  2,150,346   2,170,833  
IGF2AS GTEX Primary 51214 11  2,161,757   2,169,896  
INPP5F GTEX Primary 22876 10  121,485,608   121,588,659  
KCNQ1 GTEX Primary 3784 11  2,466,220   2,870,340  
KIF25 GTEX Primary 3834 6  168,418,552   168,445,769  
L3MBTL1 GTEX Primary 26013 20  42,136,319   42,170,534  
LPAR6 GTEX Primary 10161 13  48,985,181   49,018,840  
MAGEL2 GTEX Primary 54551 15  23,888,695   23,892,993  
MAGI2 GTEX Primary 9863 7  77,646,373   79,082,890  
MEG3 GTEX Primary 55384 14  101,292,444   101,327,360  
MEG8 GTEX Primary 79104 14  101,361,106   101,373,305  
MEST GTEX Primary 4232 7  130,126,045   130,146,131  
NAP1L5 GTEX Primary 266812 4  89,617,065   89,619,023  
NDN GTEX Primary 4692 15  23,930,553   23,932,450  
NTM GTEX Primary 50863 11  131,240,370   132,206,716  
PEG10 GTEX Primary 23089 7  94,285,636   94,299,006  
PEG3 GTEX Primary 5178 19  57,321,444   57,352,094  
PLAGL1 GTEX Primary 5325 6  144,261,436   144,385,735  
PPIEL GTEX Primary 728448 1  39,987,951   40,025,370  
PPP2R5D GTEX Primary 5528 6  42,952,329   42,980,080  
PWRN1 GTEX Primary 791114 15  24,803,303   24,832,926  
SGK2 GTEX Primary 10110 20  42,187,634   42,214,273  
SNRPN GTEX Primary 6638 15  25,068,793   25,223,729  
SNURF GTEX Primary 8926 15  25,200,069   25,223,729  
SYCE1 GTEX Primary 93426 10  135,367,403   135,382,876  
UBE3A GTEX Primary 7337 15  25,582,395   25,684,128  
UGT2B4 GTEX Primary 7363 4  70,345,882   70,361,626  
UTS2 GTEX Primary 10911 1  7,907,671   7,913,551  
ZDBF2 GTEX Primary 57683 2  207,139,522   207,179,148  
ZNF331 GTEX Primary 55422 19  54,024,176   54,083,523  
ZNF597 GTEX Primary 146434 16  3,486,109   3,493,490  
ABCA6 GTEX suggestive (S4 unique) 23460 17  67,074,846   67,138,015  
BMP8A GTEX suggestive (S4 unique) 353500 1  39,957,317   39,995,541  
CHIT1 GTEX suggestive (S4 unique) 1118 1  203,185,206   203,198,860  
DLGAP2 GTEX suggestive (S4 unique) 9228 8  1,449,568   1,656,642  
DZIP1 GTEX suggestive (S4 unique) 22873 13  96,230,455   96,296,957  
EMR1 GTEX suggestive (S4 unique) 2015 19  6,887,581   6,940,464  
FKBP10 GTEX suggestive (S4 unique) 60681 17  39,968,961   39,979,469  
GPR1 GTEX suggestive (S4 unique) 2825 2  207,040,041   207,082,771  
GTSF1 GTEX suggestive (S4 unique) 121355 12  54,849,735   54,867,386  
GUCY1B2 GTEX suggestive (S4 unique) 2974 13  51,568,646   51,640,293  
KIR3DX1 GTEX suggestive (S4 unique) 90011 19  55,043,908   55,055,195  
LRRTM1 GTEX suggestive (S4 unique) 347730 2  80,529,002   80,531,487  
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Gene Type Entrez ID Chr Gene Start site 
(bp, b37) 
Gene End site 
(bp, b37) 
MYOM2 GTEX suggestive (S4 unique) 9172 8  1,993,157   2,093,380  
RTL1 GTEX suggestive (S4 unique) 388015 14  101,346,991   101,351,184  
SERPINA6 GTEX suggestive (S4 unique) 866 14  94,770,584   94,789,688  
SLC10A2 GTEX suggestive (S4 unique) 6555 13  103,696,347   103,719,196  
THNSL2 GTEX suggestive (S4 unique) 55258 2  88,469,834   88,486,146  
ANO1 GTEX consistent (S6) 55107 11  69,924,407   70,035,652  
CALCR GTEX consistent (S6) 799 7  93,053,798   93,204,042  
CDKN1C GTEX consistent (S6) 1028 11  2,904,447   2,906,995  
COPG2 GTEX consistent (S6) 26958 7  130,146,079   130,353,598  
DCN GTEX consistent (S6) 1634 12  91,539,034   91,576,806  
DIO3 GTEX consistent (S6) 1735 14  102,027,687   102,029,789  
DLX5 GTEX consistent (S6) 1749 7  96,649,701   96,654,143  
GABRA5 GTEX consistent (S6) 2558 15  27,111,865   27,194,357  
GABRG3 GTEX consistent (S6) 2567 15  27,216,428   27,778,373  
GLIS3 GTEX consistent (S6) 169792 9  3,824,127   4,300,035  
GNAS-AS1 GTEX consistent (S6) 149775 20  57,393,972   57,425,958  
KLF14 GTEX consistent (S6) 136259 7  130,417,395   130,418,888  
MKRN3 GTEX consistent (S6) 7681 15  23,810,453   23,813,166  
NNAT GTEX consistent (S6) 4826 20  36,149,606   36,152,090  
C15orf2 GTEX consistent (S6) 23742 15  24,920,540   24,928,593  
PON3 GTEX consistent (S6) 5446 7  94,989,183   95,025,687  
RB1 GTEX consistent (S6) 5925 13  48,877,882   49,056,026  
RBP5 GTEX consistent (S6) 83758 12  7,276,279   7,281,466  
SGCE GTEX consistent (S6) 8910 7  94,214,535   94,285,521  
TH GTEX consistent (S6) 7054 11  2,185,158   2,193,035  
TSPAN32 GTEX consistent (S6) 10077 11  2,323,242   2,339,430  
TSSC4 GTEX consistent (S6) 10078 11  2,423,522   2,425,106  
These 77 regions were highlighted in reference 10: Baran Y et al. Genome Res 25, 927-936 (2015). 
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Supplementary Table 15. Comparison of variance in BW between individuals heterozygous and 
homozygous for each of the 59 autosomal BW index SNPs (plus DLK1) in 57,715 UK Biobank 
samples. 
 
Locus Index variant Alleles 
A/B 
Variance Effect 
AA AB BB β SE P-value 
WNT4-ZBTB40  rs2473248 T/C 1.008 0.971 1.007 -0.015 0.006 0.99 
ZBTB7B  rs3753639 T/C 0.994 1.004 1.026 0.002 0.005 0.34 
FCGR2B  rs72480273 A/C 0.995 1.008 1.012 0.008 0.005 6.4x10-2 
DTL rs61830764 G/A 0.997 0.993 1.031 -0.004 0.005 0.81 
ATAD2B  rs7575873 A/G 1.007 0.978 0.964 -0.014 0.006 0.99 
EPAS1  rs1374204 C/T 0.968 0.999 1.005 -0.002 0.005 0.68 
PTH1R  rs2242116 A/G 1.003 0.987 1.013 -0.010 0.005 0.98 
ADCY5  rs11719201 C/T 0.984 1.019 1.023 0.016 0.005 1.1x10-3 
CPA3  rs10935733 T/C 0.999 1.007 0.990 0.009 0.005 3.7x10-2 
CCNL1-LEKR1  rs13322435 A/G 1.016 0.993 0.981 -0.007 0.005 0.91 
LCORL  rs925098 G/A 1.011 0.996 1.001 -0.002 0.005 0.64 
HHIP  rs6537307 A/G 0.972 1.004 1.019 0.005 0.005 0.18 
5q11.2  rs854037 A/G 1.004 0.990 1.008 -0.009 0.005 0.95 
EBF1  rs7729301 G/A 1.028 0.990 1.003 -0.007 0.005 0.93 
CDKAL1  rs35261542 C/A 1.004 0.998 0.969 2x10-4 0.005 0.48 
HIST1H2BE rs9379832 A/G 1.004 0.995 0.995 -0.004 0.005 0.80 
HMGA1  rs7742369 A/G 0.995 1.005 1.044 0.002 0.005 0.36 
L3MBTL3  rs1415701 G/A 1.006 0.990 1.006 -0.009 0.005 0.96 
ESR1  rs1101081 C/T 1.003 0.999 0.979 0.001 0.005 0.39 
GNA12  rs798489 C/T 1.005 0.993 0.997 -0.005 0.005 0.81 
IGF2BP3  rs11765649 T/C 1.004 0.991 1.007 -0.005 0.005 0.83 
TBX20  rs6959887 A/G 0.998 1.001 0.999 0.004 0.005 0.21 
YKT6-GCK rs138715366 C/T 1.001 0.888 0.657 -0.070 0.019 1.00 
MLXIPL rs62466330 T/C 0.995 1.028 1.036 0.016 0.007 1.3x10-2 
ANK1-NKX6-3  rs13266210 A/G 1.007 0.984 1.009 -0.013 0.005 0.99 
TRIB1 rs6989280 G/A 0.997 1.005 0.992 0.005 0.005 0.18 
SLC45A4  rs12543725 G/A 1.009 0.994 0.999 -0.009 0.005 0.97 
PTCH1  rs28510415 A/G 0.999 0.999 1.017 1x10-4 0.007 0.49 
LPAR1  rs2150052 A/T 0.980 1.002 1.015 0.002 0.005 0.37 
PHF19  rs7847628 A/G 0.984 1.002 1.001 0.003 0.005 0.30 
STRBP  rs700059 G/A 0.989 1.018 0.994 0.015 0.006 4.4x10-3 
HHEX-IDE  rs61862780 T/C 1.005 0.996 1.003 -0.005 0.005 0.82 
NT5C2 rs74233809 T/C 0.999 0.998 1.136 3x10-4 0.007 0.48 
ADRB1  rs7076938 C/T 0.992 1.003 0.998 6x10-4 0.005 0.45 
PLEKHA1  rs2421016 C/T 0.988 1.007 0.998 0.008 0.005 6.1x10-2 
INS-IGF2  rs72851023 C/T 0.996 1.022 1.013 0.013 0.007 3.4x10-2 
MTNR1B  rs10830963 C/G 0.994 1.008 0.997 0.005 0.005 0.18 
APOLD1 rs11055034 C/A 1.002 1.000 0.985 2x10-4 0.005 0.49 
ABCC9  rs139975827 G/A 1.006 1.000 0.982 2x10-4 0.005 0.48 
ITPR2 rs12823128 T/C 1.014 0.993 0.998 -0.006 0.005 0.87 
HMGA2  rs1351394 T/C 1.003 1.001 0.993 9x10-4 0.005 0.43 
IGF1  rs7964361 G/A 0.999 1.006 0.991 0.003 0.007 0.35 
LINC00332 rs2324499 G/C 1.000 0.998 1.004 -0.003 0.005 0.70 
RB1 rs2854355 A/G 0.991 1.008 1.024 0.008 0.005 5.4x10-2 
RNF219-AS1  rs1819436 T/C 1.034 1.003 0.998 5x10-4 0.006 0.47 
DLK1 rs6575803 C/T 1.002 0.991 0.987 -0.007 0.006 0.87 
FES  rs12906125 G/A 1.004 0.993 1.010 -0.005 0.005 0.86 
IGF1R  rs7402982 A/G 0.994 0.998 1.006 -0.003 0.005 0.73 
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Locus Index variant Alleles 
A/B 
Variance Effect 
AA AB BB β SE P-value 
GPR139 rs1011939 G/A 1.022 1.006 0.991 0.005 0.005 0.14 
CLDN7  rs113086489 C/T 0.991 1.002 1.002 0.001 0.005 0.41 
SUZ12P1-CRLF3  rs144843919 G/A 1.000 0.990 0.955 -0.006 0.010 0.72 
SP6-SP2 rs12942207 C/T 1.018 1.005 0.992 0.006 0.005 0.12 
ACTL9 rs61154119 T/G 0.998 1.007 0.974 0.003 0.006 0.30 
PEPD rs10402712 G/A 1.005 0.993 0.998 -0.004 0.005 0.78 
JAG1  rs6040076 G/C 0.989 1.003 1.003 0.004 0.005 0.22 
C20orf203  rs28530618 A/G 1.002 1.000 0.997 4x10-4 0.005 0.47 
MAFB rs6016377 C/T 0.988 0.999 1.021 2x10-4 0.005 0.48 
NRIP1 rs2229742 G/C 1.002 0.991 0.939 -0.006 0.006 0.83 
KREMEN1  rs134594 C/T 1.020 1.009 0.983 0.005 0.005 0.14 
SREBF2  rs62240962 C/T 1.003 0.985 0.983 -0.008 0.007 0.89 
The beta value is a parameter of the Brown-Forsythe test that measures how different the mean absolute deviations 
(MADs) are from the respective group medians in the heterozygous vs the homozygous group. SE, standard error.
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Supplementary Table 16. Parent-of-origin specific analysis at 59 autosomal BW loci (plus DLK1) 
in 4,908 ALSPAC mother-child pairs. 
 
Locus  SNP EA/
NEA 
Paternal transmission Maternal transmission P_het 
β SE P-value β SE P-value 
WNT4-
ZBTB40  rs2473248 C/T 0.019 0.042 0.65 0.189 0.076 1.3x10-2 6.1x10-2 
ZBTB7B  rs3753639 C/T 0.012 0.034 0.72 0.078 0.045 8.5x10-2 0.34 
FCGR2B  rs72480273 C/A 0.097 0.037 8.0x10-3 0.060 0.047 0.20 0.17 
DTL rs61830764 A/G 0.067 0.031 2.8x10-2 0.096 0.030 1.7x10-3 0.44 
ATAD2B  rs7575873 A/G 0.080 0.041 5.3x10-2 0.086 0.072 0.23 0.36 
EPAS1  rs1374204 T/C 0.094 0.032 3.7x10-3 0.121 0.037 1.1x10-3 0.98 
PTH1R  rs2242116 A/G 0.007 0.031 0.83 0.064 0.033 5.2x10-2 9.8x10-2 
ADCY5  rs11719201 T/C 0.137 0.034 4.5x10-3 0.062 0.035 7.5x10-2 0.11 
CPA3  rs10935733 T/C 0.052 0.029 7.7x10-2 0.013 0.031 0.67 0.19 
CCNL1-LEKR1  rs13322435 A/G 0.117 0.031 1.4x10-4 0.088 0.032 5.9x10-3 0.48 
LCORL  rs925098 G/A 0.128 0.033 1.1x10-4 0.063 0.042 0.13 0.18 
HHIP  rs6537307 G/A 0.080 0.030 8.1x10-3 0.071 0.030 1.9x10-2 0.79 
5q11.2  rs854037 A/G 0.078 0.037 3.5x10-2 0.081 0.043 5.8x10-2 0.90 
EBF1  rs7729301 A/G -0.006 0.034 0.86 -0.028 0.041 0.50 0.67 
CDKAL1  rs35261542 C/A 0.101 0.033 2.1x10-3 0.040 0.041 0.32 8.3x10-2 
HIST1H2BE rs9379832 A/G 0.034 0.033 0.30 0.037 0.038 0.33 0.83 
HMGA1  rs7742369 G/A 0.046 0.038 0.23 0.161 0.051 1.6x10-3 0.10 
L3MBTL3  rs1415701 G/A 0.029 0.033 0.38 0.092 0.042 2.8x10-2 9.2x10-2 
ESR1  rs1101081 C/T 0.074 0.033 2.5x10-2 0.025 0.039 0.53 0.16 
GNA12  rs798489 C/T 0.011 0.033 0.74 0.043 0.040 0.29 0.35 
IGF2BP3  rs11765649 T/C -0.013 0.033 0.69 0.054 0.036 0.14 0.14 
TBX20  rs6959887 A/G 0.035 0.032 0.27 0.035 0.033 0.29 0.94 
YKT6-GCK rs138715366 C/T 0.235 0.166 0.16 0.032 0.468 0.95 0.66 
MLXIPL rs62466330 C/T 0.107 0.053 4.5x10-2 0.166 0.094 7.8x10-2 0.87 
ANK1-NKX6-3  rs13266210 A/G 0.039 0.036 0.28 -0.031 0.041 0.45 0.21 
TRIB1 rs6989280 G/A -0.012 0.034 0.73 0.018 0.040 0.66 0.60 
SLC45A4  rs12543725 G/A 0.052 0.030 8.6x10-2 0.047 0.030 0.12 0.90 
PTCH1  rs28510415 G/A 0.091 0.047 5.4x10-2 0.212 0.092 2.1x10-2 0.39 
LPAR1  rs2150052 T/A -0.001 0.030 0.97 0.092 0.030 2.0x10-3 2.4x10-3 
PHF19  rs7847628 G/A 0.038 0.032 0.23 0.004 0.037 0.92 0.28 
STRBP  rs700059 G/A 0.043 0.041 0.29 -0.029 0.070 0.68 0.22 
HHEX-IDE  rs61862780 T/C 0.085 0.030 4.7x10-3 0.050 0.030 9.6x10-2 0.32 
NT5C2 rs74233809 C/T -0.018 0.051 0.73 0.040 0.068 0.56 0.51 
ADRB1  rs7076938 T/C 0.023 0.033 0.49 0.078 0.041 5.5x10-2 0.27 
PLEKHA1  rs2421016 T/C 0.024 0.031 0.43 0.036 0.031 0.24 0.77 
INS-IGF2  rs72851023 T/C 0.116 0.051 2.2x10-2 0.108 0.107 0.31 0.56 
MTNR1B  rs10830963 G/C 0.024 0.033 0.46 0.058 0.040 0.15 0.53 
APOLD1 rs11055034 C/A 0.122 0.032 1.7x10-4 0.053 0.039 0.17 3.2x10-2 
ABCC9  rs139975827 G/A 0.045 0.031 0.15 0.017 0.032 0.59 0.46 
ITPR2 rs12823128 T/C 0.064 0.030 3.0x10-2 -0.003 0.029 0.91 7.7x10-2 
HMGA2  rs1351394 T/C 0.015 0.031 0.63 0.082 0.031 8.3x10-3 8.0x10-2 
IGF1  rs7964361 A/G -0.045 0.049 0.36 0.091 0.099 0.36 0.33 
LINC00332 rs2324499 G/C 0.012 0.032 0.70 0.041 0.034 0.22 0.70 
RB1 rs2854355 G/A 0.031 0.033 0.35 -0.012 0.042 0.77 0.25 
RNF219-AS1  rs1819436 C/T 0.038 0.042 0.36 0.136 0.079 8.4x10-2 0.39 
DLK1 rs6575803 C/T 0.104 0.045 2.2x10-2 0.205 0.091 2.5x10-2 0.40 
FES  rs12906125 G/A 0.019 0.032 0.55 0.095 0.035 6.7x10-3 9.3x10-2 
IGF1R  rs7402982 A/G 0.047 0.031 0.13 0.036 0.032 0.25 0.78 
 50 
Locus  
  
SNP 
  
EA/
NEA 
Paternal transmission  Maternal transmission P_het 
  β SE P-value β SE P-value 
GPR139 rs1011939 G/A -0.028 0.032 0.38 0.021 0.038 0.59 0.29 
CLDN7  rs113086489 T/C 0.061 0.031 4.9x10-2 0.050 0.031 0.11 0.83 
SUZ12P1-
CRLF3  rs144843919 G/A 0.003 0.071 0.96 0.182 0.113 0.11 0.20 
SP6-SP2 rs12942207 C/T 0.050 0.032 0.12 0.027 0.038 0.48 0.32 
ACTL9 rs61154119 T/G 0.056 0.038 0.14 0.164 0.062 8.7x10-3 5.6x10-2 
PEPD rs10402712 A/G 0.077 0.033 2.1x10-2 0.001 0.034 0.98 0.10 
JAG1  rs6040076 C/G 0.028 0.031 0.36 0.001 0.031 0.97 0.53 
C20orf203  rs28530618 A/G 0.053 0.031 8.3x10-2 0.013 0.031 0.68 0.26 
MAFB rs6016377 T/C 0.054 0.031 8.0x10-2 0.008 0.031 0.80 0.20 
NRIP1 rs2229742 G/C 0.020 0.046 0.66 0.030 0.095 0.75 0.89 
KREMEN1  rs134594 C/T 0.024 0.031 0.43 0.052 0.035 0.13 0.75 
SREBF2  rs62240962 C/T -0.004 0.052 0.94 0.088 0.065 0.18 0.40 
EA, effect allele; NEA, non effect allele; SE, standard error; P_het, P-value for difference in BW between AB 
heterozygote offspring inheriting allele A from mother and B from father, and those inheriting A from father and B 
from mother. 
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Supplementary Table 17. Association of BW signals with various adult metabolic and 
anthropometric traits. (GWAS look-ups) 
 
Provided in a separate Excel file. 
 
 
Supplementary Table 18. Effect of transmitted and untransmitted maternal haplotype scores on 
BW in 5,201 ALSPAC mother-child pairs. 
 
Haplotype 
score 
Height Systolic blood pressure Type 2 diabetes 
β SE P-value β SE P-value β SE P-value 
M1 (C1) 0.128 0.013 1.6x10-21 -6.82 3.36 0.04 -0.44 1.73 0.80 
M2 0.010 0.012 0.39 -6.40 2.63 0.02 1.66 1.42 0.24 
C2 0.066 0.012 1.2x10-7 0.14 2.62 0.96 -2.94 1.47 0.045 
Beta values are in grams per weighted trait-raising allele. SE, standard error. 
M1(C1), maternal transmitted haplotype score; M2, Maternal untransmitted haplotype score; C2, paternal 
transmitted haplotype score. 
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Supplementary Table 19. Reciprocal approximate conditional analyses at YKT6-GCK variants associated with birth weight (BW) or fasting 
glucose (FG), in European ancestry meta-analysis of up to 143,677 individuals. 
 
Variant 
(chr:position) 
Type EA/
NEA 
EAF 
(Eur) 
BW SNP conditioned on FG SNP FG SNP conditioned on BW SNP 
Uncondit
ioned P  
Conditioned 
on Variant type 
Conditio
ned P Variant 
Conditioned 
on 
Uncondit
ioned P  
Conditio
ned P 
rs138715366 
(7:44246271) 
  
  
BW lead SNP 
(at YKT6 
intron 1)  
  
T/C 0.0089  
7.2x10-26 unconditioned - - - - - - 
 
rs878521 
GCK FG primary 
(ENGAGE1) 1.3x10-25 rs878521 rs138715366 0.12 0.28 
 
rs10259649 
GCK FG secondary 
(ENGAGE1) 7.7x10-26 rs10259649 rs138715366 0.52 0.63 
 rs4607517 GCK FG (MAGIC2) 2.6x10-25 rs4607517 rs138715366 3.2x10-4 1.2x10-3 
 rs10278336 GCK T2D (DIAGRAM3) 1.8x10-25 rs10278336 rs138715366 0.057 0.19 
rs78412508 
(7:44223858) 
  
  
BW second 
strongest 
SNP (at GCK 
intron 3) 
  
A/G 0.0095 
8.9x10-24 unconditioned - - - - - - 
 
rs878521 
GCK FG primary 
(ENGAGE1) 1.6x10-23 rs878521 rs78412508 0.12 0.27 
 
rs10259649 
GCK FG secondary 
(ENGAGE1) 9.7x10-24 rs10259649 rs78412508 0.52 0.66 
 rs4607517 GCK FG (MAGIC2) 3.1x10-23 rs4607517 rs78412508 3.2x10-4 1.2x10-3 
 rs10278336 GCK T2D (DIAGRAM3) 2.2x10-23 rs10278336 rs78412508 0.057 0.18 
EA, effect allele; NEA, non effect allele, EAF, effect allele frequency; Eur, European; BW, birth weight; FG, fasting glucose; T2D, type 2 diabetes. 
1. Horikoshi M et al. PLoS Genet 11, e1005230 (2015). 
2. Dupuis J et al. Nat Genet 42, 105-116 (2010). 
3. Morris AP et al. Nat Genet 44, 981-990 (2012). 
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Supplementary Figure 1. BW association enrichment for DNaseI hypersensitive (DHS) sites in 128 
cell types and four genic annotations. a, Each cell type DHS annotation and four gene-based 
annotations were individually tested for enrichment using the Bayes Factors for all variants in the 
62 credible sets. The effect estimate (filled circle) and 95% CI (horizontal line) are plotted on the x 
axis. The 128 cell types (listed on the y axis; see Supplementary Table 8 for details) are categorised 
according to the description fields from ENCODE (stem cell, neonatal, foetal, embryonic and adult 
groups). We considered an annotation enriched if the 95% CI did not overlap zero (highlighted in 
red). b, Estimated effect of enrichment (filled circle) and 95% CI (horizontal line) for each 
categorical field, tested in a joint model, are plotted (see Methods).   
 
a                                                                                        b 
 
 
 
<-2 -1 0 1 2 3
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-2 -1 0 1 2
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Adult DHS
Embryonic DHS
ln(Enrichment) +/- 95% CI
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Supplementary Figure 2. Estimates of phenotypic, genetic and residual correlations (a) and 
estimates of genetic and residual covariance (b) between birth weight and adult metabolic or 
anthropometric traits in UK Biobank ‘white British’ samples (up to N=57,715). See details in 
Supplementary Table 13.  
a 
 
b 
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